Amedeo Smart

Free Medical Literature Service

 

Amedeo

Influenza
  Free Subscription

Articles published in
J Infect Dis
    April 2024
  1. RECTO C, Fourati S, Khellaf M, Pawlotsky JM, et al
    Respiratory syncytial virus vs. Influenza virus infection: mortality and morbidity comparison over 7 epidemic seasons in an elderly population.
    J Infect Dis. 2024 Apr 4:jiae171. doi: 10.1093.
    >> Share

    March 2024
  2. FINSTERER J
    Cerebrospinal Fluid Biomarkers of Neuronal/Glial Damage or Immune Activation Are Unsuitable for Assessing Post-COVID Cognitive Impairment.
    J Infect Dis. 2024;229:918-919.
    >> Share

  3. ROSSLER A, Knabl L, Netzl A, Bante D, et al
    Durability of Cross-Neutralizing Antibodies 5.5 Months After Bivalent Coronavirus Disease 2019 Vaccine Booster.
    J Infect Dis. 2024;229:644-647.
    >> Share

  4. LI X, Zhou G, Sun X, Qu S, et al
    NLRP12 Senses the SARS-CoV-2 Membrane Protein and Promotes an Inflammatory Response.
    J Infect Dis. 2024;229:660-670.
    >> Share

  5. JENSEN TO, Grandits GA, Jain MK, Murray TA, et al
    Effect of Neutralizing Monoclonal Antibody Treatment on Early Trajectories of Virologic and Immunologic Biomarkers in Patients Hospitalized With COVID-19.
    J Infect Dis. 2024;229:671-679.
    >> Share

  6. BAY P, Loegel C, Ly A, Soulier A, et al
    Clinical Phenotypes and Molecular Characteristics of Respiratory Syncytial Virus in Adults: A Monocentric Prospective Study Between 2019 and 2022.
    J Infect Dis. 2024;229:728-732.
    >> Share

  7. ALI YM, Carnell GW, Fumagalli S, Mercurio D, et al
    Inhibition of the Lectin Pathway of Complement Activation Reduces Acute Respiratory Distress Syndrome Severity in a Mouse Model of SARS-CoV-2 Infection.
    J Infect Dis. 2024;229:680-690.
    >> Share

  8. SCOTT N, Martinovich KM, Granland CM, Seppanen EJ, et al
    Nasal Delivery of Haemophilus haemolyticus Is Safe, Reduces Influenza Severity, and Prevents Development of Otitis Media in Mice.
    J Infect Dis. 2024 Mar 12:jiae069. doi: 10.1093.
    >> Share

  9. LIM WW, Shuo F, Wong SS, Sullivan SG, et al
    Hemagglutination inhibition antibody titers mediate influenza vaccine efficacy against symptomatic influenza A(H1N1), A(H3N2), and B/Victoria infections.
    J Infect Dis. 2024 Mar 7:jiae122. doi: 10.1093.
    >> Share

  10. HAK SF, Venekamp RP, Billard MN, van Houten MA, et al
    Substantial Burden of Nonmedically Attended RSV Infection in Healthy-Term Infants: An International Prospective Birth Cohort Study.
    J Infect Dis. 2024;229.
    >> Share

  11. JOHNSON M, Chelysheva I, Oner D, McGinley J, et al
    A Genome-Wide Association Study of Respiratory Syncytial Virus Infection Severity in Infants.
    J Infect Dis. 2024;229.
    >> Share

  12. OSEI-YEBOAH R, Johannesen CK, Egeskov-Cavling AM, Chen J, et al
    Respiratory Syncytial Virus-Associated Hospitalization in Adults With Comorbidities in 2 European Countries: A Modeling Study.
    J Infect Dis. 2024;229.
    >> Share

  13. CHAPPIN K, Besteman SB, Hennus MP, Wildenbeest JG, et al
    Airway and Blood Monocyte Transcriptomic Profiling Reveals an Antiviral Phenotype in Infants With Severe Respiratory Syncytial Virus Infection.
    J Infect Dis. 2024;229.
    >> Share

  14. VAN ROEKEL C, Poukka E, Turunen T, Nohynek H, et al
    Effectiveness of Immunization Products Against Medically Attended Respiratory Syncytial Virus Infection: Generic Protocol for a Test-Negative Case-Control Study.
    J Infect Dis. 2024;229.
    >> Share

  15. KENMOE S, Chu HY, Dawood FS, Milucky J, et al
    Burden of Respiratory Syncytial Virus-Associated Acute Respiratory Infections During Pregnancy.
    J Infect Dis. 2024;229.
    >> Share

  16. OSEI-YEBOAH R, Zhu F, Wang X, Nair H, et al
    Respiratory Syncytial Virus-Associated Hospital Admissions by Deprivation Levels Among Children and Adults in Scotland.
    J Infect Dis. 2024;229.
    >> Share

  17. SHEIKH Z, Potter E, Li Y, Cohen RA, et al
    Validity of Clinical Severity Scores for Respiratory Syncytial Virus: A Systematic Review.
    J Infect Dis. 2024;229.
    >> Share

  18. EGESKOV-CAVLING AM, Johannesen CK, Lindegaard B, Fischer TK, et al
    Underreporting and Misclassification of Respiratory Syncytial Virus-Coded Hospitalization Among Adults in Denmark Between 2015-2016 and 2017-2018.
    J Infect Dis. 2024;229.
    >> Share

    February 2024
  19. CASADEVALL A, Sullivan DJ
    Late Administration and Corticosteroid Usage Explain Inefficacy in COVID-19 Convalescent Plasma Trial.
    J Infect Dis. 2024;229:617-618.
    >> Share

  20. KANBERG N, Grahn A, Stentoft E, Bremell D, et al
    COVID-19 Recovery: Consistent Absence of Cerebrospinal Fluid Biomarker Abnormalities in Patients With Neurocognitive Post-COVID Complications.
    J Infect Dis. 2024;229:493-501.
    >> Share

  21. YOUNG BR, Ho F, Lin Y, Lau EHY, et al
    Estimation of the Time-Varying Effective Reproductive Number of COVID-19 Based on Multivariate Time Series of Severe Health Outcomes.
    J Infect Dis. 2024;229:502-506.
    >> Share

  22. VUJKOVIC A, Ha M, de Block T, van Petersen L, et al
    Diagnosing Viral Infections Through T-Cell Receptor Sequencing of Activated CD8+ T Cells.
    J Infect Dis. 2024;229:507-516.
    >> Share

  23. MONROE JM, Quach HQ, Punia S, Enninga EAL, et al
    Vertical Transmission of SARS-CoV-2-Specific Antibodies and Cytokine Profiles in Pregnancy.
    J Infect Dis. 2024;229:473-484.
    >> Share

  24. HEIMONEN J, Chow EJ, Wang Y, Hughes JP, et al
    Risk of Subsequent Respiratory Virus Detection After Primary Virus Detection in a Community Household Study-King County, Washington, 2019-2021.
    J Infect Dis. 2024;229:422-431.
    >> Share

  25. MAKHSOUS N, Goya S, Avendano CC, Rupp J, et al
    Within-Host Rhinovirus Evolution in Upper and Lower Respiratory Tract Highlights Capsid Variability and Mutation-Independent Compartmentalization.
    J Infect Dis. 2024;229:403-412.
    >> Share

  26. AMINISANI N, Wood T, Jelley L, Wong C, et al
    The burden of HMPV and influenza associated hospitalizations in adults in New Zealand, 2012-2015.
    J Infect Dis. 2024 Feb 13:jiae064. doi: 10.1093.
    >> Share

  27. MUNOZ-QUILES C, Lopez-Lacort M, Urchueguia A, Diez-Domingo J, et al
    Risk of cardiovascular events after influenza: A population-based Self Controlled Case Series study, Spain 2011-2018.
    J Infect Dis. 2024 Feb 8:jiae070. doi: 10.1093.
    >> Share

    January 2024
  28. HEDBERG P, Naucler P
    Post-COVID-19 Condition After SARS-CoV-2 Infections During the Omicron Surge vs the Delta, Alpha, and Wild Type Periods in Stockholm, Sweden.
    J Infect Dis. 2024;229:133-136.
    >> Share

  29. WEI SC, Freeman D, Himschoot A, Clarke KEN, et al
    Who Gets Sick From COVID-19? Sociodemographic Correlates of Severe Adult Health Outcomes During Alpha- and Delta-Variant Predominant Periods: September 2020-November 2021.
    J Infect Dis. 2024;229:122-132.
    >> Share

  30. SULLIVAN T
    Lessons (Machine) Learned From COVID-19.
    J Infect Dis. 2024;229:7-9.
    >> Share

  31. HOWARD LM, Jensen TL, Goll JB, Gelber CE, et al
    Metabolomic Signatures Differentiate Immune Responses in Avian Influenza Vaccine Recipients.
    J Infect Dis. 2024 Jan 5:jiad611. doi: 10.1093.
    >> Share

    December 2023
  32. SAJKOV D, Woodman R, Honda-Okubo Y, Barbara J, et al
    A Multi-Season Randomised Controlled Trial of Advax-Adjuvanted Seasonal Influenza Vaccine in Participants with Chronic Disease or Older Age.
    J Infect Dis. 2023 Dec 29:jiad589. doi: 10.1093.
    >> Share

  33. WIDAGDO W, Bastian AR, Jastorff AM, Scheys I, et al
    Concomitant Administration of Ad26.RSV.preF/RSV preF Protein Vaccine and High-dose Influenza Vaccine in Adults 65 Years and Older: a Noninferiority Trial.
    J Infect Dis. 2023 Dec 22:jiad594. doi: 10.1093.
    >> Share

  34. YAMAMOTO S, Matsuda K, Maeda K, Horii K, et al
    Preinfection Neutralizing Antibodies, Omicron BA.5 Breakthrough Infection, and Long COVID: A Propensity Score-Matched Analysis.
    J Infect Dis. 2023;228:1652-1661.
    >> Share

  35. PENETRA SLS, Santos HFP, Resende PC, Bastos LS, et al
    SARS-CoV-2 Reinfection Cases in a Household-Based Prospective Cohort in Rio de Janeiro.
    J Infect Dis. 2023;228:1680-1689.
    >> Share

  36. CHENE A, Desrames A, Tomlinson A, Ruffie C, et al
    An ACE2-Based Bimodular Fusion Protein Enables Reorientation of Endogenous Anti-Epstein-Barr Virus Antibodies Toward SARS-CoV-2 Spike.
    J Infect Dis. 2023;228:1675-1679.
    >> Share

  37. WEST AC, Harpur CM, Le Page MA, Lam M, et al
    Harnessing endogenous peptide compounds as potential therapeutics for severe influenza.
    J Infect Dis. 2023 Dec 7:jiad566. doi: 10.1093.
    >> Share

  38. TENFORDE MW, Weber ZA, Yang DH, DeSilva MB, et al
    Influenza vaccine effectiveness against influenza-A-associated emergency department, urgent care, and hospitalization encounters among U.S. adults, 2022-2023.
    J Infect Dis. 2023 Dec 2:jiad542. doi: 10.1093.
    >> Share

    November 2023
  39. FELL DB, Russell M, Fung SG, Swayze S, et al
    Effectiveness of maternal influenza vaccination during pregnancy against laboratory-confirmed seasonal influenza among infants under 6 months of age in Ontario, Canada.
    J Infect Dis. 2023 Nov 29:jiad539. doi: 10.1093.
    >> Share

  40. LEE K, Williams KV, Englund JA, Sullivan SG, et al
    The potential benefits of delaying seasonal influenza vaccine selections for the Northern Hemisphere: a retrospective modeling study in the United States.
    J Infect Dis. 2023 Nov 29:jiad541. doi: 10.1093.
    >> Share

  41. FRANKLIN A, John TM, Khawaja F, Jiang Y, et al
    Utility of Bronchoalveolar Lavage for the Diagnosis and Management of COVID-19 in Patients With Cancer.
    J Infect Dis. 2023;228:1549-1558.
    >> Share

  42. ERNST T, Ryan MC, Liang HJ, Wang JP, et al
    Neuronal and Glial Metabolite Abnormalities in Participants With Persistent Neuropsychiatric Symptoms After COVID-19: A Brain Proton Magnetic Resonance Spectroscopy Study.
    J Infect Dis. 2023;228:1559-1570.
    >> Share

  43. ONWUCHEKWA C, Atwell J, Moreo LM, Menon S, et al
    Pediatric Respiratory Syncytial Virus Diagnostic Testing Performance: A Systematic Review and Meta-analysis.
    J Infect Dis. 2023;228:1516-1527.
    >> Share

  44. OSEI-YEBOAH R, Spreeuwenberg P, Del Riccio M, Fischer TK, et al
    Estimation of the Number of Respiratory Syncytial Virus-Associated Hospitalizations in Adults in the European Union.
    J Infect Dis. 2023;228:1539-1548.
    >> Share

  45. DEL RICCIO M, Spreeuwenberg P, Osei-Yeboah R, Johannesen CK, et al
    Burden of Respiratory Syncytial Virus in the European Union: estimation of RSV-associated hospitalizations in children under 5 years.
    J Infect Dis. 2023;228:1528-1538.
    >> Share

  46. LU X, Liu F, Tzeng WP, York IA, et al
    Antibody-mediated Suppression Regulates the Humoral Immune Response to Influenza Vaccination in Humans.
    J Infect Dis. 2023 Nov 20:jiad493. doi: 10.1093.
    >> Share

  47. JI W, Guthmiller J
    Goldilocks zone of preexisting immunity: too little or too much suppresses diverse antibody responses against influenza viruses.
    J Infect Dis. 2023 Nov 18:jiad494. doi: 10.1093.
    >> Share

  48. LASRADO N, Barouch DH
    SARS-CoV-2 Hybrid Immunity: The Best of Both Worlds.
    J Infect Dis. 2023;228:1311-1313.
    >> Share

  49. LOWENSTEYN YN, Zheng Z, Rave N, Bannier MAGE, et al
    Year-Round Respiratory Syncytial Virus Transmission in The Netherlands Following the COVID-19 Pandemic: A Prospective Nationwide Observational and Modeling Study.
    J Infect Dis. 2023;228:1394-1399.
    >> Share

  50. JITTAMALA P, Schilling WHK, Watson JA, Luvira V, et al
    Clinical Antiviral Efficacy of Remdesivir in Coronavirus Disease 2019: An Open-Label, Randomized Controlled Adaptive Platform Trial (PLATCOV).
    J Infect Dis. 2023;228:1318-1325.
    >> Share

  51. KYO M, Zhu Z, Shibata R, Fujiogi M, et al
    Respiratory Virus-Specific Nasopharyngeal Lipidome Signatures and Severity in Infants With Bronchiolitis: A Prospective Multicenter Study.
    J Infect Dis. 2023;228:1410-1420.
    >> Share

  52. NAKAJO K, Nishiura H
    Age-Dependent Risk of Respiratory Syncytial Virus Infection: A Systematic Review and Hazard Modeling From Serological Data.
    J Infect Dis. 2023;228:1400-1409.
    >> Share

  53. ZHONG S, Ng TWY, Skowronski DM, Iuliano AD, et al
    Standard-dose versus MF59-adjuvanted, high-dose or recombinant-hemagglutinin influenza vaccine immunogenicity in older adults: comparison of A(H3N2) antibody response by prior season's vaccine status.
    J Infect Dis. 2023 Nov 10:jiad497. doi: 10.1093.
    >> Share

  54. HEDSKOG C, Rodriguez L, Roychoudhury P, Huang ML, et al
    Viral Resistance Analyses From the Remdesivir Phase 3 Adaptive COVID-19 Treatment Trial-1 (ACTT-1).
    J Infect Dis. 2023;228:1263-1273.
    >> Share

  55. WONG JY, Cheung JK, Lin Y, Bond HS, et al
    Intrinsic and Effective Severity of Coronavirus Disease 2019 Cases Infected With the Ancestral Strain and Omicron BA.2 Variant in Hong Kong.
    J Infect Dis. 2023;228:1231-1239.
    >> Share

  56. EVANS MV, Ramiadantsoa T, Kauffman K, Moody J, et al
    Sociodemographic Variables Can Guide Prioritized Testing Strategies for Epidemic Control in Resource-Limited Contexts.
    J Infect Dis. 2023;228:1189-1197.
    >> Share

    October 2023
  57. RUDOLPH AE, Khan FL, Shah A, Singh TG, et al
    Effectiveness of BNT162b2 BA.4/5 bivalent mRNA vaccine against symptomatic COVID-19 among immunocompetent individuals testing at a large US retail pharmacy.
    J Infect Dis. 2023 Oct 31:jiad474. doi: 10.1093.
    >> Share

  58. TURCINOVIC J, Kuhfeldt K, Sullivan M, Landaverde L, et al
    Transmission Dynamics and Rare Clustered Transmission Within an Urban University Population Before Widespread Vaccination.
    J Infect Dis. 2023 Oct 19:jiad397. doi: 10.1093.
    >> Share

  59. ANDINO R, Kirkegaard K, Macadam A, Racaniello VR, et al
    The Picornaviridae Family: Knowledge Gaps, Animal Models, Countermeasures, and Prototype Pathogens.
    J Infect Dis. 2023;228.
    >> Share

  60. MORABITO KM, Cassetti MC, DeRocco AJ, Deschamps AM, et al
    Viral Prototypes for Pandemic Preparedness: The Road Ahead.
    J Infect Dis. 2023;228.
    >> Share

  61. DALMAT RR, Hao L, Prabhu R, Rechkina E, et al
    Rapid Antigen and Antibody Microfluidic Immunofluorescence Assays Compared to Culture, PCR, and Laboratory Reference Tests: Performance in a Longitudinal Cohort.
    J Infect Dis. 2023;228:1066-1070.
    >> Share

  62. TUFFY KM, Ahani B, Aksyuk AA, Avila M, et al
    Breakthrough SARS-CoV-2 Infections in the PROVENT Prevention Trial Were Not Associated With AZD7442 (Tixagevimab/Cilgavimab) Resistant Variants.
    J Infect Dis. 2023;228:1055-1059.
    >> Share

  63. BUTT AA, Yan P, Shaikh OS, Omer SB, et al
    Molnupiravir Use and 30-Day Hospitalizations or Death in a Previously Uninfected Nonhospitalized High-risk Population With COVID-19.
    J Infect Dis. 2023;228:1033-1041.
    >> Share

  64. ADHIKARI EH, Lu P, Kang YJ, McDonald AR, et al
    Diverging maternal and cord antibody functions from SARS-CoV-2 infection and vaccination in pregnancy.
    J Infect Dis. 2023 Oct 10:jiad421. doi: 10.1093.
    >> Share

  65. LEDDEROSE C, Valsami EA, Elevado M, Junger WG, et al
    ATP release from influenza-infected lungs enhances neutrophil activation and promotes disease progression.
    J Infect Dis. 2023 Oct 6:jiad442. doi: 10.1093.
    >> Share

  66. HSU FC, Pan LC, Huang YF, Yang CH, et al
    A Dynamic Model for Estimating the Retention Duration of Neutralizing Antibody Titers after Vaccination in a COVID-19 Convalescent Population.
    J Infect Dis. 2023 Oct 5:jiad431. doi: 10.1093.
    >> Share

  67. GREWAL R, Buchan SA, Nguyen L, Nasreen S, et al
    Effectiveness of mRNA COVID-19 monovalent and bivalent vaccine booster doses against Omicron severe outcomes among adults aged >/=50 years in Ontario, Canada: a Canadian Immunization Research Network (CIRN) Study.
    J Infect Dis. 2023 Oct 5:jiad419. doi: 10.1093.
    >> Share

  68. CHU WT, Reza SMS, Anibal JT, Landa A, et al
    Artificial Intelligence and Infectious Disease Imaging.
    J Infect Dis. 2023;228.
    >> Share

  69. HAMMOUD DA, Clifford Lane H, Jain SK
    Molecular Imaging of Infections: Advancing the Search for the Hidden Enemy.
    J Infect Dis. 2023;228.
    >> Share

  70. LEE E, Bates B, Kuhrt N, Andersen KM, et al
    National Trends in Anticoagulation Therapy for COVID-19 Hospitalized Adults in the United States: Analyses of the National COVID Cohort Collaborative.
    J Infect Dis. 2023;228:895-906.
    >> Share

  71. YUNOKI M, Kubota-Koketsu R, Imada T, Furuyama K, et al
    Changes in Anti-SARS-CoV-2 Antibody Titers of Pooled Plasma Derived From Donors in Japan: A Potential Tool for Mass-Immunity Evaluation.
    J Infect Dis. 2023;228:889-894.
    >> Share

  72. SKARBINSKI J, Nugent JR, Wood MS, Liu L, et al
    Severe Acute Respiratory Syndrome Coronavirus 2 Delta Variant Genomic Variation Associated With Breakthrough Infection in Northern California: A Retrospective Cohort Study.
    J Infect Dis. 2023;228:878-888.
    >> Share

  73. MUNOZ-QUILES C, Lopez-Lacort M, Diez-Domingo J, Orrico-Sanchez A, et al
    Bronchiolitis, Regardless of Its Etiology and Severity, Is Associated With Increased Risk of Asthma: A Population-Based Study.
    J Infect Dis. 2023;228:840-850.
    >> Share

    September 2023
  74. MADSEN AMR, Schaltz-Buchholzer F, Nielsen S, Benfield T, et al
    Using BCG vaccine to enhance non-specific protection of health care workers during the COVID-19 pandemic: a randomized controlled trial.
    J Infect Dis. 2023 Sep 29:jiad422. doi: 10.1093.
    >> Share

  75. ANDREEV K, Jones JC, Seiler P, Kandeil A, et al
    Antiviral Susceptibility of Highly Pathogenic Avian Influenza A(H5N1) Viruses Circulating Globally in 2022-2023.
    J Infect Dis. 2023 Sep 28:jiad418. doi: 10.1093.
    >> Share

  76. HOWA AC, Zhu Y, Wyatt D, Markus T, et al
    Estimating the Burden of Influenza Hospitalizations Across Multiple Seasons Using Capture-Recapture.
    J Infect Dis. 2023 Sep 28:jiad417. doi: 10.1093.
    >> Share

  77. HAYDEN FG, Lenk RP, Epstein C, Kang LL, et al
    Oral Favipiravir Exposure and Pharmacodynamic Effects in Outpatient Adults with Acute Influenza.
    J Infect Dis. 2023 Sep 22:jiad409. doi: 10.1093.
    >> Share

  78. BASU THAKUR P, Mrotz VJ, Maines TR, Belser JA, et al
    Ferrets as a mammalian model to study influenza virus-bacteria interactions.
    J Infect Dis. 2023 Sep 22:jiad408. doi: 10.1093.
    >> Share

  79. CHEEMARLA NR, Watkins TA, Mihaylova VT, Foxman EF, et al
    Viral interference during influenza A-SARS-CoV-2 coinfection of the human airway epithelium and reversal by oseltamivir.
    J Infect Dis. 2023 Sep 18:jiad402. doi: 10.1093.
    >> Share

  80. REBELO M, Tang C, Coelho AR, Labao-Almeida C, et al
    De Novo Human Angiotensin-Converting Enzyme 2 Decoy NL-CVX1 Protects Mice From Severe Disease After Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
    J Infect Dis. 2023;228:723-733.
    >> Share

  81. BUTT AA, Yan P, Shaikh OS, Talisa VB, et al
    Nirmatrelvir/ritonavir Use and Hospitalizations or Death in Previously Uninfected Non-hospitalized High-risk Population with COVID-19: A matched cohort study.
    J Infect Dis. 2023 Sep 15:jiad393. doi: 10.1093.
    >> Share

  82. LEROUX-ROELS I, Van Ranst M, Vandermeulen C, Abeele CV, et al
    Safety and Immunogenicity of a Revaccination With a Respiratory Syncytial Virus Prefusion F Vaccine in Older Adults: A Phase 2b Study.
    J Infect Dis. 2023 Sep 12:jiad321. doi: 10.1093.
    >> Share

  83. FROBERG J, Koomen VJCH, van der Gaast-de Jongh CE, Philipsen R, et al
    Primary exposure to SARS-CoV-2 via infection or vaccination determines mucosal antibody-dependent ACE2 binding inhibition.
    J Infect Dis. 2023 Sep 7:jiad385. doi: 10.1093.
    >> Share

  84. MARTIN JM, Moehling Geffel K, Ortiz MA, Rajasundaram D, et al
    Differential Induction of Interferon Stimulated Genes by Cell-based Versus Egg-based Quadrivalent Influenza Vaccines in Children During the 2018-19 Season.
    J Infect Dis. 2023 Sep 4:jiad380. doi: 10.1093.
    >> Share

    August 2023
  85. CHEW KW, Moser C, Yeh E, Wohl DA, et al
    Validity and Characterization of Time to Symptom Resolution Outcome Measures in the ACTIV-2/A5401 Outpatient COVID-19 Treatment Trial.
    J Infect Dis. 2023;228.
    >> Share

  86. EVERING TH, Moser CB, Jilg N, Yeh E, et al
    Long COVID After Bamlanivimab Treatment.
    J Infect Dis. 2023;228.
    >> Share

  87. MOSER CB, Chew KW, Giganti MJ, Li JZ, et al
    Statistical Challenges When Analyzing SARS-CoV-2 RNA Measurements Below the Assay Limit of Quantification in COVID-19 Clinical Trials.
    J Infect Dis. 2023;228.
    >> Share

  88. MOSER CB, Chew KW, Ritz J, Newell M, et al
    Pooling Different Placebos as a Control Group in a Randomized Platform Trial: Benefits and Challenges From Experience in the ACTIV-2 COVID-19 Trial.
    J Infect Dis. 2023;228.
    >> Share

  89. RIBEIRO RM, Choudhary MC, Deo R, Giganti MJ, et al
    Variant-Specific Viral Kinetics in Acute COVID-19.
    J Infect Dis. 2023;228.
    >> Share

  90. LI Y, Moser C, Aga E, Currier JS, et al
    Immune Status and SARS-CoV-2 Viral Dynamics.
    J Infect Dis. 2023;228.
    >> Share

  91. CURRIER JS, Moser C, Eron JJ, Chew KW, et al
    ACTIV-2: A Platform Trial for the Evaluation of Novel Therapeutics for the Treatment of Early COVID-19 in Outpatients.
    J Infect Dis. 2023;228.
    >> Share

  92. GIGANTI MJ, Chew KW, Eron JJ, Li JZ, et al
    Association Between Anterior Nasal and Plasma SARS-CoV-2 RNA Levels and Hospitalization or Death in Nonhospitalized Adults With Mild-to-Moderate COVID-19.
    J Infect Dis. 2023;228.
    >> Share

  93. WAYHAM NP, Niedecken AR, Simons JF, Chiang YY, et al
    A Potent Recombinant Polyclonal Antibody Therapeutic for Protection Against New Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern.
    J Infect Dis. 2023;228:555-563.
    >> Share

  94. SUNG MH, Billings W, Carlock MA, Hanley HB, et al
    Assessment of humoral immune responses to repeated influenza vaccination in a multiyear cohort: a five-year follow-up.
    J Infect Dis. 2023 Aug 25:jiad319. doi: 10.1093.
    >> Share

  95. SUN X, Belser JA, Pulit-Penaloza JA, Brock N, et al
    Pathogenesis and transmission assessment of three swine-origin influenza A(H3N2) viruses with zoonotic risk to humans isolated in the U.S from 2017-2020.
    J Infect Dis. 2023 Aug 21:jiad359. doi: 10.1093.
    >> Share

  96. MERENSTEIN C, Fitzgerald AS, Khatib LA, Graham-Wooten J, et al
    Effects of Mask Reuse on the Oropharyngeal, Skin, and Mask Microbiome.
    J Infect Dis. 2023;228:479-486.
    >> Share

  97. YOUNG BR, Yang B, Wu P, Adam DC, et al
    Residential Clustering of Coronavirus Disease 2019 Cases and Efficiency of Building-Wide Compulsory Testing Notices as a Transmission Control Measure in Hong Kong.
    J Infect Dis. 2023;228:426-430.
    >> Share

  98. FAUCI AS, Folkers GK
    Pandemic Preparedness and Response: Lessons From COVID-19.
    J Infect Dis. 2023;228:422-425.
    >> Share

  99. ROWLEY AH, Arrollo D, Shulman ST, Torres A, et al
    Analysis of Plasmablasts From Children With Kawasaki Disease Reveals Evidence of a Convergent Antibody Response to a Specific Protein Epitope.
    J Infect Dis. 2023;228:412-421.
    >> Share

  100. DUARTE LF, Vazquez Y, Diethelm-Varela B, Pavez V, et al
    Differential Sars-Cov-2-Specific Humoral Response in Inactivated Virus-Vaccinated, Convalescent, and Breakthrough Subjects.
    J Infect Dis. 2023 Aug 12:jiad320. doi: 10.1093.
    >> Share

  101. ZAVALIS EA, Contopoulos-Ioannidis DG, Ioannidis JPA
    Transparency in Infectious Disease Research: Meta-research Survey of Specialty Journals.
    J Infect Dis. 2023;228:227-234.
    >> Share

  102. ANDEREGG N, Schwab T, Borcard L, Mugglin C, et al
    Population-Based Severe Acute Respiratory Syndrome Coronavirus 2 Whole-Genome Sequencing and Contact Tracing During the Coronavirus Disease 2019 Pandemic in Switzerland.
    J Infect Dis. 2023;228:251-260.
    >> Share

  103. DIMCHEFF DE, Blair CN, Zhu Y, Chappell JD, et al
    Total and Subgenomic RNA Viral Load in Patients Infected With SARS-CoV-2 Alpha, Delta, and Omicron Variants.
    J Infect Dis. 2023;228:235-244.
    >> Share

  104. PARASKEVIS D, Gkova M, Mellou K, Gerolymatos G, et al
    Real-world effectiveness of molnupiravir and nirmatrelvir/ritonavir as treatments for COVID-19 in high-risk patients.
    J Infect Dis. 2023 Aug 11:jiad324. doi: 10.1093.
    >> Share

  105. WANG FZ, Zhang CH, Tang L, Rodewald LE, et al
    An observational prospective cohort study of vaccine effectiveness against SARS-CoV-2 infection of an aerosolized, inhaled adenovirus-type-5-vectored COVID-19 vaccine given as a second booster dose in Guangzhou city, China.
    J Infect Dis. 2023 Aug 11:jiad338. doi: 10.1093.
    >> Share

  106. NOBLE CC, Messina NL, Pittet LF, Curtis N, et al
    Interpreting the results of trials of BCG vaccination for protection against COVID-19.
    J Infect Dis. 2023 Aug 10:jiad316. doi: 10.1093.
    >> Share

  107. YOON JG, Kim YE, Choi MJ, Choi WS, et al
    Herpes zoster reactivation after mRNA and adenovirus-vectored coronavirus disease 2019 vaccination: Analysis of National Health Insurance Database.
    J Infect Dis. 2023 Aug 7:jiad297. doi: 10.1093.
    >> Share

  108. HALL VG, Teh BW
    COVID-19 Vaccination in Patients With Cancer and Patients Receiving HSCT or CAR-T Therapy: Immune Response, Real-World Effectiveness, and Implications for the Future.
    J Infect Dis. 2023;228.
    >> Share

  109. ANTINORI A, Bausch-Jurken M
    The Burden of COVID-19 in the Immunocompromised Patient: Implications for Vaccination and Needs for the Future.
    J Infect Dis. 2023;228.
    >> Share

  110. BONANNI P, Ceddia F, Dawson R
    A Call to Action: Current Challenges and Considerations for COVID-19 Vaccination in Immunocompromised Populations.
    J Infect Dis. 2023;228.
    >> Share

  111. SUBRAMANIAN V
    Susceptibility to SARS-CoV-2 Infection and Immune Responses to COVID-19 Vaccination Among Recipients of Solid Organ Transplants.
    J Infect Dis. 2023;228.
    >> Share

  112. ROUPHAEL N, Bausch-Jurken M
    COVID-19 Vaccination Among Patients Receiving Maintenance Renal Replacement Therapy: Immune Response, Real-World Effectiveness, and Implications for the Future.
    J Infect Dis. 2023;228.
    >> Share

  113. WILLICOMBE M
    Foreword: Preventing COVID-19 Among the Immunocompromised Population.
    J Infect Dis. 2023;228.
    >> Share

  114. PARIS R
    SARS-CoV-2 Infection and Response to COVID-19 Vaccination in Patients With Primary Immunodeficiencies.
    J Infect Dis. 2023;228.
    >> Share

  115. FINCKH A, Ciurea A, Raptis CE, Rubbert-Roth A, et al
    Susceptibility to COVID-19 and Immunologic Response to Vaccination in Patients With Immune-Mediated Inflammatory Diseases.
    J Infect Dis. 2023;228.
    >> Share

  116. LIU J, Cao F, Luo C, Guo Y, et al
    Stroke Following COVID-19 Vaccination: Evidence Based on Different Designs of Real-World Studies.
    J Infect Dis. 2023 Aug 3:jiad306. doi: 10.1093.
    >> Share

  117. BRAUNSTEIN SL, Wahnich A, Lazar R
    COVID-19 outcomes among people with HIV and COVID-19 in New York City.
    J Infect Dis. 2023 Aug 3:jiad311. doi: 10.1093.
    >> Share

  118. COHEN LE, Hansen CL, Andrew MK, McNeil SA, et al
    Predictors of severity of influenza-related hospitalizations: Results from the Global Influenza Hospital Surveillance Network (GIHSN).
    J Infect Dis. 2023 Aug 1:jiad303. doi: 10.1093.
    >> Share

    July 2023
  119. KARRON RA, Luongo C, Woods S, Oliva J, et al
    Evaluation of the live-attenuated intranasal respiratory syncytial virus (RSV) vaccine RSV/6120/DeltaNS2/1030s in RSV-seronegative young children.
    J Infect Dis. 2023 Jul 26:jiad281. doi: 10.1093.
    >> Share

  120. SAEZ-LLORENS X, Norero X, Mussi-Pinhata MM, Luciani K, et al
    Safety and immunogenicity of a ChAd155-vectored respiratory syncytial virus vaccine in infants 6-7 months of age: a phase 1/2 randomized trial.
    J Infect Dis. 2023 Jul 21:jiad271. doi: 10.1093.
    >> Share

  121. EL SAHLY HM, Yildirim I, Frey SE, Winokur P, et al
    Safety and Immunogenicity of a Delayed Heterologous Avian Influenza A(H7N9) Vaccine Boost Following Different Priming Regimens: A Randomized Clinical Trial.
    J Infect Dis. 2023 Jul 19:jiad276. doi: 10.1093.
    >> Share

  122. JAGER M, Diem G, Sahanic S, Fux V, et al
    Immunity of Heterologously and Homologously Boosted or Convalescent Individuals Against Omicron BA.1, BA.2, and BA.4/5 Variants.
    J Infect Dis. 2023;228:160-168.
    >> Share

  123. TAIWO BO, Chew KW, Moser C, Wohl DA, et al
    Phase 2 Safety and Antiviral Activity of SAB-185, a Novel Polyclonal Antibody Therapy for Nonhospitalized Adults With COVID-19.
    J Infect Dis. 2023;228:133-142.
    >> Share

  124. ONWUCHEKWA C, Moreo LM, Menon S, Machado B, et al
    Underascertainment of Respiratory Syncytial Virus Infection in Adults Due to Diagnostic Testing Limitations: A Systematic Literature Review and Meta-analysis.
    J Infect Dis. 2023;228:173-184.
    >> Share

  125. ROA CC, de Los Reyes MRA, Plennevaux E, Smolenov I, et al
    Superior boosting of neutralizing titers against Omicron SARS-CoV-2 variants by heterologous SCB-2019 vaccine vs a homologous booster in CoronaVac-primed adults.
    J Infect Dis. 2023 Jul 13:jiad262. doi: 10.1093.
    >> Share

  126. COMEAUX CA, Bart S, Bastian AR, Klyashtornyy V, et al
    Safety, Immunogenicity, and Regimen Selection of Ad26.RSV.preF-based Vaccine Combinations: A Randomized, Double-blind, Placebo-Controlled, Phase 1/2a Study.
    J Infect Dis. 2023 Jul 11:jiad220. doi: 10.1093.
    >> Share

  127. FERNANDEZ-GONZALEZ M, Agullo V, Garcia JA, Padilla S, et al
    T-cell immunity against SARS-CoV-2 measured by an interferon-gamma release assay is strongly associated with patient outcomes in vaccinated persons hospitalized with Delta or Omicron variants.
    J Infect Dis. 2023 Jul 7:jiad260. doi: 10.1093.
    >> Share

    June 2023
  128. SRINIVASA VR, Griffith MP, Waggle KD, Johnson M, et al
    Genomic Epidemiology of Severe Acute Respiratory Syndrome Coronavirus 2 Transmission Among University Students in Western Pennsylvania.
    J Infect Dis. 2023;228:37-45.
    >> Share

  129. NAYAK N, Pati A, Pavani Y, Sahu S, et al
    CCL19 (rs3136658) and CCL21 (rs2812377) Variants Are Associated With Susceptibility and Related Mortality of SARS-CoV-2 Infection.
    J Infect Dis. 2023;228:101-102.
    >> Share

  130. RAMILO O, Rodriguez-Fernandez R, Mejias A
    Respiratory Syncytial Virus Infection: Old Challenges and New Approaches.
    J Infect Dis. 2023;228:4-7.
    >> Share

  131. FUJITA S, Uriu K, Pan L, Nao N, et al
    Impact of imprinted immunity induced by mRNA vaccination in an experimental animal model.
    J Infect Dis. 2023 Jun 27:jiad230. doi: 10.1093.
    >> Share

  132. ARTENIE A, Stone J, Facente SN, Fraser H, et al
    Impact of HCV Testing and Treatment on HCV Transmission Among Men Who Have Sex With Men and Who Inject Drugs in San Francisco: A Modelling Analysis.
    J Infect Dis. 2023 Jun 24:jiad169. doi: 10.1093.
    >> Share

  133. RODRIGUES TS, Caetano CCS, de Sa KSG, Almeida L, et al
    CASP4/11 Contributes to NLRP3 Activation and COVID-19 Exacerbation.
    J Infect Dis. 2023;227:1364-1375.
    >> Share

  134. DEYOE JE, Kelly JD, Grijalva CG, Bonenfant G, et al
    Association of Culturable-Virus Detection and Household Transmission of SARS-CoV-2, California and Tennessee, 2020-2022.
    J Infect Dis. 2023;227:1343-1347.
    >> Share

  135. SCHIFFER JT
    The Continuing Puzzle of Defining Duration of Severe Acute Respiratory Syndrome Coronavirus 2 Infectivity.
    J Infect Dis. 2023;227:1339-1342.
    >> Share

  136. LEE KH, Won D, Kim J, Lee JA, et al
    Clinical Accuracy and Utility of Plasma Microbial Cell-Free DNA Whole-Genome Sequencing for the Diagnosis of Invasive Aspergillosis in Patients with Hematologic Malignancies or Coronavirus Disease 2019.
    J Infect Dis. 2023 Jun 15:jiad213. doi: 10.1093.
    >> Share

  137. ZHOU S, Long N, Moeser M, Hill CS, et al
    Use of Next Generation Sequencing in a State-Wide Strategy of HIV-1 Surveillance: Impact of the SARS-CoV-2 Pandemic on HIV-1 Diagnosis and Transmission.
    J Infect Dis. 2023 Jun 7:jiad211. doi: 10.1093.
    >> Share

  138. WANG W, Goguet E, Paz Padilla S, Vassell R, et al
    Bivalent COVID-19 vaccine antibody responses to Omicron variants suggest that responses to divergent variants would be improved with matched vaccine antigens.
    J Infect Dis. 2023 Jun 6:jiad111. doi: 10.1093.
    >> Share

  139. BROWN JA, Hauser A, Abela IA, Pasin C, et al
    Seroprofiling of antibodies against endemic human coronaviruses and SARS-CoV-2 in an HIV cohort in Lesotho: correlates of antibody response and seropositivity.
    J Infect Dis. 2023 Jun 1:jiad197. doi: 10.1093.
    >> Share

    May 2023
  140. KEELEY AJ, Groves D, Armitage EP, Senghore E, et al
    Streptococcus pyogenes colonization in children aged 24-59 months in The Gambia: Impact of Live Attenuated Influenza Vaccine and associated serological responses.
    J Infect Dis. 2023 May 29:jiad153. doi: 10.1093.
    >> Share

  141. SCHIFANELLA L, Anderson J, Wieking G, Southern PJ, et al
    The Defenders of the Alveolus Succumb in COVID-19 Pneumonia to SARS-CoV-2 and Necroptosis, Pyroptosis, and PANoptosis.
    J Infect Dis. 2023;227:1245-1254.
    >> Share

  142. BAKSH SN, Heath SL, Fukuta Y, Shade D, et al
    Symptom Duration and Resolution With Early Outpatient Treatment of Convalescent Plasma for Coronavirus Disease 2019: A Randomized Trial.
    J Infect Dis. 2023;227:1266-1273.
    >> Share

  143. FRIES L, Formica N, Mallory RM, Zhou H, et al
    Strong CD4+ T-Cell Responses to Ancestral and Variant Spike Proteins Are Established by NVX-CoV2373 SARS-CoV-2 Primary Vaccination.
    J Infect Dis. 2023 May 21:jiad163. doi: 10.1093.
    >> Share

  144. XIA X, Tan ZM, Wan P, Zheng H, et al
    Environmental impact assessment for the use of an orally aerosolised adenovirus type-5 vector-based COVID-19 vaccine in randomised clinical trials.
    J Infect Dis. 2023 May 18:jiad134. doi: 10.1093.
    >> Share

  145. FORTE-SOTO P, Albayaty M, Brooks D, Arends RH, et al
    Safety, Tolerability and Pharmacokinetics of Half-Life Extended Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Monoclonal Antibodies AZD7442 (Tixagevimab-Cilgavimab) in Healthy Adults.
    J Infect Dis. 2023;227:1153-1163.
    >> Share

  146. LAWLESS D, McKennan CG, Das SR, Junier T, et al
    Viral Genetic Determinants of Prolonged Respiratory Syncytial Virus Infection Among Infants in a Healthy Term Birth Cohort.
    J Infect Dis. 2023;227:1194-1202.
    >> Share

  147. SU W, Choy KT, Gu H, Sia SF, et al
    Reduced Pathogenicity and Transmission Potential of Omicron BA.1 and BA.2 Sublineages Compared with the Early Severe Acute Respiratory Syndrome Coronavirus 2 D614G Variant in Syrian Hamsters.
    J Infect Dis. 2023;227:1143-1152.
    >> Share

  148. DURSTENFELD MS, Peluso MJ, Kaveti P, Hill C, et al
    Reduced exercise capacity, chronotropic incompetence, and early systemic inflammation in cardiopulmonary phenotype Long COVID.
    J Infect Dis. 2023 May 11:jiad131. doi: 10.1093.
    >> Share

  149. ASSANTACHAI P, Niyomnaitham S, Chatthanawaree W, Intalapaporn S, et al
    Immunogenicity and reactogenicity of mRNA COVID-19 vaccine booster administered by intradermal or intramuscular route in Thai Older adults.
    J Infect Dis. 2023 May 4:jiad133. doi: 10.1093.
    >> Share

    April 2023
  150. TAMAI M, Taba S, Mise T, Yamashita M, et al
    Ethanol vapor inhalation treatment inhibits lethal respiratory viral infection with Influenza A.
    J Infect Dis. 2023 Apr 27:jiad089. doi: 10.1093.
    >> Share

  151. SINGH G, Abbad A, Tcheou J, Mendu DR, et al
    Binding and avidity signatures of polyclonal sera from individuals with different exposure histories to SARS-CoV-2 infection, vaccination, and Omicron breakthrough infections.
    J Infect Dis. 2023 Apr 27:jiad116. doi: 10.1093.
    >> Share

  152. IONESCU IG, Skowronski DM, Sauvageau C, Chuang E, et al
    BNT162b2 Effectiveness Against Delta and Omicron Variants of Severe Acute Respiratory Syndrome Coronavirus 2 in Adolescents Aged 12-17 Years, by Dosing Interval and Duration.
    J Infect Dis. 2023;227:1073-10783.
    >> Share

  153. VAN DER MAADEN T, Mutubuki EN, de Bruijn S, Leung KY, et al
    Prevalence and Severity of Symptoms 3 Months After Infection With SARS-CoV-2 Compared to Test-Negative and Population Controls in the Netherlands.
    J Infect Dis. 2023;227:1059-1067.
    >> Share

  154. KOBAYASHI H, Mori Y, Ahmed S, Hirao Y, et al
    Oxidative DNA Damage by N4-hydroxycytidine, a Metabolite of the SARS-CoV-2 Antiviral Molnupiravir.
    J Infect Dis. 2023;227:1068-1072.
    >> Share

  155. ALVAREZ-HEREDIA P, Reina-Alfonso I, Dominguez-Del Castillo JJ, Gutierrez-Gonzalez C, et al
    Accelerated T cell immunosenescence in CMV-seropositive individuals after SARS-CoV-2 infection.
    J Infect Dis. 2023 Apr 26:jiad119. doi: 10.1093.
    >> Share

  156. HOEVE CE, de Gier B, Huiberts AJ, de Melker HE, et al
    Vaccine effectiveness against SARS-CoV-2 Delta and Omicron infection and infectiousness within households in the Netherlands between July 2021 and August 2022.
    J Infect Dis. 2023 Apr 24:jiad110. doi: 10.1093.
    >> Share

  157. JORDAN E, Kabir G, Schultz S, Silbernagl G, et al
    Reduced Respiratory Syncytial Virus Load, Symptoms, and Infections: a Human Challenge Trial of MVA-BN-RSV Vaccine.
    J Infect Dis. 2023 Apr 20:jiad108. doi: 10.1093.
    >> Share

  158. RAN S, Yao J, Liu B
    Association Between Coronavirus Disease 2019 and Lung Function: A Mendelian Randomization Analysis.
    J Infect Dis. 2023;227:1019-1020.
    >> Share

  159. HWANG HS, Lo CM, Murphy M, Grudda T, et al
    Characterizing SARS-CoV-2 Transcription of Subgenomic and Genomic RNAs During Early Human Infection Using Multiplexed Droplet Digital Polymerase Chain Reaction.
    J Infect Dis. 2023;227:981-992.
    >> Share

  160. PRASAD N, Rhodes J, Deng L, McCarthy NL, et al
    Changes in the Incidence of Invasive Bacterial Disease During the COVID-19 Pandemic in the United States, 2014-2020.
    J Infect Dis. 2023;227:907-916.
    >> Share

  161. TENFORDE MW, Devine OJ, Reese HE, Silk BJ, et al
    Point Prevalence Estimates of Activity-Limiting Long-term Symptoms Among United States Adults >/=1 Month After Reported Severe Acute Respiratory Syndrome Coronavirus 2 Infection, 1 November 2021.
    J Infect Dis. 2023;227:855-863.
    >> Share

  162. TIMI P, Kellerhals SE, Joseph NT, Dude CM, et al
    Placental Injury and Antibody Transfer after Coronavirus Disease 2019 in Pregnancy.
    J Infect Dis. 2023;227:850-854.
    >> Share

  163. BLANKSON JN
    Bivalent COVID Vaccines; Can the Original Antigenic Sin be Forgiven?
    J Infect Dis. 2023 Apr 5:jiad073. doi: 10.1093.
    >> Share

  164. TANG L, Wang FZ, Rodewald LE, Wang XY, et al
    Real-world effectiveness of primary series and booster doses of inactivated COVID-19 vaccine against Omicron BA.2 variant infection in China: a retrospective cohort study.
    J Infect Dis. 2023 Apr 3:jiad090. doi: 10.1093.
    >> Share

    March 2023
  165. WINCHESTER NE, Shrestha NK, Kim P, Tereshchenko LG, et al
    Protection Conferred by Delta and BA.1/BA.2 Infection Against BA.4/BA.5 Infection and Hospitalization: A Retrospective Cohort Study.
    J Infect Dis. 2023;227:800-805.
    >> Share

  166. CHU Y, Milner J, Lamb M, Maryamchik E, et al
    Manufacture and Characterization of Good Manufacturing Practice-Compliant SARS-COV-2 Cytotoxic T Lymphocytes.
    J Infect Dis. 2023;227:788-799.
    >> Share

  167. THOUVENIN G, Prevost B, Corvol H
    Omicron Wave Modification of the Coronavirus Disease 2019 Paradigm in Children With Cystic Fibrosis.
    J Infect Dis. 2023;227:831-832.
    >> Share

  168. NURMI V, Knight C, Estcourt L, Hepojoki J, et al
    The relationship between SARS-CoV-2 neutralising antibody titres and avidity in plasma collected from convalescent non-vaccinated and vaccinated blood donors.
    J Infect Dis. 2023 Mar 27:jiad070. doi: 10.1093.
    >> Share

  169. SMITH CL, Bednarchik B, Aung H, Wilk DJ, et al
    Humoral and Cellular Immunity Induced by Adjuvanted and Standard Trivalent Influenza Vaccine in Older Nursing Home Residents.
    J Infect Dis. 2023 Mar 23:jiad071. doi: 10.1093.
    >> Share

  170. FEDSON DS
    In-Hospital Statin Treatment of COVID-19.
    J Infect Dis. 2023;227:731-732.
    >> Share

  171. SUN P, Balinsky CA, Jiang L, Jani V, et al
    Antibody Responses to the SARS-CoV-2 Ancestral Strain and Omicron Variants in Moderna mRNA-1273 Vaccinated Active-Duty U.S. Navy Sailors and Marines.
    J Infect Dis. 2023 Mar 1:jiad054. doi: 10.1093.
    >> Share

    February 2023
  172. CORTESE MM, Taylor AW, Akinbami LJ, Thames-Allen A, et al
    Surveillance for multisystem inflammatory syndrome in U.S. children aged 5-11 years who received Pfizer-BioNTech COVID-19 vaccine, November 2021-March 2022.
    J Infect Dis. 2023 Feb 23:jiad051. doi: 10.1093.
    >> Share

  173. BOZIO CH, Butterfield KA, Briggs Hagen M, Grannis S, et al
    Protection from COVID-19 mRNA vaccination and prior SARS-CoV-2 infection against COVID-19-associated encounters in adults during Delta and Omicron predominance.
    J Infect Dis. 2023 Feb 18:jiad040. doi: 10.1093.
    >> Share

  174. HUAPAYA JA, Higgins J, Kanth S, Demirkale C, et al
    Vaccination Ameliorates Cellular Inflammatory Responses in SARS-CoV-2 Breakthrough Infections.
    J Infect Dis. 2023 Feb 18:jiad045. doi: 10.1093.
    >> Share

  175. CHANDRA S
    Evolution of a 7-Mutant Strain of SARS-CoV-2 Within an Immunocompromised Person May Elucidate the Mechanism for the Generation of New Variants.
    J Infect Dis. 2023;227:602.
    >> Share

  176. ALTHAUS T, Landier J, Zhu F, Raps H, et al
    The impact of SARS-CoV-2 vaccination and infection on neutralising antibodies: a nation-wide cross-sectional analysis.
    J Infect Dis. 2023 Feb 14:jiad030. doi: 10.1093.
    >> Share

  177. HITCHINGS MDT, Borgert BA, Shir A, Yang B, et al
    Dynamics of anti-influenza mucosal IgA over a season in a cohort of individuals living or working in a long-term care facility.
    J Infect Dis. 2023 Feb 6:jiad029. doi: 10.1093.
    >> Share

  178. DESANTIS SM, Yaseen A, Hao T, Leon-Novelo L, et al
    Incidence and predictors of breakthrough and severe breakthrough infections of SARS-CoV-2 after primary series vaccination in adults: A population-based survey of 22,575 participants.
    J Infect Dis. 2023 Feb 2:jiad020. doi: 10.1093.
    >> Share

  179. BINDER RA, Fujimori GF, Forconi CS, Reed GW, et al
    SARS-CoV-2 Serosurveys: How Antigen, Isotype and Threshold Choices Affect the Outcome.
    J Infect Dis. 2023;227:371-380.
    >> Share

  180. CLARKE KEN, Kim Y, Jones J, Lee A, et al
    Pediatric Infection-Induced SARS-CoV-2 Seroprevalence Increases and Seroprevalence by Type of Clinical CareSeptember 2021 to February 2022.
    J Infect Dis. 2023;227:364-370.
    >> Share

  181. ESPER FP, Adhikari TM, Tu ZJ, Cheng YW, et al
    Alpha to Omicron: Disease Severity and Clinical Outcomes of Major SARS-CoV-2 Variants.
    J Infect Dis. 2023;227:344-352.
    >> Share

  182. TROBAJO-SANMARTN C, Miqueleiz A, Guevara M, Fernndez-Huerta M, et al
    Comparison of the Risk of Hospitalization and Severe Disease Among Co-circulating Severe Acute Respiratory Syndrome Coronavirus 2 Variants.
    J Infect Dis. 2023;227:332-338.
    >> Share

  183. PETERSON DR, Baran AM, Bhattacharya S, Branche AR, et al
    Gene Expression Risk Scores for COVID-19 Illness Severity.
    J Infect Dis. 2023;227:322-331.
    >> Share

  184. BEBIA Z, Reyes O, Jeanfreau R, Kantele A, et al
    Safety and immunogenicity of an investigational respiratory syncytial virus vaccine (RSVPreF3) in mothers and their infants: a phase 2 randomized trial.
    J Infect Dis. 2023 Feb 1:jiad024. doi: 10.1093.
    >> Share

    January 2023
  185. ORTIZ JR, Bernstein DI, Hoft DF, Woods CW, et al
    A Multi-Center, Controlled Human Infection Study of Influenza A (H1N1)pdm09 in Healthy Adults.
    J Infect Dis. 2023 Jan 26:jiad021. doi: 10.1093.
    >> Share

  186. TENFORDE MW, Weber ZA, DeSilva MB, Stenehjem E, et al
    Vaccine effectiveness against influenza-associated urgent care, emergency department, and hospital encounters during the 2021-2022 season, VISION Network.
    J Infect Dis. 2023 Jan 23:jiad015. doi: 10.1093.
    >> Share

  187. TSANG TK, Gostic KM, Chen S, Wang Y, et al
    Investigation of impact of childhood immune imprinting on birth year-specific risk of clinical infection during influenza A virus epidemics in Hong Kong.
    J Infect Dis. 2023 Jan 13:jiad009. doi: 10.1093.
    >> Share

  188. LAMPL BMJ, Leitzmann MF, Salzberger B
    Prevalence of Post-COVID-19 Conditions Depends on the Method of Assessment.
    J Infect Dis. 2023;227:306.
    >> Share

  189. CAMBOU MC, Liu CM, Mok T, Fajardo-Martinez V, et al
    Longitudinal Evaluation of Antibody Persistence in Mother-Infant Dyads After Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Pregnancy.
    J Infect Dis. 2023;227:236-245.
    >> Share

  190. SHEHADEH F, Benitez G, Mylona EK, Tran QL, et al
    A Pilot Trial of Thymalfasin (Thymosin-alpha-1) to Treat Hospitalized Patients With Hypoxemia and Lymphocytopenia Due to Coronavirus Disease 2019 Infection.
    J Infect Dis. 2023;227:226-235.
    >> Share

  191. HUYGENS S, Hofsink Q, Nijhof IS, Goorhuis A, et al
    Hyperimmune Globulin for Severely Immunocompromised Patients Hospitalized With Coronavirus Disease 2019: A Randomized, Controlled Trial.
    J Infect Dis. 2023;227:206-210.
    >> Share

  192. STAUFT CB, Sangare K, Wang TT
    Differences in New Variant of Concern Replication at Physiological Temperatures In Vitro.
    J Infect Dis. 2023;227:202-205.
    >> Share

  193. SWARTZ MD, DeSantis SM, Yaseen A, Brito FA, et al
    Antibody Duration After Infection From SARS-CoV-2 in the Texas Coronavirus Antibody Response Survey.
    J Infect Dis. 2023;227:193-201.
    >> Share

  194. PEEBLES K, Arciuolo RJ, Romano AS, Sell J, et al
    Pfizer-BioNTech COVID-19 vaccine effectiveness against SARS-CoV-2 infection among long-term care facility staff with and without prior infection in New York City, January-June 2021.
    J Infect Dis. 2023 Jan 10:jiac448. doi: 10.1093.
    >> Share

  195. WURSTER S, Garcia JP, Albert ND, Jiang Y, et al
    Development of a corticosteroid-immunosuppressed mouse model to study the pathogenesis and therapy of influenza-associated pulmonary aspergillosis.
    J Infect Dis. 2023 Jan 6:jiad001. doi: 10.1093.
    >> Share

    December 2022
  196. FALSEY AR, Cameron A, Branche AR, Walsh EE, et al
    Perturbations in Respiratory Syncytial Virus Activity During the SARS-CoV-2 Pandemic.
    J Infect Dis. 2022;227:83-86.
    >> Share

  197. TAVERAS J, Garcia-Maurino C, Moore-Clingenpeel M, Xu Z, et al
    Type III Interferons, Viral Loads, Age, and Disease Severity in Young Children With Respiratory Syncytial Virus Infection.
    J Infect Dis. 2022;227:61-70.
    >> Share

  198. LUCZKOWIAK J, Radreau P, Nguyen L, Labiod N, et al
    Potent Neutralizing Activity of Polyclonal Equine Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern.
    J Infect Dis. 2022;227:35-39.
    >> Share

  199. MANALI M, Bissett LA, Amat JAR, Logan N, et al
    SARS-CoV-2 Evolution and Patient Immunological History Shape the Breadth and Potency of Antibody-Mediated Immunity.
    J Infect Dis. 2022;227:40-49.
    >> Share

  200. SOMERSAN-KARAKAYA S, Mylonakis E, Menon VP, Wells JC, et al
    Casirivimab and Imdevimab for the Treatment of Hospitalized Patients With COVID-19.
    J Infect Dis. 2022;227:23-34.
    >> Share

  201. KATO Y, Bloom NI, Sun P, Balinsky CA, et al
    Memory B-Cell Development After Asymptomatic or Mild Symptomatic SARS-CoV-2 Infection.
    J Infect Dis. 2022;227:18-22.
    >> Share

  202. BINNY RN, Priest P, French NP, Parry M, et al
    Sensitivity of Reverse Transcription Polymerase Chain Reaction Tests for Severe Acute Respiratory Syndrome Coronavirus 2 Through Time.
    J Infect Dis. 2022;227:9-17.
    >> Share

  203. DEE K, Schultz V, Haney J, Bissett LA, et al
    Influenza A and respiratory syncytial virus trigger a cellular response that blocks severe acute respiratory syndrome virus 2 infection in the respiratory tract.
    J Infect Dis. 2022 Dec 23:jiac494. doi: 10.1093.
    >> Share

  204. NAKAGAMA Y, Candray K, Kaku N, Komase Y, et al
    Antibody avidity maturation, following recovery from infection or the booster vaccination, grants breadth in SARS-CoV-2 neutralizing capacity.
    J Infect Dis. 2022 Dec 22:jiac492. doi: 10.1093.
    >> Share

  205. GANLY KH, Bowyer JC, Bird PW, Willford NJ, et al
    Prospective Surveillance of Respiratory Infections in British Antarctic Survey Bases During the COVID-19 Pandemic.
    J Infect Dis. 2022;226:2105-2112.
    >> Share

  206. MCINTOSH K, Perlman S, Monto A, Englund JA, et al
    A Proposal to Refer to Four Coronaviruses of Limited Human Virulence "Common Cold Coronaviruses".
    J Infect Dis. 2022;226:2047-2049.
    >> Share

  207. PIZZORNO A, Padey B, Duliere V, Mouton W, et al
    Interactions Between Severe Acute Respiratory Syndrome Coronavirus 2 Replication and Major Respiratory Viruses in Human Nasal Epithelium.
    J Infect Dis. 2022;226:2095-2104.
    >> Share

  208. TVEITA A, Murphy SL, Holter JC, Kildal AB, et al
    High Circulating Levels of the Homeostatic Chemokines CCL19 and CCL21 Predict Mortality and Disease Severity in COVID-19.
    J Infect Dis. 2022;226:2150-2160.
    >> Share

  209. SCHWAB LSU, Farrukee R, Eleouet JF, Rameix-Welti MA, et al
    Retinoic Acid-Inducible Gene I Activation Inhibits Human Respiratory Syncytial Virus Replication in Mammalian Cells and in Mouse and Ferret Models of Infection.
    J Infect Dis. 2022;226:2079-2088.
    >> Share

  210. VASYLYEVA TI, Fang CE, Su M, Havens JL, et al
    Introduction and Establishment of SARS-CoV-2 Gamma Variant in New York City in Early 2021.
    J Infect Dis. 2022;226:2142-2149.
    >> Share

  211. FAHNOE U, Ronit A, Berg RMG, Jorgensen SE, et al
    A Distinct Dexamethasone-Dependent Gene Expression Profile in the Lungs of COVID-19 Patients.
    J Infect Dis. 2022;226:2137-2141.
    >> Share

  212. ZOBRIST S, Oliveira-Silva M, Vieira AM, Bansil P, et al
    Screening for Severe Acute Respiratory Syndrome Coronavirus 2 in Close Contacts of Individuals With Confirmed Infection: Performance and Operational Considerations.
    J Infect Dis. 2022;226:2118-2128.
    >> Share

  213. AGGARWAL NR, Beaty LE, Bennett TD, Carlson NE, et al
    Real-World Evidence of the Neutralizing Monoclonal Antibody Sotrovimab for Preventing Hospitalization and Mortality in COVID-19 Outpatients.
    J Infect Dis. 2022;226:2129-2136.
    >> Share

  214. REICHERZ F, Xu RY, Abu-Raya B, Majdoubi A, et al
    Waning Immunity Against Respiratory Syncytial Virus During the Coronavirus Disease 2019 Pandemic.
    J Infect Dis. 2022;226:2064-2068.
    >> Share

  215. GALLOWAY A, Park Y, Tanukonda V, Ho YL, et al
    Impact of Coronavirus Disease 2019 (COVID-19) Severity on Long-term Events in United States Veterans Using the Veterans Affairs Severity Index for COVID-19 (VASIC).
    J Infect Dis. 2022;226:2113-2117.
    >> Share

  216. MEYER M, Ruebsteck E, Eifinger F, Klein F, et al
    Morbidity of Respiratory Syncytial Virus (RSV) Infections: RSV Compared With Severe Acute Respiratory Syndrome Coronavirus 2 Infections in Children Aged 0-4 Years in Cologne, Germany.
    J Infect Dis. 2022;226:2050-2053.
    >> Share

  217. DIEZ-DOMINGO J, Saez-Llorens X, Rodriguez-Weber MA, Epalza C, et al
    Safety and immunogenicity of a ChAd155-vectored RSV vaccine (ChAd155-RSV) in healthy RSV-seropositive children 12-23 months of age.
    J Infect Dis. 2022 Dec 9:jiac481. doi: 10.1093.
    >> Share

  218. SHIODA K, Chen Y, Collins MH, Lopman BA, et al
    Population-Level Relative Effectiveness of the COVID-19 Vaccines and the Contribution of Naturally Acquired Immunity.
    J Infect Dis. 2022 Dec 7:jiac483. doi: 10.1093.
    >> Share

  219. GREWAL R, Nguyen L, Buchan SA, Wilson SE, et al
    Effectiveness and Duration of Protection of a Fourth Dose of COVID-19 mRNA Vaccine among Long-Term Care Residents in Ontario, Canada.
    J Infect Dis. 2022 Dec 3:jiac468. doi: 10.1093.
    >> Share

    November 2022
  220. PADHI S, Nayak N, Sarangi S, Nahak SK, et al
    Association of Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Related Mortality Rates With Mental Disorders: An Epidemiological Correlation in the Indian Population.
    J Infect Dis. 2022;226:2037-2038.
    >> Share

  221. STIRRUP O, Krutikov M, Tut G, Palmer T, et al
    Severe Acute Respiratory Syndrome Coronavirus 2 Anti-Spike Antibody Levels Following Second Dose of ChAdOx1 nCov-19 or BNT162b2 Vaccine in Residents of Long-term Care Facilities in England (VIVALDI).
    J Infect Dis. 2022;226:1877-1881.
    >> Share

  222. MONTO AS, Lauring AS, Martin ET
    SARS-CoV-2 Vaccine Strain Selection: Guidance from Influenza.
    J Infect Dis. 2022 Nov 25:jiac454. doi: 10.1093.
    >> Share

  223. WANG X, Zein J, Ji X, Lin DY, et al
    Impact of Vaccination, Prior Infection and Therapy on Omicron Infection and Mortality.
    J Infect Dis. 2022 Nov 23:jiac460. doi: 10.1093.
    >> Share

  224. DESILVA MB, Mitchell PK, Klein NP, Dixon BE, et al
    Protection of 2 and 3 mRNA Vaccine Doses Against Severe Outcomes Among Adults Hospitalized with COVID-19 - VISION Network, August 2021 - March 2022.
    J Infect Dis. 2022 Nov 23:jiac458. doi: 10.1093.
    >> Share

  225. HAMUSONDE K, Nicca D, Gunthard HF, Stockle M, et al
    Triggers of change in sexual behavior among people with HIV: The Swiss U = U statement and Covid-19 compared.
    J Infect Dis. 2022 Nov 21:jiac459. doi: 10.1093.
    >> Share

  226. PERERA MR, Greenwood EJ, Crozier TW, Elder EG, et al
    Human cytomegalovirus infection of epithelial cells increases SARS-CoV-2 superinfection by upregulating the ACE2 receptor.
    J Infect Dis. 2022 Nov 21:jiac452. doi: 10.1093.
    >> Share

  227. TOMETTEN I, Landmann S, Kantauskaite M, Lamberti J, et al
    Factors associated with vaccine-induced T cell immune responses against SARS-CoV-2 in kidney transplant recipients.
    J Infect Dis. 2022 Nov 21:jiac449. doi: 10.1093.
    >> Share

  228. LIND ML, Copin R, McCarthy S, Coppi A, et al
    Use of whole genome sequencing to estimate the contribution of immune evasion and waning immunity on decreasing COVID-19 vaccine effectiveness.
    J Infect Dis. 2022 Nov 21:jiac453. doi: 10.1093.
    >> Share

  229. JONGKEES MJ, Geers D, Hensley KS, Huisman W, et al
    Immunogenicity of an additional mRNA-1273 SARS-CoV-2 vaccination in people with HIV with hyporesponse after primary vaccination.
    J Infect Dis. 2022 Nov 19:jiac451. doi: 10.1093.
    >> Share

  230. TURCINOVIC J, Schaeffer B, Taylor BP, Bouton TC, et al
    Understanding Early Pandemic Severe Acute Respiratory Syndrome Coronavirus 2 Transmission in a Medical Center by Incorporating Public Sequencing Databases to Mitigate Bias.
    J Infect Dis. 2022;226:1704-1711.
    >> Share

  231. DEWALD F, Detmer S, Pirkl M, Hellmich M, et al
    Viral Load Dynamics in SARS-CoV-2 Omicron Breakthrough Infections.
    J Infect Dis. 2022;226:1721-1725.
    >> Share

  232. HAKRE S, Lakhal-Naouar I, King DB, Burns JL, et al
    Virological and Serological Assessment of US Army Trainees Isolated for Coronavirus Disease 2019.
    J Infect Dis. 2022;226:1743-1752.
    >> Share

  233. MELLIS AM, Meece JK, Halasa NB, Chappell JD, et al
    SARS-CoV-2 Virus Dynamics in Recently Infected People-Data From a Household Transmission Study.
    J Infect Dis. 2022;226:1699-1703.
    >> Share

  234. EIDEN J, Fierro C, Schwartz H, Adams M, et al
    Intranasal M2SR (M2-deficient Single Replication) H3N2 Influenza Vaccine Provides Enhanced Mucosal and Serum Antibodies In Adults.
    J Infect Dis. 2022 Nov 9. pii: 6807529. doi: 10.1093.
    >> Share

  235. VERKERKE HP, Damhorst GL, Graciaa DS, McLendon K, et al
    Nucleocapsid Antigenemia Is a Marker of Acute SARS-CoV-2 Infection.
    J Infect Dis. 2022;226:1577-1587.
    >> Share

  236. ZHANG Y, Gao J, Huang K, Zhao Y, et al
    SARS-CoV-2 Infection Causes Hyperglycemia in Cats.
    J Infect Dis. 2022;226:1568-1576.
    >> Share

  237. SHIH PY, Chou YH, Wei JC
    The Potential Confounders Hiding in a United States Cohort About Severe Acute Respiratory Syndrome Coronavirus 2 Infection During Pregnancy.
    J Infect Dis. 2022;226:1678.
    >> Share

  238. ARAH OA, Sullivan SG, Fell DB, Regan AK, et al
    Analyzing Uncontrolled Confounding of the Perinatal Health Effects of Severe Acute Respiratory Syndrome Coronavirus 2 Infection During Pregnancy.
    J Infect Dis. 2022;226:1678-1680.
    >> Share

  239. MEISTER TL, Dreismeier M, Blanco EV, Bruggemann Y, et al
    Low Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Transmission by Fomites: A Clinical Observational Study in Highly Infectious Coronavirus Disease 2019 Patients.
    J Infect Dis. 2022;226:1608-1615.
    >> Share

  240. KUO TY, Lien CE, Lin YJ, Lin MY, et al
    Hamsters Protected from SARS-CoV-2 Delta Variant Challenge after Two Doses of Adjuvanted SARS-CoV-2 Recombinant Spike Protein (S-2P) and One Dose of Beta S-2P.
    J Infect Dis. 2022;226:1562-1567.
    >> Share

  241. BEDDINGFIELD BJ, Rowe LA, Russell-Lodrigue KE, Doyle-Meyers LA, et al
    Breakthrough Gastrointestinal COVID-19 and Intrahost Evolution Consequent to Combination Monoclonal Antibody Prophylaxis.
    J Infect Dis. 2022;226:1588-1592.
    >> Share

  242. CHEN C, Haupert SR, Zimmermann L, Shi X, et al
    Global Prevalence of Post-Coronavirus Disease 2019 (COVID-19) Condition or Long COVID: A Meta-Analysis and Systematic Review.
    J Infect Dis. 2022;226:1593-1607.
    >> Share

  243. JAGER M, Dichtl S, Bellmann-Weiler R, Reindl M, et al
    Serum neutralization against SARS-CoV-2 variants is heterogenic and depends on vaccination regimen.
    J Infect Dis. 2022 Nov 1. pii: 6783141. doi: 10.1093.
    >> Share

    October 2022
  244. ROE MK, Perez MA, Hsiao HM, Lapp SA, et al
    An RSV live-attenuated vaccine candidate lacking G protein mucin domains is attenuated, immunogenic, and effective in preventing RSV in BALB/c mice.
    J Infect Dis. 2022 Oct 25. pii: 6770706. doi: 10.1093.
    >> Share

  245. ANDERSON M, Stec M, Gosha A, Mohammad T, et al
    Longitudinal SARS-CoV-2 Vaccine Antibody Responses and Identification of Vaccine Breakthrough Infections Among Healthcare Workers Using Nucleocapsid IgG.
    J Infect Dis. 2022 Oct 20. pii: 6764413. doi: 10.1093.
    >> Share

  246. LAAKE I, Skodvin SN, Blix K, Caspersen IH, et al
    Effectiveness of mRNA booster vaccination against mild, moderate, and severe COVID-19 caused by the Omicron variant in a large, population-based, Norwegian cohort.
    J Infect Dis. 2022 Oct 19. pii: 6763324. doi: 10.1093.
    >> Share

  247. STUART A, Virta M, Williams K, Seppa I, et al
    Phase 1/2a Safety and Immunogenicity of an Adenovirus 26 Vector RSV Vaccine Encoding Prefusion F in Adults 18-50 Years and RSV Seropositive Children 12-24 Months.
    J Infect Dis. 2022 Oct 19. pii: 6763323. doi: 10.1093.
    >> Share

  248. AGALLOU M, Koutsoni OS, Michail M, Zisimopoulou P, et al
    Antibody and T cell subsets analysis unveils an immune profile heterogeneity mediating long-term responses in individuals vaccinated against SARS-CoV-2.
    J Infect Dis. 2022 Oct 19. pii: 6763327. doi: 10.1093.
    >> Share

  249. FARCET MR, Karbiener M, Knotzer S, Schwaiger J, et al
    Omicron Severe Acute Respiratory Syndrome Coronavirus 2 Neutralization by Immunoglobulin Preparations Manufactured From Plasma Collected in the United States and Europe.
    J Infect Dis. 2022;226:1396-1400.
    >> Share

  250. JOHNSON R, Mangwana N, Sharma JR, Muller CJF, et al
    Delineating the Spread and Prevalence of SARS-CoV-2 Omicron Sublineages (BA.1-BA.5) and Deltacron Using Wastewater in the Western Cape, South Africa.
    J Infect Dis. 2022;226:1418-1427.
    >> Share

  251. BUTOWT R, Bilinska K, von Bartheld C
    Why Does the Omicron Variant Largely Spare Olfactory Function? Implications for the Pathogenesis of Anosmia in Coronavirus Disease 2019.
    J Infect Dis. 2022;226:1304-1308.
    >> Share

  252. FARCET MR, Karbiener M, Schwaiger J, Ilk R, et al
    Rapidly Increasing Severe Acute Respiratory Syndrome Coronavirus 2 Neutralization by Intravenous Immunoglobulins Produced From Plasma Collected During the 2020 Pandemic.
    J Infect Dis. 2022;226:1357-1361.
    >> Share

  253. JONES PS, Yeh KW, Brosnan HK, Regos-Stewart D, et al
    Evaluation of the Homeless Management Information System for COVID-19 Surveillance Among People Experiencing Homelessness.
    J Infect Dis. 2022;226.
    >> Share

  254. SHOVER CL, Rosen A, Mata J, Robie B, et al
    Engaging Same-Day Peer Ambassadors to Increase Coronavirus Disease 2019 Vaccination Among People Experiencing Unsheltered Homelessness in Los Angeles County: A Hybrid Feasibility-Evaluation Study.
    J Infect Dis. 2022;226.
    >> Share

  255. GIBSON C, Schumann C, Neuschel K, McBride JA, et al
    COVID-19 Vaccination Coverage Among People Experiencing Homelessness in a Highly Vaccinated Midwest County-Dane County, Wisconsin, 2021.
    J Infect Dis. 2022;226.
    >> Share

  256. ALLEN EM, Smither B, Barranco L, Reynolds J, et al
    Communicating Effectively With People Experiencing Homelessness to Prevent Infectious Diseases.
    J Infect Dis. 2022;226.
    >> Share

  257. CHOW EJ, Casto AM, Roychoudhury P, Han PD, et al
    The Clinical and Genomic Epidemiology of Rhinovirus in Homeless Shelters-King County, Washington.
    J Infect Dis. 2022;226.
    >> Share

  258. BENET S, Blanch-Lombarte O, Ainsua-Enrich E, Pedreno-Lopez N, et al
    Limited humoral and specific T-cell responses after SARS-CoV-2 vaccination in PLWH with poor immune reconstitution.
    J Infect Dis. 2022 Oct 6. pii: 6749018. doi: 10.1093.
    >> Share

  259. ASAMOAH-BOAHENG M, Goldfarb DM, Karim ME, O'Brien SF, et al
    The relationship between anti-spike SARS-CoV-2 antibody levels and risk of breakthrough COVID-19 among fully vaccinated adults.
    J Infect Dis. 2022 Oct 5. pii: 6748952. doi: 10.1093.
    >> Share

    September 2022
  260. KUMAR NP, Venkataraman A, Nancy A, Moideen K, et al
    Enhanced Severe Acute Respiratory Syndrome Coronavirus 2 Antigen-Specific Systemic Immune Responses in Multisystem Inflammatory Syndrome in Children and Reversal After Recovery.
    J Infect Dis. 2022;226:1215-1223.
    >> Share

  261. GOMEZ-CARBALLA A, Pischedda S, Rivero-Calle I, Montoto-Louzao J, et al
    CD14 and Related Genes in Respiratory Morbidity After Respiratory Syncytial Virus Infection.
    J Infect Dis. 2022;226:1295-1297.
    >> Share

  262. CHOE PG, Hong J, Park J, Chang E, et al
    Persistent Antibody Responses Up to 18 Months After Mild Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
    J Infect Dis. 2022;226:1224-1230.
    >> Share

  263. WRIGHT PF, Prevost-Reilly AC, Natarajan H, Brickley EB, et al
    Longitudinal Systemic and Mucosal Immune Responses to SARS-CoV-2 Infection.
    J Infect Dis. 2022;226:1204-1214.
    >> Share

  264. URIU K, Cardenas P, Munoz E, Barragan V, et al
    Characterization of the Immune Resistance of Severe Acute Respiratory Syndrome Coronavirus 2 Mu Variant and the Robust Immunity Induced by Mu Infection.
    J Infect Dis. 2022;226:1200-1203.
    >> Share

  265. FURUKAWA K, Kurahashi Y, Ishimaru H, Nishimura M, et al
    The number of COVID-19 vaccine doses and severe clinical outcomes in older patients infected with a SARS-CoV-2 Omicron variant.
    J Infect Dis. 2022 Sep 26. pii: 6717967. doi: 10.1093.
    >> Share

  266. LUNA-MUSCHI A, Noguera SV, Borges IC, De Paula AV, et al
    Characterization of SARS-CoV-2 Omicron variant shedding and predictors of viral culture positivity on vaccinated healthcare workers with mild COVID-19.
    J Infect Dis. 2022 Sep 22. pii: 6711076. doi: 10.1093.
    >> Share

  267. AMANO M, Otsu S, Ichikawa Y, Higashi-Kuwata N, et al
    Restoration of neutralization activity against Omicrons BA.2 and BA.5 in older adults and individuals with risk factors following the 4th-dose of SARS-CoV-2 BNT162b2 vaccine.
    J Infect Dis. 2022 Sep 22. pii: 6711120. doi: 10.1093.
    >> Share

  268. NOH JY, Yang JS, Hwang SY, Hyun H, et al
    Duration of Humoral Immunity and Cross-Neutralizing Activity Against the Alpha, Beta, and Delta Variants After Wild-Type Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Prospective Cohort Study.
    J Infect Dis. 2022;226:975-978.
    >> Share

  269. FEROLLA FM, Yfran EW, Ballerini MG, Caratozzolo A, et al
    Serum Vitamin D Levels and Life-Threatening Respiratory Syncytial Virus Infection in Previously Healthy Infants.
    J Infect Dis. 2022;226:958-966.
    >> Share

  270. AVERY RK, Prono MVD
    Bebtelovimab in the Real World: Promise and Fulfillment.
    J Infect Dis. 2022 Sep 17. pii: 6702587. doi: 10.1093.
    >> Share

  271. RAZONABLE RR, O'Horo JC, Hanson SN, Arndt RF, et al
    Outcomes of Bebtelovimab Treatment is Comparable to Ritonavir-boosted Nirmatrelvir among High-Risk Patients with Coronavirus Disease-2019 during SARS-CoV-2 BA.2 Omicron Epoch.
    J Infect Dis. 2022 Sep 17. pii: 6702534. doi: 10.1093.
    >> Share

  272. ROSSLER A, Kimpel J, Fleischer V, Huber S, et al
    Regimen of COVID-19 vaccination influences extent and kinetics of antibody avidity.
    J Infect Dis. 2022 Sep 16. pii: 6701886. doi: 10.1093.
    >> Share

  273. ATKINSON TP
    Defective Immune Response to SARS-CoV-2 Immunization in Down Syndrome Correlates With Increased Susceptibility to Severe Illness With Infection.
    J Infect Dis. 2022;226:755-756.
    >> Share

  274. KU JH, Levin MJ, Luo Y, Florea A, et al
    Risk of Severe Coronavirus Disease 2019 Disease in Individuals With Down Syndrome: A Matched Cohort Study From a Large, Integrated Health Care System.
    J Infect Dis. 2022;226:757-765.
    >> Share

  275. PEART AKINDELE N, Pieterse L, Suwanmanee S, Griffin DE, et al
    B-Cell Responses in Hospitalized Severe Acute Respiratory Syndrome Coronavirus 2-Infected Children With and Without Multisystem Inflammatory Syndrome.
    J Infect Dis. 2022;226:822-832.
    >> Share

  276. FRICKE-GALINDO I, Buendia-Roldan I, Ruiz A, Palacios Y, et al
    TNFRSF1B and TNF Variants Are Associated With Differences in Levels of Soluble Tumor Necrosis Factor Receptors in Patients With Severe COVID-19.
    J Infect Dis. 2022;226:778-787.
    >> Share

  277. CASTANHA PMS, Tuttle DJ, Kitsios GD, Jacobs JL, et al
    Contribution of Coronavirus-Specific Immunoglobulin G Responses to Complement Overactivation in Patients with Severe Coronavirus Disease 2019.
    J Infect Dis. 2022;226:766-777.
    >> Share

  278. VEYRENCHE N, Pisoni A, Debiesse S, Bollore K, et al
    Severe Acute Respiratory Syndrome Coronavirus 2 Nucleocapsid Antigen in Urine of Hospitalized Patients With Coronavirus Disease 2019.
    J Infect Dis. 2022;226:812-821.
    >> Share

  279. NYBERG T, Harman K, Zaidi A, Seaman SR, et al
    Hospitalization and Mortality Risk for COVID-19 Cases With SARS-CoV-2 AY.4.2 (VUI-21OCT-01) Compared to Non-AY.4.2 Delta Variant Sublineages.
    J Infect Dis. 2022;226:808-811.
    >> Share

  280. DEMING ME, Dong TQ, Agrawal V, Mills MG, et al
    Detection and Kinetics of Subgenomic Severe Acute Respiratory Syndrome Coronavirus 2 RNA Viral Load in Longitudinal Diagnostic RNA-Positive Samples.
    J Infect Dis. 2022;226:788-796.
    >> Share

  281. PELUSO MJ, Mitchell A, Wang CY, Takahashi S, et al
    Low Prevalence of Interferon-alpha Autoantibodies in People Experiencing Long COVID Symptoms.
    J Infect Dis. 2022 Sep 12. pii: 6696027. doi: 10.1093.
    >> Share

  282. ACOSTA-AMPUDIA Y, Anaya JM
    Reply to Cimolai: Post-COVID syndrome and autoimmunity.
    J Infect Dis. 2022;226:753-754.
    >> Share

  283. CIMOLAI N
    Autoantibodies and COVID-19: Rediscovering Nonspecific Polyclonal B-Cell Activation?
    J Infect Dis. 2022;226:751-752.
    >> Share

  284. TANG J, Grubbs G, Lee Y, Wu H, et al
    Increased Antibody Avidity and Cross-Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 Variants by Hyperimmunized Transchromosomic Bovine-Derived Human Immunoglobulins for Treatment of Coronavirus Disease 2019.
    J Infect Dis. 2022;226:655-663.
    >> Share

  285. KANNENBERG J, Trawinski H, Henschler R, Buhmann R, et al
    Antibody Course and Memory B-Cell Response in the First Year After Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
    J Infect Dis. 2022;226:664-672.
    >> Share

  286. YANG B, Wong IOL, Xiao J, Tsang TK, et al
    Effectiveness of CoronaVac and BNT162b2 vaccine against SARS-CoV-2 Omicron BA.2 infections in Hong Kong.
    J Infect Dis. 2022 Sep 2. pii: 6687716. doi: 10.1093.
    >> Share

    August 2022
  287. LANGLEY JM, Bianco V, Domachowske JB, Madhi SA, et al
    Incidence of Respiratory Syncytial Virus Lower Respiratory Tract Infections During the First 2 Years of Life: A Prospective Study Across Diverse Global Settings.
    J Infect Dis. 2022;226:374-385.
    >> Share

  288. HARTMANN K, Liese JG, Kemmling D, Prifert C, et al
    Clinical Burden of Respiratory Syncytial Virus in Hospitalized Children Aged
    J Infect Dis. 2022;226:386-395.
    >> Share

  289. WANG J, Li D, Cameron A, Zhou Q, et al
    IgG Against Human Betacoronavirus Spike Proteins Correlates With SARS-CoV-2 Anti-Spike IgG Responses and COVID-19 Disease Severity.
    J Infect Dis. 2022;226:474-484.
    >> Share

  290. SADOFF J, De Paepe E, DeVincenzo J, Gymnopoulou E, et al
    Prevention of Respiratory Syncytial Virus Infection in Healthy Adults by a Single Immunization of Ad26.RSV.preF in a Human Challenge Study.
    J Infect Dis. 2022;226:396-406.
    >> Share

  291. KLOMPAS M, Rhee C
    Optimizing and Unifying Infection Control Precautions for Respiratory Viral Infections.
    J Infect Dis. 2022;226:191-194.
    >> Share

  292. LANDRY SA, Subedi D, Barr JJ, MacDonald MI, et al
    Fit-Tested N95 Masks Combined With Portable High-Efficiency Particulate Air Filtration Can Protect Against High Aerosolized Viral Loads Over Prolonged Periods at Close Range.
    J Infect Dis. 2022;226:199-207.
    >> Share

  293. BESTEMAN SB, Phung E, Raeven HHM, Amatngalim GD, et al
    Recurrent Respiratory Syncytial Virus Infection in a CD14-Deficient Patient.
    J Infect Dis. 2022;226:258-269.
    >> Share

  294. MORENS DM, Folkers GK, Fauci AS
    The Concept of Classical Herd Immunity May Not Apply to COVID-19.
    J Infect Dis. 2022;226:195-198.
    >> Share

  295. FRIEDMAN-KLABANOFF DJ, Fitzpatrick MC, Deming ME, Agrawal V, et al
    Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Acquisition Is Associated With Individual Exposure but Not Community-Level Transmission.
    J Infect Dis. 2022;226:225-235.
    >> Share

  296. CASTO AM, Rogers JH, Link AC, Boeckh M, et al
    Phylogenomics of Severe Acute Respiratory Syndrome Coronavirus 2 in Emergency Shelters for People Experiencing Homelessness.
    J Infect Dis. 2022;226:217-224.
    >> Share

  297. TORNELL A, Grauers Wiktorin H, Ringlander J, Arabpour M, et al
    Rapid Cytokine Release Assays for Analysis of Severe Acute Respiratory Syndrome Coronavirus 2-Specific T Cells in Whole Blood.
    J Infect Dis. 2022;226:208-216.
    >> Share

  298. BALTRUSAITIS K, Reed C, Sewalk K, Brownstein JS, et al
    Healthcare-Seeking Behavior for Respiratory Illness Among Flu Near You Participants in the United States During the 2015-2016 Through 2018-2019 Influenza Seasons.
    J Infect Dis. 2022;226:270-277.
    >> Share

  299. WAGHMARE A, Krantz EM, Baral S, Vasquez E, et al
    Reliability of Self-Sampling for Accurate Assessment of Respiratory Virus Viral and Immunologic Kinetics.
    J Infect Dis. 2022;226:278-286.
    >> Share

  300. LEE S, Zhang Y, Newhams M, Novak T, et al
    DDX58 is Associated with Susceptibility to Severe Influenza Virus Infection in Children and Adolescents.
    J Infect Dis. 2022 Aug 20. pii: 6672861. doi: 10.1093.
    >> Share

  301. MIYAKAWA K, Kato H, Ohtake N, Stanleyraj Jeremiah S, et al
    Enhancement of humoral and cellular immunity against SARS-CoV-2 by a third dose of BNT162b2 vaccine in Japanese healthcare workers.
    J Infect Dis. 2022 Aug 18. pii: 6670905. doi: 10.1093.
    >> Share

  302. GREEN WD, Alwarawrah Y, Al-Shaer AE, Shi Q, et al
    Inflammation and metabolism of influenza-stimulated PBMCs from adults with obesity following bariatric surgery.
    J Infect Dis. 2022 Aug 17. pii: 6670556. doi: 10.1093.
    >> Share

  303. HWA SH, Snyman J, Bernstein M, Ganga Y, et al
    HIV viremia is associated with compromised SARS-CoV-2 Beta variant neutralization.
    J Infect Dis. 2022 Aug 17. pii: 6670446. doi: 10.1093.
    >> Share

  304. SUH M, Movva N, Jiang X, Reichert H, et al
    Respiratory Syncytial Virus Burden and Healthcare Utilization in United States Infants <1 Year of Age: Study of Nationally Representative Databases, 2011-2019.
    J Infect Dis. 2022;226.
    >> Share

  305. SUH M, Movva N, Jiang X, Bylsma LC, et al
    Respiratory Syncytial Virus Is the Leading Cause of United States Infant Hospitalizations, 2009-2019: A Study of the National (Nationwide) Inpatient Sample.
    J Infect Dis. 2022;226.
    >> Share

  306. REICHERT H, Suh M, Jiang X, Movva N, et al
    Mortality Associated With Respiratory Syncytial Virus, Bronchiolitis, and Influenza Among Infants in the United States: A Birth Cohort Study From 1999 to 2018.
    J Infect Dis. 2022;226.
    >> Share

  307. SUH M, Movva N, Bylsma LC, Fryzek JP, et al
    A Systematic Literature Review of the Burden of Respiratory Syncytial Virus and Health Care Utilization Among United States Infants Younger Than 1 Year.
    J Infect Dis. 2022;226.
    >> Share

  308. BOWSER DM, Rowlands KR, Hariharan D, Gervasio RM, et al
    Cost of Respiratory Syncytial Virus Infections in US Infants: Systematic Literature Review and Analysis.
    J Infect Dis. 2022;226.
    >> Share

  309. MOVVA N, Suh M, Bylsma LC, Fryzek JP, et al
    Systematic Literature Review of Respiratory Syncytial Virus Laboratory Testing Practices and Incidence in United States Infants and Children <5 Years of Age.
    J Infect Dis. 2022;226.
    >> Share

  310. GLASER EL, Hariharan D, Bowser DM, Gervasio RM, et al
    Impact of Respiratory Syncytial Virus on Child, Caregiver, and Family Quality of Life in the United States: Systematic Literature Review and Analysis.
    J Infect Dis. 2022;226.
    >> Share

  311. HANSEN CL, Viboud C, Chaves SS
    The Use of Death Certificate Data to Characterize Mortality Associated With Respiratory Syncytial Virus, Unspecified Bronchiolitis, and Influenza in the United States, 1999-2018.
    J Infect Dis. 2022;226.
    >> Share

  312. BYLSMA LC, Suh M, Movva N, Fryzek JP, et al
    Mortality Among US Infants and Children Under 5 Years of Age with Respiratory Syncytial Virus and Bronchiolitis: A Systematic Literature Review.
    J Infect Dis. 2022;226.
    >> Share

  313. HODGES EN, White M, Nelson CB
    All Infants Are at Risk of Developing Medically Attended Respiratory Syncytial Virus Lower Respiratory Tract Infection and Deserve Protection.
    J Infect Dis. 2022;226.
    >> Share

  314. GANTENBERG JR, van Aalst R, Zimmerman N, Limone B, et al
    Medically Attended Illness due to Respiratory Syncytial Virus Infection Among Infants Born in the United States Between 2016 and 2020.
    J Infect Dis. 2022;226.
    >> Share

  315. MOVVA N, Suh M, Reichert H, Hintze B, et al
    Respiratory Syncytial Virus During the COVID-19 Pandemic Compared to Historic Levels: A Retrospective Cohort Study of a Health System.
    J Infect Dis. 2022;226.
    >> Share

  316. SIMOES EAF
    The Burden of Respiratory Syncytial Virus Lower Respiratory Tract Disease in Infants in the United States: A Synthesis.
    J Infect Dis. 2022;226.
    >> Share

  317. KIEFFER A, Beuvelet M, Sardesai A, Musci R, et al
    Expected Impact of Universal Immunization With Nirsevimab Against RSV-Related Outcomes and Costs Among All US Infants in Their First RSV Season: A Static Model.
    J Infect Dis. 2022;226.
    >> Share

  318. GOMEZ GB, Nelson CB, Rizzo C, Shepard DS, et al
    Inequalities in Health Impact of Alternative Reimbursement Pathways for Nirsevimab in the United States.
    J Infect Dis. 2022;226.
    >> Share

  319. MAO Z, Li X, Korsten K, Bont L, et al
    Economic Burden and Health-Related Quality of Life of Respiratory Syncytial Virus and Influenza Infection in European Community-Dwelling Older Adults.
    J Infect Dis. 2022;226.
    >> Share

  320. MCGINLEY JP, Lin GL, Oner D, Golubchik T, et al
    Clinical and Viral Factors Associated With Disease Severity and Subsequent Wheezing in Infants With Respiratory Syncytial Virus Infection.
    J Infect Dis. 2022;226.
    >> Share

  321. SIMOES EAF
    Respiratory Syncytial Virus Disease in Young Children and Older Adults in Europe: A Burden and Economic Perspective.
    J Infect Dis. 2022;226.
    >> Share

  322. JOHANNESEN CK, van Wijhe M, Tong S, Fernandez LV, et al
    Age-Specific Estimates of Respiratory Syncytial Virus-Associated Hospitalizations in 6 European Countries: A Time Series Analysis.
    J Infect Dis. 2022;226.
    >> Share

  323. DERKSEN-LAZET ND, Parmentier CEJ, Wildenbeest JG, Bont LJ, et al
    Patient Involvement in RSV Research: Towards Patients Setting the Research Agenda.
    J Infect Dis. 2022;226.
    >> Share

  324. WANG X, Li Y, Shi T, Ma Y, et al
    Global Disease Burden of Respiratory Syncytial Virus in Preterm Children in 2019: A Systematic Review and Individual Participant Data Meta-Analysis Protocol.
    J Infect Dis. 2022;226.
    >> Share

  325. VAN WIJHE M, Johannesen CK, Simonsen L, Jorgensen IM, et al
    A Retrospective Cohort Study on Infant Respiratory Tract Infection Hospitalizations and Recurrent Wheeze and Asthma Risk: Impact of Respiratory Syncytial Virus.
    J Infect Dis. 2022;226.
    >> Share

  326. GUISADO-VASCO P, Aguarles Gorines J, Carralon Gonzalez MM, Sotres Fernandez G, et al
    Flipped Inflammatory Time and the Role of Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2: Optimizing Tocilizumab Against Coronavirus Disease 2019.
    J Infect Dis. 2022;226:1-5.
    >> Share

  327. KAO CC, Liaw YP
    Comment on " Infants Younger Than 6 Months Infected With SARS-CoV-2 Show the Highest Respiratory Viral Loads".
    J Infect Dis. 2022;226:188.
    >> Share

  328. ZUURBIER RP, Korsten K, Verheij TJM, Butler C, et al
    Performance Assessment of a Rapid Molecular Respiratory Syncytial Virus Point-of-Care Test: A Prospective Community Study in Older Adults.
    J Infect Dis. 2022;226.
    >> Share

  329. WANG X, Li Y, Vazquez Fernandez L, Teirlinck AC, et al
    Respiratory Syncytial Virus-Associated Hospital Admissions and Bed Days in Children <5 Years of Age in 7 European Countries.
    J Infect Dis. 2022;226.
    >> Share

  330. MCGINLEY J, Thwaites R, Brebner W, Greenan-Barrett L, et al
    A Systematic Review and Meta-analysis of Animal Studies Investigating the Relationship Between Serum Antibody, T Lymphocytes, and Respiratory Syncytial Virus Disease.
    J Infect Dis. 2022;226.
    >> Share

  331. WANG X, Li Y, Nair H, Campbell H, et al
    Time-Varying Association Between Severe Respiratory Syncytial Virus Infections and Subsequent Severe Asthma and Wheeze and Influences of Age at the Infection.
    J Infect Dis. 2022;226.
    >> Share

  332. SHI T, Vennard S, Jasiewicz F, Brogden R, et al
    Disease Burden Estimates of Respiratory Syncytial Virus related Acute Respiratory Infections in Adults With Comorbidity: A Systematic Review and Meta-Analysis.
    J Infect Dis. 2022;226.
    >> Share

  333. SHI T, Vennard S, Mahdy S, Nair H, et al
    Risk Factors for Poor Outcome or Death in Young Children With Respiratory Syncytial Virus-Associated Acute Lower Respiratory Tract Infection: A Systematic Review and Meta-Analysis.
    J Infect Dis. 2022;226.
    >> Share

  334. O'NEIL B, Ison MG, Hallouin-Bernard MC, Nilsson AC, et al
    A Phase 2 Study of Pimodivir (JNJ-63623872) in Combination With Oseltamivir in Elderly and Nonelderly Adults Hospitalized With Influenza A Infection: OPAL Study.
    J Infect Dis. 2022;226:109-118.
    >> Share

  335. HOA LNM, Sullivan SG, Mai LQ, Khvorov A, et al
    Influenza A(H1N1)pdm09 But Not A(H3N2) Virus Infection Induces Durable Seroprotection: Results From the Ha Nam Cohort.
    J Infect Dis. 2022;226:59-69.
    >> Share

  336. SAMSUNDER N, de Vos M, Ngcapu S, Giandhari J, et al
    Clinical evaluation of SARS-CoV-2 rapid antigen tests during the Omicron wave in South Africa.
    J Infect Dis. 2022 Aug 3. pii: 6654839. doi: 10.1093.
    >> Share

  337. GREBE E, Yu EA, Bravo MD, Welte A, et al
    COVID-19 vaccine effectiveness against SARS-CoV-2 infection in the United States prior to the Delta and Omicron-associated surges: a retrospective cohort study of repeat blood donors.
    J Infect Dis. 2022 Aug 3. pii: 6654836. doi: 10.1093.
    >> Share

    July 2022
  338. VIVALDI G, Jolliffe DA, Faustini S, Shields AM, et al
    Correlation between post-vaccination anti-Spike antibody titres and protection against breakthrough SARS-CoV-2 infection: a population-based longitudinal study.
    J Infect Dis. 2022 Jul 30. pii: 6652292. doi: 10.1093.
    >> Share

  339. LEROUX-ROELS I, Davis MG, Steenackers K, Essink B, et al
    Safety and immunogenicity of a respiratory syncytial virus prefusion F (RSVPreF3) candidate vaccine in older adults: phase I/II randomized clinical trial.
    J Infect Dis. 2022 Jul 29. pii: 6651941. doi: 10.1093.
    >> Share

  340. BRITTO C, Mohorianu I, Yeung T, Cheung E, et al
    Host respiratory transcriptome signature associated with poor outcome in children with influenza-Staphylococcus aureus pneumonia.
    J Infect Dis. 2022 Jul 28. pii: 6650994. doi: 10.1093.
    >> Share

  341. CHU WM, Lee YH, Cheng-Chung Wei J, Lee YH, et al
    Comment on Recombinant Adjuvanted Zoster Vaccine and Reduced Risk of Coronavirus Disease 2019 Diagnosis and Hospitalization in Older Adults.
    J Infect Dis. 2022 Jul 26. pii: 6649924. doi: 10.1093.
    >> Share

  342. CRISTINA CASSETTI M, Pierson TC, Jean Patterson L, Bok K, et al
    Prototype Pathogen Approach for Vaccine and Monoclonal Antibody Development: A Critical Component of the NIAID Plan for Pandemic Preparedness.
    J Infect Dis. 2022 Jul 25. pii: 6649664. doi: 10.1093.
    >> Share

  343. WAGNER AL, Sanchez N, Kubale J, Kuan G, et al
    Single dose vaccination among infants and toddlers provides modest protection against influenza illness which wanes after 5 months.
    J Infect Dis. 2022 Jul 7. pii: 6633354. doi: 10.1093.
    >> Share

  344. COSSU MV, Mileto D, Giacomelli A, Oreni L, et al
    Does the co-morbidity burden contribute to suboptimal immunological responses to COVID-19 vaccination in people living with HIV?
    J Infect Dis. 2022 Jul 7. pii: 6633353. doi: 10.1093.
    >> Share

  345. ASSAWAKOSRI S, Suntronwong N, Yorsaeng R, Kanokudom S, et al
    Breakthrough infection by SARS-CoV-2 Delta and Omicron variants elicited immune response comparable to mRNA booster vaccination.
    J Infect Dis. 2022 Jul 5. pii: 6631219. doi: 10.1093.
    >> Share

  346. REN Z, Sun R, Cui G, Wang H, et al
    Effects of Inactivated Vaccination on Humoral Immune Responses in Patients Infected with Delta or Omicron Variants.
    J Infect Dis. 2022 Jul 5. pii: 6631218. doi: 10.1093.
    >> Share

    June 2022
  347. VENCALEK O, Beran J, Furst T, Kratka Z, et al
    Protection by vaccines and previous infection against the Omicron variant of SARS-CoV-2.
    J Infect Dis. 2022 Jun 28. pii: 6619238. doi: 10.1093.
    >> Share

  348. LLIBRE JM, Revollo B, Aguilar S, Calomarde-Gomez C, et al
    Protection against severe clinical outcomes with adenovirus or mRNA SARS-CoV-2 vaccines in patients hospitalized with Covid-19.
    J Infect Dis. 2022 Jun 28. pii: 6619237. doi: 10.1093.
    >> Share

  349. TEMPLE DS, Hegarty-Craver M, Furberg RD, Preble EA, et al
    Wearable sensor-based detection of influenza in presymptomatic and asymptomatic individuals.
    J Infect Dis. 2022 Jun 27. pii: 6618641. doi: 10.1093.
    >> Share

  350. MOY JN, Anderson M, Shen X, Fu J, et al
    Neutralizing Antibody Activity to SARS-CoV-2 Delta (B.1.617.2) and Omicron (B.1.1.529) After One and Two Doses of BNT162b2 Vaccine in Infection-Naive and Previously-Infected Individuals.
    J Infect Dis. 2022 Jun 27. pii: 6618640. doi: 10.1093.
    >> Share

  351. AMJADI MF, Adyniec RR, Gupta S, Bashar SJ, et al
    Anti-membrane antibodies persist at least one year and discriminate between past COVID-19 infection and vaccination.
    J Infect Dis. 2022 Jun 27. pii: 6618636. doi: 10.1093.
    >> Share

  352. STRENG BMM, Bont M, Delemarre EM, Binnendijk RS, et al
    Decreased antibody response after SARS-CoV-2 vaccination in patients with Down Syndrome.
    J Infect Dis. 2022 Jun 24. pii: 6617441. doi: 10.1093.
    >> Share

  353. CUNNINGHAM CK, Karron RA, Muresan P, Kelly MS, et al
    Evaluation of Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccines RSV/DeltaNS2/Delta1313/I1314L and RSV/276 in RSV Seronegative Children.
    J Infect Dis. 2022 Jun 23. pii: 6613410. doi: 10.1093.
    >> Share

  354. GUIRAKHOO F, Wang S, Wang CY, Kuo HK, et al
    High neutralizing antibody levels against SARS-CoV-2 Omicron BA.1 and BA.2 after UB-612 vaccine booster.
    J Infect Dis. 2022 Jun 20. pii: 6611838. doi: 10.1093.
    >> Share

  355. VARESE A, Mazzitelli B, Diaz FE, Kjolhede MV, et al
    Omicron breakthrough infection after heterologous prime-boost vaccination induces a vigorous antibody response.
    J Infect Dis. 2022 Jun 20. pii: 6611839. doi: 10.1093.
    >> Share

  356. LEMASTER C, Geanes ES, Fraley ER, Selvarangan R, et al
    Vaccination after SARS-CoV-2 infection increased antibody avidity against the Omicron variant compared to vaccination alone.
    J Infect Dis. 2022 Jun 18. pii: 6609994. doi: 10.1093.
    >> Share

  357. ACOSTA-AMPUDIA Y, Monsalve DM, Rojas M, Rodriguez Y, et al
    Persistent Autoimmune Activation and Proinflammatory State in Post-Coronavirus Disease 2019 Syndrome.
    J Infect Dis. 2022;225:2155-2162.
    >> Share

  358. VEDHARA K, Ayling K, Jia R, Fairclough L, et al
    Relationship Between Anxiety, Depression, and Susceptibility to Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Proof of Concept.
    J Infect Dis. 2022;225:2137-2141.
    >> Share

  359. TURNBULL J, Jha RR, Ortori CA, Lunt E, et al
    Serum Levels of Proinflammatory Lipid Mediators and Specialized Proresolving Molecules Are Increased in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 and Correlate With Markers of the Adaptive Immune Response.
    J Infect Dis. 2022;225:2142-2154.
    >> Share

  360. CHANG YH, Kao CC, Fang JJ, Lee YH, et al
    Correspondence to Morbidity and Mortality Among Adults Experiencing Homelessness Hospitalized With Coronavirus Disease 2019.
    J Infect Dis. 2022;225:2235.
    >> Share

  361. DEVINCENZO J, Cass L, Murray A, Woodward K, et al
    Safety and Antiviral Effects of Nebulized PC786 in a Respiratory Syncytial Virus Challenge Study.
    J Infect Dis. 2022;225:2087-2096.
    >> Share

  362. NYAWANDA BO, Otieno NA, Otieno MO, Emukule GO, et al
    The Impact of Maternal Human Immunodeficiency Virus Infection on the Burden of Respiratory Syncytial Virus Among Pregnant Women and Their Infants, Western Kenya.
    J Infect Dis. 2022;225:2097-2105.
    >> Share

  363. SIEDNER MJ, Alba C, Fitzmaurice KP, Gilbert RF, et al
    Cost-effectiveness of COVID-19 vaccination in low- and middle-income countries.
    J Infect Dis. 2022 Jun 13. pii: 6606162. doi: 10.1093.
    >> Share

  364. JACOBSON JM
    Immune Responses to SARS-CoV-2 Vaccination in People With HIV: A Tale of Two Pandemics.
    J Infect Dis. 2022 Jun 7. pii: 6603522. doi: 10.1093.
    >> Share

  365. LAPOINTE HR, Mwimanzi F, Cheung PK, Sang Y, et al
    People with HIV receiving suppressive antiretroviral therapy show typical antibody durability after dual COVID-19 vaccination, and strong third dose responses.
    J Infect Dis. 2022 Jun 7. pii: 6603521. doi: 10.1093.
    >> Share

  366. STORCH GA
    Respiratory syncytial virus (RSV) around the globe: data to help guide wise use of vaccines and anti-virals.
    J Infect Dis. 2022 Jun 6. pii: 6603523. doi: 10.1093.
    >> Share

  367. LAURIE MT, Liu J, Sunshine S, Peng J, et al
    SARS-CoV-2 Variant Exposures Elicit Antibody Responses With Differential Cross-Neutralization of Established and Emerging Strains Including Delta and Omicron.
    J Infect Dis. 2022;225:1909-1914.
    >> Share

    May 2022
  368. HAYDEN FG, Lenk RP, Stonis L, Oldham-Creamer C, et al
    Favipiravir Treatment of Uncomplicated Influenza in Adults: Results of Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Trials.
    J Infect Dis. 2022 May 26. pii: 6568151. doi: 10.1093.
    >> Share

  369. ROSTAD CA, Chen X, Sun HY, Hussaini L, et al
    Functional antibody responses to SARS-CoV-2 variants in children with COVID-19, MIS-C, and after two doses of BNT162b2 vaccination.
    J Infect Dis. 2022 May 26. pii: 6593309. doi: 10.1093.
    >> Share

  370. AMANO M, Maeda K, Tsuchiya K, Shimada S, et al
    Third-dose BNT162b2 vaccination elicits markedly high-level SARS-CoV-2-neutralizing antibodies in vaccinees who poorly responded to second dose in Japan.
    J Infect Dis. 2022 May 17. pii: 6587098. doi: 10.1093.
    >> Share

  371. MONDELLI MU
    Antibodies: A Double Leg Takedown Against COVID-19.
    J Infect Dis. 2022;225:1685-1687.
    >> Share

  372. PATI A, Nayak N, Sarangi S, Barik D, et al
    CCL5 rs2107538 Variant Is Associated With Protection Against SARS-CoV-2 Infection and Related Mortality: A Population-Based Study.
    J Infect Dis. 2022;225:1865-1866.
    >> Share

  373. PEREZ-GARCIA F, Martin-Vicente M, Bermejo-Martin JF, Resino S, et al
    Reply to Pati et al.
    J Infect Dis. 2022;225:1866-1868.
    >> Share

  374. MWIMANZI F, Lapointe HR, Cheung PK, Sang Y, et al
    Older adults mount less durable humoral responses to two doses of COVID-19 mRNA vaccine, but strong initial responses to a third dose.
    J Infect Dis. 2022 May 11. pii: 6583561. doi: 10.1093.
    >> Share

  375. BABER J, Arya M, Moodley Y, Jaques A, et al
    A Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine With and Without Adjuvant in Healthy Older Adults.
    J Infect Dis. 2022 May 11. pii: 6583554. doi: 10.1093.
    >> Share

  376. EL SAHLY HM, Baden LR, Essink B, Montefiori D, et al
    Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 COVE Trial.
    J Infect Dis. 2022 May 10. pii: 6583011. doi: 10.1093.
    >> Share

  377. LIU B, Stepien S, Pye V, Law C, et al
    High attack rate of SARS-CoV-2 B.1.1.529 among two-dose vaccinated populations in two indoor entertainment setting outbreaks.
    J Infect Dis. 2022 May 7. pii: 6582820. doi: 10.1093.
    >> Share

  378. KURAHASHI Y, Furukawa K, Sutandhio S, Tjan LH, et al
    Cross-neutralizing activity against Omicron could be obtained in SARS-CoV-2 convalescent patients who received two doses of mRNA vaccination.
    J Infect Dis. 2022 May 5. pii: 6580685. doi: 10.1093.
    >> Share

  379. HAN T, Park H, Jeong Y, Lee J, et al
    COVID-19 Cluster Linked to Aerosol Transmission of SARS-CoV-2 via Floor Drains.
    J Infect Dis. 2022;225:1554-1560.
    >> Share

  380. BAHL P, Doolan C, de Silva C, Chughtai AA, et al
    Airborne or Droplet Precautions for Health Workers Treating Coronavirus Disease 2019?
    J Infect Dis. 2022;225:1561-1568.
    >> Share

  381. JACOBS JL, Naqvi A, Shah FA, Boltz VF, et al
    Plasma SARS-CoV-2 RNA levels as a biomarker of lower respiratory tract SARS-CoV-2 infection in critically ill patients with COVID-19.
    J Infect Dis. 2022 May 2. pii: 6576503. doi: 10.1093.
    >> Share

    April 2022
  382. SMID M, Berec L, Pribylova L, Majek O, et al
    Protection by vaccines and previous infection against the Omicron variant of SARS-CoV-2.
    J Infect Dis. 2022 Apr 28. pii: 6575414. doi: 10.1093.
    >> Share

  383. TJAN LH, Furukawa K, Kurahashi Y, Sutandhio S, et al
    As well as Omicron BA.1, high neutralizing activity against Omicron BA.2 can be induced by COVID-19 mRNA booster vaccination.
    J Infect Dis. 2022 Apr 28. pii: 6575227. doi: 10.1093.
    >> Share

  384. OKUDA M, Sakai-Tagawa Y, Koga M, Koibuchi T, et al
    Immunological correlates of prevention of the onset of seasonal H3N2 influenza.
    J Infect Dis. 2022 Apr 27. pii: 6574940. doi: 10.1093.
    >> Share

  385. ASSAWAKOSRI S, Kanokudom S, Suntronwong N, Puenpa J, et al
    Omicron BA.1, BA.2 and COVID-19 booster vaccination.
    J Infect Dis. 2022 Apr 27. pii: 6575160. doi: 10.1093.
    >> Share

  386. LIN DY, Zeng D, Gu Y, Krause PR, et al
    Reliably Assessing Duration of Protection for COVID-19 Vaccines.
    J Infect Dis. 2022 Apr 21. pii: 6571630. doi: 10.1093.
    >> Share

  387. REYES J, Stiehl B, Delgado J, Kinzel M, et al
    Human Research Study of Particulate Propagation Distance From Human Respiratory Function.
    J Infect Dis. 2022;225:1321-1329.
    >> Share

  388. IVERSEN KK, Afzal S, Ahlstrom MG, Nordestgaard BG, et al
    Lung Function Decline in Relation to COVID-19 in the General Population: A Matched Cohort Study With Prepandemic Assessment of Lung Function.
    J Infect Dis. 2022;225:1308-1316.
    >> Share

  389. AULD SC
    Lung Function After Coronavirus Disease 2019: Some Answers, More Questions.
    J Infect Dis. 2022;225:1305-1307.
    >> Share

  390. CHANG YH, Liaw YP
    Correspondence to Maternal-Fetal Immunologic Response to SARS-CoV-2 Infection in a Symptomatic Vulnerable Population: A Prospective Cohort.
    J Infect Dis. 2022;225:1494.
    >> Share

  391. SKOWRONSKI DM, Leir S, Sabaiduc S, Chambers C, et al
    Influenza Vaccine Effectiveness by A(H3N2) Phylogenetic Subcluster and Prior Vaccination History: 2016-2017 and 2017-2018 Epidemics in Canada.
    J Infect Dis. 2022;225:1387-1398.
    >> Share

  392. LE GARS M, Sadoff J, Struyf F, Heerwegh D, et al
    Impact of preexisting anti-Ad26 humoral immunity on immunogenicity of the Ad26.COV2.S COVID-19 vaccine.
    J Infect Dis. 2022 Apr 16. pii: 6569363. doi: 10.1093.
    >> Share

  393. ZHU KL, Gao HX, Yao L, Rong J, et al
    Delta infection following vaccination elicits potent neutralizing immunity against the SARS-CoV-2 Omicron.
    J Infect Dis. 2022 Apr 16. pii: 6569353. doi: 10.1093.
    >> Share

  394. KWON JH, Tenforde MW, Gaglani M, Talbot HK, et al
    mRNA Vaccine Effectiveness Against COVID-19 Hospitalization Among Solid Organ Transplant Recipients.
    J Infect Dis. 2022 Apr 6. pii: 6564370. doi: 10.1093.
    >> Share

  395. XIONG W, Tsang TK, Perera RAPM, Leung NHL, et al
    Biphasic waning of hemagglutination inhibition antibody titers after influenza vaccination in children.
    J Infect Dis. 2022 Apr 5. pii: 6563665. doi: 10.1093.
    >> Share

  396. LEMIEUX JE, Luban J
    Consulting the Oracle of SARS-CoV-2 Infection.
    J Infect Dis. 2022;225:1115-1117.
    >> Share

  397. NUSSENBLATT V, Roder AE, Das S, de Wit E, et al
    Yearlong COVID-19 Infection Reveals Within-Host Evolution of SARS-CoV-2 in a Patient With B-Cell Depletion.
    J Infect Dis. 2022;225:1118-1123.
    >> Share

  398. KOIVISTO K, Nieminen T, Mejias A, Capella Gonzalez C, et al
    Respiratory Syncytial Virus (RSV)-Specific Antibodies in Pregnant Women and Subsequent Risk of RSV Hospitalization in Young Infants.
    J Infect Dis. 2022;225:1189-1196.
    >> Share

  399. FERGIE J, Suh M, Jiang X, Fryzek JP, et al
    Respiratory Syncytial Virus and All-Cause Bronchiolitis Hospitalizations Among Preterm Infants Using the Pediatric Health Information System (PHIS).
    J Infect Dis. 2022;225:1197-1204.
    >> Share

    March 2022
  400. REEVES RM, van Wijhe M, Lehtonen T, Stona L, et al
    A Systematic Review of European Clinical Practice Guidelines for Respiratory Syncytial Virus Prophylaxis.
    J Infect Dis. 2022 Mar 25. pii: 6554001. doi: 10.1093.
    >> Share

  401. MARON JS, Conroy M, Naranbai V, Samarakoon U, et al
    Differential SARS-CoV-2 Antibody Profiles after Allergic Reactions to mRNA COVID-19 Vaccine.
    J Infect Dis. 2022 Mar 23. pii: 6553054. doi: 10.1093.
    >> Share

  402. RIEKE GJ, van Bremen K, Bischoff J, To Vinh M, et al
    Induction of NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC) against SARS-CoV-2 after natural infection is more potent than after vaccination.
    J Infect Dis. 2022 Mar 22. pii: 6552258. doi: 10.1093.
    >> Share

  403. LI X, Bilcke J, Vazquez Fernandez L, Bont L, et al
    Cost-effectiveness of Respiratory Syncytial Virus Disease Prevention Strategies: Maternal Vaccine Versus Seasonal or Year-Round Monoclonal Antibody Program in Norwegian Children.
    J Infect Dis. 2022 Mar 16. pii: 6549175. doi: 10.1093.
    >> Share

  404. PEREZ-GARCIA F, Martin-Vicente M, Rojas-Garcia RL, Castilla-Garcia L, et al
    High SARS-CoV-2 Viral Load and Low CCL5 Expression Levels in the Upper Respiratory Tract Are Associated With COVID-19 Severity.
    J Infect Dis. 2022;225:977-982.
    >> Share

  405. LI Y, Wang X, Cong B, Deng S, et al
    Understanding the Potential Drivers for Respiratory Syncytial Virus Rebound During the Coronavirus Disease 2019 Pandemic.
    J Infect Dis. 2022;225:957-964.
    >> Share

  406. LYSKI ZL, Brunton AE, Strnad MI, Sullivan PE, et al
    Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Specific Memory B Cells From Individuals With Diverse Disease Severities Recognize SARS-CoV-2 Variants of Concern.
    J Infect Dis. 2022;225:947-956.
    >> Share

  407. NGUYEN D, Xiao J, Simmonds P, Lamikanra A, et al
    Effects of Severe Acute Respiratory Syndrome Coronavirus 2 Strain Variation on Virus Neutralization Titers: Therapeutic Use of Convalescent Plasma.
    J Infect Dis. 2022;225:971-976.
    >> Share

  408. DIEZ JM, Romero C, Cruz M, Vandeberg P, et al
    Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Hyperimmune Immunoglobulin Demonstrates Potent Neutralization and Antibody-Dependent Cellular Cytotoxicity and Phagocytosis Through N and S Proteins.
    J Infect Dis. 2022;225:938-946.
    >> Share

  409. ROHRIG A, Eyal N
    The Ethics of Human Challenge Trials Using Emerging Severe Acute Respiratory Syndrome 2 Variants.
    J Infect Dis. 2022;225:934-937.
    >> Share

  410. CUNNINGHAM JL, Virhammar J, Ronnberg B, Dopico XC, et al
    Antibody Responses to Severe Acute Respiratory Syndrome Coronavirus 2 in the Serum and Cerebrospinal Fluid of Patients With Coronavirus Disease 2019 and Neurological Symptoms.
    J Infect Dis. 2022;225:965-970.
    >> Share

  411. MCLAUGHLIN JM, Khan F, Schmitt HJ, Agosti Y, et al
    Respiratory Syncytial Virus-Associated Hospitalization Rates among US Infants: A Systematic Review and Meta-Analysis.
    J Infect Dis. 2022;225:1100-1111.
    >> Share

  412. ASSAWAKOSRI S, Kanokudom S, Suntronwong N, Auphimai C, et al
    Neutralizing Activities against the Omicron Variant after a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination.
    J Infect Dis. 2022 Mar 10. pii: 6546425. doi: 10.1093.
    >> Share

  413. DEBIASI RL
    Severe Acute Respiratory Syndrome-Coronavirus-2 Effects at the Maternal-Fetal Interface.
    J Infect Dis. 2022;225:745-747.
    >> Share

  414. SHOOK LL, Brigida S, Regan J, Flynn JP, et al
    SARS-CoV-2 Placentitis Associated With B.1.617.2 (Delta) Variant and Fetal Distress or Demise.
    J Infect Dis. 2022;225:754-758.
    >> Share

  415. REGAN AK, Arah OA, Fell DB, Sullivan SG, et al
    SARS-CoV-2 Infection During Pregnancy and Associated Perinatal Health Outcomes: A National US Cohort Study.
    J Infect Dis. 2022;225:759-767.
    >> Share

  416. WELCH JL, Xiang J, Chang Q, Houtman JCD, et al
    T-Cell Expression of Angiotensin-Converting Enzyme 2 and Binding of Severe Acute Respiratory Coronavirus 2.
    J Infect Dis. 2022;225:810-819.
    >> Share

  417. LARCADE R, DeShea L, Lang GA, Caballero MT, et al
    Maternal-Fetal Immunologic Response to SARS-CoV-2 Infection in a Symptomatic Vulnerable Population: A Prospective Cohort.
    J Infect Dis. 2022;225:800-809.
    >> Share

  418. HWANG H, Lim JS, Song SA, Achangwa C, et al
    Transmission Dynamics of the Delta Variant of SARS-CoV-2 Infections in South Korea.
    J Infect Dis. 2022;225:793-799.
    >> Share

  419. KOTWA JD, Jamal AJ, Mbareche H, Yip L, et al
    Surface and Air Contamination With Severe Acute Respiratory Syndrome Coronavirus 2 From Hospitalized Coronavirus Disease 2019 Patients in Toronto, Canada, March-May 2020.
    J Infect Dis. 2022;225:768-776.
    >> Share

  420. PULVIRENTI F, Milito C, Cinetto F, Fernandez Salinas A, et al
    Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Combination Therapy in Patients With Coronavirus Disease 2019 and Primary Antibody Deficiency.
    J Infect Dis. 2022;225:820-824.
    >> Share

  421. DIAZ-DIAZ A, Bunsow E, Garcia-Maurino C, Moore-Clingenpeel M, et al
    Nasopharyngeal Codetection of Haemophilus influenzae and Streptococcus pneumoniae Shapes Respiratory Syncytial Virus Disease Outcomes in Children.
    J Infect Dis. 2022;225:912-923.
    >> Share

    February 2022
  422. MORITZKY SA, Richards KA, Glover MA, Krammer F, et al
    The negative effect of pre-existing immunity on influenza vaccine responses transcends the impact of vaccine formulation type and vaccination history.
    J Infect Dis. 2022 Feb 24. pii: 6535476. doi: 10.1093.
    >> Share

  423. BURNETT E, Parashar UD, Winn A, Tate JE, et al
    Trends in rotavirus laboratory detections and internet search volume before and after rotavirus vaccine introduction and in the context of the COVID-19 pandemic-- United States 2000-2021.
    J Infect Dis. 2022 Feb 20. pii: 6532606. doi: 10.1093.
    >> Share

  424. ROACH M, Hiatt RA, Black S
    Commentary: Race, COVID-19 and Nursing Homes.
    J Infect Dis. 2022;225:555-556.
    >> Share

  425. LORCA-ORO C, Vila J, Pleguezuelos P, Vergara-Alert J, et al
    Rapid SARS-CoV-2 Inactivation in a Simulated Hospital Room Using a Mobile and Autonomous Robot Emitting Ultraviolet-C Light.
    J Infect Dis. 2022;225:587-592.
    >> Share

  426. MONTAGUE BT, Wipperman MF, Hooper AT, Hamon SC, et al
    Anti-SARS-CoV-2 IgA Identifies Asymptomatic Infection in First Responders.
    J Infect Dis. 2022;225:578-586.
    >> Share

  427. ELHARAKE JA, Shafiq M, McFadden SM, Malik AA, et al
    The Association of Coronavirus Disease 2019 Risk Perception, County Death Rates, and Voluntary Health Behaviors Among United States Adult Population.
    J Infect Dis. 2022;225:593-597.
    >> Share

  428. HARALAMBIEVA IH, Monroe JM, Ovsyannikova IG, Grill DE, et al
    Distinct Homologous and Variant-Specific Memory B-Cell and Antibody Response Over Time after SARS-CoV-2 mRNA Vaccination.
    J Infect Dis. 2022 Feb 8. pii: 6524526. doi: 10.1093.
    >> Share

  429. ALANIO C, Verma A, Mathew D, Gouma S, et al
    Cytomegalovirus latent infection is associated with an increased risk of COVID-19-related hospitalization.
    J Infect Dis. 2022 Feb 2. pii: 6520490. doi: 10.1093.
    >> Share

  430. RYAN KA, Schewe KE, Crowe J, Fotheringham SA, et al
    Sequential Delivery of Live Attenuated Influenza Vaccine and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in the Ferret Model Can Reduce SARS-CoV-2 Shedding and Does Not Result in Enhanced Lung Pathology.
    J Infect Dis. 2022;225:404-412.
    >> Share

  431. OCHOA V, Diaz FE, Ramirez E, Fentini MC, et al
    Infants Younger Than 6 Months Infected With SARS-CoV-2 Show the Highest Respiratory Viral Loads.
    J Infect Dis. 2022;225:392-395.
    >> Share

  432. LEBREIL AL, Greux V, Glenet M, Huguenin A, et al
    Surfaces and Air Contamination by Severe Acute Respiratory Syndrome Coronavirus 2 Using High-Flow Nasal Oxygenation or Assisted Mechanical Ventilation in Intensive Care Unit Rooms of Patients With Coronavirus Disease 2019.
    J Infect Dis. 2022;225:385-391.
    >> Share

  433. KLEIN J, Brito AF, Trubin P, Lu P, et al
    Longitudinal Immune Profiling of a Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection in a Solid Organ Transplant Recipient.
    J Infect Dis. 2022;225:374-384.
    >> Share

  434. CHAMBERLAIN AT, Toomey KE, Bradley H, Hall EW, et al
    Cumulative Incidence of SARS-CoV-2 Infections Among Adults in Georgia, United States, August to December 2020.
    J Infect Dis. 2022;225:396-403.
    >> Share

  435. MALENFANT JH, Eslami M, Dao BL, Moore L, et al
    Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Among Skilled Nursing Facility Residents and Staff Members-Los Angeles County, August-September 2020.
    J Infect Dis. 2022;225:367-373.
    >> Share

  436. KIM N, Shin S, Minn D, Park S, et al
    SARS-CoV-2 Infectivity and Antibody Titer Reduction for 6 Months After Second Dose of BNT162b2 mRNA Vaccine in Healthcare Workers: A Prospective Cohort Study.
    J Infect Dis. 2022 Feb 1. pii: 6519374. doi: 10.1093.
    >> Share

    January 2022
  437. SKOWRONSKI DM, Setayeshgar S, Zou M, Prystajecky N, et al
    Comparative single-dose mRNA and ChAdOx1 vaccine effectiveness against SARS-CoV-2, including variants of concern: test-negative design, British Columbia, Canada.
    J Infect Dis. 2022 Jan 27. pii: 6515934. doi: 10.1093.
    >> Share

  438. KRAYNYAK KA, Blackwood E, Agnes J, Tebas P, et al
    SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial.
    J Infect Dis. 2022 Jan 25. pii: 6515374. doi: 10.1093.
    >> Share

  439. PUING AG, Ho S, Frankel P, Tegtmeier B, et al
    Severe Acute Respiratory Syndrome Coronavirus 2-Specific Monoclonal Antibody for the Treatment of Mild to Moderate Coronavirus Disease 2019 in Cancer Patients: A Single-Center Experience.
    J Infect Dis. 2022;225:352-354.
    >> Share

  440. KASPERSEN KA, Hindhede L, Boldsen JK, Mikkelsen S, et al
    Estimation of SARS-CoV-2 Infection Fatality Rate by Age and Comorbidity Status Using Antibody Screening of Blood Donors During the COVID-19 Epidemic in Denmark.
    J Infect Dis. 2022;225:219-228.
    >> Share

  441. STAPLETON EM, Welch JL, Ubeda EA, Xiang J, et al
    Urban Particulate Matter Impairment of Airway Surface Liquid-Mediated Coronavirus Inactivation.
    J Infect Dis. 2022;225:214-218.
    >> Share

  442. MERTZ C, Glowinski R, Cohen SH, Mertz S, et al
    Severe Acute Respiratory Syndrome Coronavirus 2 RNAemia and Clinical Outcomes in Children With Coronavirus Disease 2019.
    J Infect Dis. 2022;225:208-213.
    >> Share

  443. KOVACEVIC A, Eggo RM, Baguelin M, Domenech de Celles M, et al
    The Impact of Cocirculating Pathogens on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)/Coronavirus Disease 2019 Surveillance: How Concurrent Epidemics May Introduce Bias and Decrease the Observed SARS-CoV-2 Percentage Positivity.
    J Infect Dis. 2022;225:199-207.
    >> Share

  444. BUDER F, Bauswein M, Magnus CL, Audebert F, et al
    Contribution of High Viral Loads, Detection of Viral Antigen and Seroconversion to Severe Acute Respiratory Syndrome Coronavirus 2 Infectivity.
    J Infect Dis. 2022;225:190-198.
    >> Share

  445. SHRAGAI T, Smith-Jeffcoat SE, Koh M, Schechter MC, et al
    Epidemiologic, Immunologic, and Virus Characteristics in Patients With Paired Severe Acute Respiratory Syndrome Coronavirus 2 Serology and Reverse-Transcription Polymerase Chain Reaction Testing.
    J Infect Dis. 2022;225:229-237.
    >> Share

  446. GUAN M, Johannesen E, Tang CY, Hsu AL, et al
    Intrauterine fetal demise in the third trimester of pregnancy associated with mild infection with the SARS-CoV-2 Delta variant without protection from vaccination.
    J Infect Dis. 2022 Jan 13. pii: 6506263. doi: 10.1093.
    >> Share

  447. KRISTENSEN JH, Hasselbalch RB, Pries-Heje M, Nielsen PB, et al
    Effect of influenza vaccination on risk of COVID-19 - A prospective cohort study of 46,000 health care workers.
    J Infect Dis. 2022 Jan 5. pii: 6497955. doi: 10.1093.
    >> Share

  448. MEMEL ZN, Lee JJ, Foulkes AS, Chung RT, et al
    Association of Statins and 28-Day Mortality Rates in Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
    J Infect Dis. 2022;225:19-29.
    >> Share

  449. PATEL EU, Bloch EM, Tobian AAR
    Severe Acute Respiratory Syndrome Coronavirus 2 Serosurveillance in Blood Donor Populations.
    J Infect Dis. 2022;225:1-4.
    >> Share

  450. FRANCIS RV, Billam H, Clarke M, Yates C, et al
    The Impact of Real-Time Whole-Genome Sequencing in Controlling Healthcare-Associated SARS-CoV-2 Outbreaks.
    J Infect Dis. 2022;225:10-18.
    >> Share

    December 2021
  451. LUCZKOWIAK J, Labiod N, Rivas G, Rolo M, et al
    Neutralizing response against SARS-CoV-2 variants 8 months after BNT162b2 vaccination in naive and COVID-19 convalescent individuals.
    J Infect Dis. 2021 Dec 28. pii: 6486499. doi: 10.1093.
    >> Share

  452. BRUXVOORT KJ, Ackerson B, Sy LS, Bhavsar A, et al
    Recombinant adjuvanted zoster vaccine and reduced risk of COVID-19 diagnosis and hospitalization in older adults.
    J Infect Dis. 2021 Dec 28. pii: 6486498. doi: 10.1093.
    >> Share

  453. ABARA WE, Gee J, Delorey M, Tun Y, et al
    Expected Rates of Select Adverse Events following Immunization for COVID-19 Vaccine Safety Monitoring.
    J Infect Dis. 2021 Dec 27. pii: 6484617. doi: 10.1093.
    >> Share

  454. LIU J, Huang B, Li G, Chang X, et al
    Immunogenicity and Safety of a Three-Dose Regimen of a SARS-CoV-2 Inactivated Vaccine in Adults: A Randomized, Double-blind, Placebo-controlled Phase 2 Trial.
    J Infect Dis. 2021 Dec 27. pii: 6484920. doi: 10.1093.
    >> Share

  455. KIM SS, Naioti EA, Halasa NB, Stewart LS, et al
    Vaccine Effectiveness against Influenza Hospitalization and Emergency Department Visits in Two A(H3N2) Dominant Influenza Seasons among Children <18 Years Old, New Vaccine Surveillance Network 2016-17 and 2017-18.
    J Infect Dis. 2021 Dec 24. pii: 6482612. doi: 10.1093.
    >> Share

  456. FALSEY AR, Walsh EE, Scott DA, Gurtman A, et al
    Phase 1/2 Randomized Study of the Immunogenicity, Safety and Tolerability of an RSV Prefusion F Vaccine in Adults With Concomitant Inactivated Influenza Vaccine.
    J Infect Dis. 2021 Dec 21. pii: 6472733. doi: 10.1093.
    >> Share

  457. WALSH EE, Falsey AR, Scott DA, Gurtman A, et al
    A Randomized Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine.
    J Infect Dis. 2021 Dec 21. pii: 6472747. doi: 10.1093.
    >> Share

  458. LEWIS NM, Naioti EA, Self WH, Ginde AA, et al
    Effectiveness of mRNA vaccines in preventing COVID-19 hospitalization by age and burden of chronic medical conditions among immunocompetent US adults, March-August 2021.
    J Infect Dis. 2021 Dec 21. pii: 6472998. doi: 10.1093.
    >> Share

  459. PHIJFFER EWEM, Bont LJ
    Are we ready for maternal RSV vaccination?
    J Infect Dis. 2021 Dec 21. pii: 6472740. doi: 10.1093.
    >> Share

  460. FAHIM SM, Hossain MS, Sen S, Das S, et al
    Nutrition and Food Security in Bangladesh: Achievements, Challenges, and Impact of the COVID-19 Pandemic.
    J Infect Dis. 2021;224.
    >> Share

  461. VERBURGH ML, Boyd A, Wit FWNM, Schim van der Loeff MF, et al
    Similar risk of SARS-CoV-2 infection and similar nucleocapsid antibody levels in people with well-controlled HIV and a comparable cohort of people without HIV.
    J Infect Dis. 2021 Dec 20. pii: 6470931. doi: 10.1093.
    >> Share

  462. GERIC C, Saroufim M, Landsman D, Richard J, et al
    Impact of Covid-19 on Tuberculosis Prevention and Treatment in Canada: a multicentre analysis of 10,833 patients.
    J Infect Dis. 2021 Dec 17. pii: 6469005. doi: 10.1093.
    >> Share

  463. LU Z, Laing ED, Pena DaMata J, Pohida K, et al
    Durability of SARS-CoV-2-Specific T-Cell Responses at 12 Months Postinfection.
    J Infect Dis. 2021;224:2010-2019.
    >> Share

  464. SCHULZE J, Mache C, Balazs A, Frey D, et al
    Analysis of Severe Acute Respiratory Syndrome 2 Replication in Explant Cultures of the Human Upper Respiratory Tract Reveals Broad Tissue Tropism of Wild-Type and B.1.1.7 Variant Viruses.
    J Infect Dis. 2021;224:2020-2024.
    >> Share

  465. PATI A, Padhi S, Nayak TKS, Panda AK, et al
    Angiotensin-Converting Enzyme 2 Genetic Variants Are Associated With Coronavirus Disease 2019.
    J Infect Dis. 2021;224:2181-2183.
    >> Share

  466. WOODFORD J, Sagara I, Dicko A, Zeguime A, et al
    Severe Acute Respiratory Syndrome Coronavirus 2 Seroassay Performance and Optimization in a Population With High Background Reactivity in Mali.
    J Infect Dis. 2021;224:2001-2009.
    >> Share

  467. KORSTEN K, Adriaenssens N, Coenen S, Butler CC, et al
    World Health Organization Influenza-Like Illness Underestimates the Burden of Respiratory Syncytial Virus Infection in Community-Dwelling Older Adults.
    J Infect Dis. 2021 Dec 14. pii: 6460601. doi: 10.1093.
    >> Share

  468. BROCKMAN MA, Mwimanzi F, Lapointe HR, Sang Y, et al
    Reduced magnitude and durability of humoral immune responses to COVID-19 mRNA vaccines among older adults.
    J Infect Dis. 2021 Dec 9. pii: 6458430. doi: 10.1093.
    >> Share

  469. NARANBHAI V, Garcia-Beltran WF, Chang CC, Mairena CB, et al
    Comparative immunogenicity and effectiveness of mRNA-1273, BNT162b2 and Ad26.COV2.S COVID-19 vaccines.
    J Infect Dis. 2021 Dec 9. pii: 6458467. doi: 10.1093.
    >> Share

  470. SHOOK LL, Bordt EA, Meinsohn MC, Pepin D, et al
    Placental Expression of ACE2 and TMPRSS2 in Maternal Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Are Placental Defenses Mediated by Fetal Sex?
    J Infect Dis. 2021;224.
    >> Share

  471. ZHOU J, Choi S, Liu H, Zhang J, et al
    Is SARS-CoV-2 Infection a Risk Factor for Early Pregnancy Loss? ACE2 and TMPRSS2 Coexpression and Persistent Replicative Infection in Primitive Trophoblast.
    J Infect Dis. 2021;224.
    >> Share

  472. ROBERTS DJ, Bebell LM, Edlow AG
    Severe Acute Respiratory Syndrome Coronavirus 2 ACE2 and TMPRSS2 Receptor Protein Expression Patterns Throughout Gestation.
    J Infect Dis. 2021;224.
    >> Share

  473. HALFMANN P, Nakajima N, Sato Y, Takahashi K, et al
    SARS-CoV-2 Interference of Influenza Virus Replication in Syrian Hamsters.
    J Infect Dis. 2021 Dec 7. pii: 6454972. doi: 10.1093.
    >> Share

  474. KIM G, Kim DH, Oh H, Bae S, et al
    Germinal Center-Induced Immunity Is Correlated With Protection Against SARS-CoV-2 Reinfection But Not Lung Damage.
    J Infect Dis. 2021;224:1861-1872.
    >> Share

  475. BENDER JK, Meyer ED, Sandfort M, Matysiak-Klose D, et al
    Low Sensitivity of Rapid Antigen Tests to Detect Severe Acute Respiratory Syndrome Coronavirus 2 Infections Before and on the Day of Symptom Onset in Nursing Home Staff and Residents, Germany, January-March 2021.
    J Infect Dis. 2021;224:1987-1989.
    >> Share

  476. YONKER LM, Boucau J, Regan J, Choudhary MC, et al
    Virologic Features of Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Children.
    J Infect Dis. 2021;224:1821-1829.
    >> Share

  477. BOPPANA SB, Pinninti SG, Britt WJ
    Coronavirus Disease 2019 and Children.
    J Infect Dis. 2021;224:1807-1809.
    >> Share

  478. LAU CS, Aw TC
    Frequent Severe Acute Respiratory Syndrome Coronavirus 2 Antigen Testing in a Disease-Free Population.
    J Infect Dis. 2021;224:1986-1987.
    >> Share

  479. BIGGERSTAFF BJ, Akinbami LJ, Hales C, Chan PA, et al
    Duration of Viral Nucleic Acid Shedding and Early Reinfection With Severe Respiratory Syndrome Coronavirus 2 in Healthcare Workers and First Responders.
    J Infect Dis. 2021;224:1873-1877.
    >> Share

  480. BOYAPATI A, Wipperman MF, Ehmann PJ, Hamon S, et al
    Baseline Severe Acute Respiratory Syndrome Viral Load Is Associated With Coronavirus Disease 2019 Severity and Clinical Outcomes: Post Hoc Analyses of a Phase 2/3 Trial.
    J Infect Dis. 2021;224:1830-1838.
    >> Share

  481. PARK S, Michelow IC, Choe YJ
    Shifting Patterns of Respiratory Virus Activity Following Social Distancing Measures for Coronavirus Disease 2019 in South Korea.
    J Infect Dis. 2021;224:1900-1906.
    >> Share

    November 2021
  482. GILBOA M, Mandelboim M, Indenbaum V, Lustig Y, et al
    Early Immunogenicity and safety of the third dose of BNT162b2 mRNA Covid-19 vaccine among adults older than 60 years; real world experience.
    J Infect Dis. 2021 Nov 29. pii: 6446235. doi: 10.1093.
    >> Share

  483. KIM JY, Lim SY, Park S, Kwon JS, et al
    Immune responses to the ChAdOx1 nCoV-19 and BNT162b2 vaccines and to natural COVID-19 infections over a three-month period.
    J Infect Dis. 2021 Nov 25. pii: 6440288. doi: 10.1093.
    >> Share

  484. KUMAR S, Ghosh RS, Iyer H, Ray A, et al
    Typhoid in India: An Age-old Problem With an Existing Solution.
    J Infect Dis. 2021;224.
    >> Share

  485. MELTZER E, Regev-Yochay G
    Mobile Phones and Respiratory Viral Infections.
    J Infect Dis. 2021;224:1629-1630.
    >> Share

  486. HICKS JT, Das S, Matanock A, Griego-Fisher A, et al
    Characteristics of Persons With Secondary Detection of Severe Acute Respiratory Syndrome Coronavirus 2 >/=90 days After First Detection, New Mexico 2020.
    J Infect Dis. 2021;224:1684-1689.
    >> Share

  487. ARCANJO A, Guimaraes Pinto K, Logullo J, Leite PEC, et al
    Critically Ill Coronavirus Disease 2019 Patients Exhibit Hyperactive Cytokine Responses Associated With Effector Exhausted Senescent T Cells in Acute Infection.
    J Infect Dis. 2021;224:1672-1683.
    >> Share

  488. LAU YC, Tsang TK, Kennedy-Shaffer L, Kahn R, et al
    Joint Estimation of Generation Time and Incubation Period for Coronavirus Disease 2019.
    J Infect Dis. 2021;224:1664-1671.
    >> Share

  489. LENNON NJ, Bhattacharyya RP, Mina MJ, Rehm HL, et al
    Cross-Sectional Assessment of SARS-CoV-2 Viral Load by Symptom Status in Massachusetts Congregate Living Facilities.
    J Infect Dis. 2021;224:1658-1663.
    >> Share

  490. SYMANSKI E, Ensor KB, Piedra PA, Sheth K, et al
    Population-Based Estimates of SARS-CoV-2 Seroprevalence in Houston, Texas as of September 2020.
    J Infect Dis. 2021;224:1649-1657.
    >> Share

  491. MOST ZM, Holcomb M, Jamieson AR, Perl TM, et al
    A Silver Lining? Fewer Non-Severe Acute Respiratory Syndrome Coronavirus 2 Respiratory Viruses During the Coronavirus Disease 2019 Pandemic.
    J Infect Dis. 2021;224:1751-1755.
    >> Share

  492. SCHUIT M, Biryukov J, Beck K, Yolitz J, et al
    The Stability of an Isolate of the SARS-CoV-2 B.1.1.7 Lineage in Aerosols Is Similar to 3 Earlier Isolates.
    J Infect Dis. 2021;224:1641-1648.
    >> Share

  493. AMBROSINO D, Han HH, Hu B, Liang J, et al
    Immunogenicity of SCB-2019 Coronavirus Disease 2019 Vaccine Compared With 4 Approved Vaccines.
    J Infect Dis. 2021 Nov 19. pii: 6431853. doi: 10.1093.
    >> Share

  494. FULDA ES, Fitch KV, Overton ET, Zanni MV, et al
    COVID-19 Vaccination Rates in a Global HIV Cohort.
    J Infect Dis. 2021 Nov 18. pii: 6431673. doi: 10.1093.
    >> Share

  495. COLLIER AY, Yu J, Mcmahan K, Liu J, et al
    COVID-19 mRNA Vaccine Immunogenicity in Immunosuppressed Individuals.
    J Infect Dis. 2021 Nov 18. pii: 6430790. doi: 10.1093.
    >> Share

  496. LEWIS AM, Zhang X, Brestoff JR
    Coronavirus Disease 2019 Severity in Obese Patients May Be Linked to Viral Load and Immune Response.
    J Infect Dis. 2021;224:1449-1451.
    >> Share

  497. EPSI NJ, Richard SA, Laing ED, Fries AC, et al
    Clinical, Immunological, and Virological SARS-CoV-2 Phenotypes in Obese and Nonobese Military Health System Beneficiaries.
    J Infect Dis. 2021;224:1462-1472.
    >> Share

  498. PELLEAU S, Woudenberg T, Rosado J, Donnadieu F, et al
    Kinetics of the Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Response and Serological Estimation of Time Since Infection.
    J Infect Dis. 2021;224:1489-1499.
    >> Share

  499. ZHOU M, Yin Z, Xu J, Wang S, et al
    Inflammatory Profiles and Clinical Features of Coronavirus 2019 Survivors 3 Months After Discharge in Wuhan, China.
    J Infect Dis. 2021;224:1473-1488.
    >> Share

  500. QUEEN J, Karaba S, Albin J, Karaba A, et al
    The Time is Now: A Call for Renewed Support of Infectious Diseases Physician-Scientist Trainees in the Era of Coronavirus Disease 2019.
    J Infect Dis. 2021;224:1452-1454.
    >> Share

  501. BIERLE DM, Ganesh R, Tulledge-Scheitel S, Hanson SN, et al
    Monoclonal Antibody Treatment of Breakthrough COVID-19 in Fully Vaccinated Individuals with High-Risk Comorbidities.
    J Infect Dis. 2021 Nov 16. pii: 6429422. doi: 10.1093.
    >> Share

  502. JOHNSON S, Martinez CI, Tedjakusuma SN, Peinovich N, et al
    Oral vaccination protects against SARS-CoV-2 in a Syrian hamster challenge model.
    J Infect Dis. 2021 Nov 10. pii: 6425228. doi: 10.1093.
    >> Share

  503. FERREIRA VH, Marinelli T, Ierullo M, Ku T, et al
    SARS-CoV-2 infection induces greater T-cell responses compared to vaccination in solid organ transplant recipients.
    J Infect Dis. 2021 Nov 5. pii: 6406613. doi: 10.1093.
    >> Share

  504. SACIUK Y, Kertes J, Shamir Stein N, Ekka Zohar A, et al
    Effectiveness of a third dose of BNT162b2 mRNA vaccine.
    J Infect Dis. 2021 Nov 2. pii: 6415586. doi: 10.1093.
    >> Share

    October 2021
  505. HUKIC M, Avdihodzic H, Veledar E, Korkut E, et al
    Potential Effect of Previous Human Coronavirus NL63 Infection on the Rate of Infection and the Clinical Course of Coronavirus Disease 2019.
    J Infect Dis. 2021;224:1444-1445.
    >> Share

  506. STOSOR V, Angarone MP
    Not All Monoclonal Antibodies for Coronavirus Disease 2019 Are Created Equal.
    J Infect Dis. 2021;224:1275-1277.
    >> Share

  507. HORTON DB, Barrett ES, Roy J, Gennaro ML, et al
    Determinants and Dynamics of SARS-CoV-2 Infection in a Diverse Population: 6-Month Evaluation of a Prospective Cohort Study.
    J Infect Dis. 2021;224:1345-1356.
    >> Share

  508. YANG Y, Kuang L, Li L, Wu Y, et al
    Distinct Mitochondria-Mediated T-Cell Apoptosis Responses in Children and Adults With Coronavirus Disease 2019.
    J Infect Dis. 2021;224:1333-1344.
    >> Share

  509. SANTOS BRAVO M, Nicolas D, Berengua C, Fernandez M, et al
    Severe Acute Respiratory Syndrome Coronavirus 2 Normalized Viral Loads and Subgenomic RNA Detection as Tools for Improving Clinical Decision Making and Work Reincorporation.
    J Infect Dis. 2021;224:1325-1332.
    >> Share

  510. BJORKMAN KK, Saldi TK, Lasda E, Bauer LC, et al
    Higher Viral Load Drives Infrequent Severe Acute Respiratory Syndrome Coronavirus 2 Transmission Between Asymptomatic Residence Hall Roommates.
    J Infect Dis. 2021;224:1316-1324.
    >> Share

  511. LI K, Wohlford-Lenane C, Bartlett JA, McCray PB, et al
    Intersubject Variation in ACE2 Protein Expression in Human Airway Epithelia and Its Relationship to Severe Acute Respiratory Syndrome Coronavirus 2.
    J Infect Dis. 2021;224:1357-1361.
    >> Share

  512. GANESH R, Philpot LM, Bierle DM, Anderson RJ, et al
    Real-World Clinical Outcomes of Bamlanivimab and Casirivimab-Imdevimab Among High-Risk Patients With Mild to Moderate Coronavirus Disease 2019.
    J Infect Dis. 2021;224:1278-1286.
    >> Share

  513. SHRWANI K, Sharma R, Krishnan M, Jones T, et al
    Detection of Serum Cross-Reactive Antibodies and Memory Response to SARS-CoV-2 in Prepandemic and Post-COVID-19 Convalescent Samples.
    J Infect Dis. 2021;224:1305-1315.
    >> Share

  514. DE GIORGI V, West KA, Henning AN, Chen LN, et al
    Naturally Acquired SARS-CoV-2 Immunity Persists for Up to 11 Months Following Infection.
    J Infect Dis. 2021;224:1294-1304.
    >> Share

  515. DIMCHEFF DE, Valesano AL, Rumfelt KE, Fitzsimmons WJ, et al
    Severe Acute Respiratory Syndrome Coronavirus 2 Total and Subgenomic RNA Viral Load in Hospitalized Patients.
    J Infect Dis. 2021;224:1287-1293.
    >> Share

  516. OWUSU D, Pomeroy MA, Lewis NM, Wadhwa A, et al
    Persistent SARS-CoV-2 RNA Shedding Without Evidence of Infectiousness: A Cohort Study of Individuals With COVID-19.
    J Infect Dis. 2021;224:1362-1371.
    >> Share

  517. MEIJIDE MIGUEZ H, Ochando Gomez M, Montes Garcia I, Garcia Merino IM, et al
    Cellular and humoral response, six months after two doses of BNT162b2 mRNA Covid 19 vaccination, in residents and staff of nursing homes for the elderly.
    J Infect Dis. 2021 Oct 28. pii: 6413766. doi: 10.1093.
    >> Share

  518. WITHANAGE K, De Coster I, Cools N, Viviani S, et al
    Phase 1 randomized, placebo-controlled, dose-escalating study to evaluate OVX836, a nucleoprotein-based influenza vaccine: intramuscular results.
    J Infect Dis. 2021 Oct 15. pii: 6398205. doi: 10.1093.
    >> Share

  519. WIDERA M, Wilhelm A, Hoehl S, Pallas C, et al
    Limited Neutralization of Authentic Severe Acute Respiratory Syndrome Coronavirus 2 Variants Carrying E484K In Vitro.
    J Infect Dis. 2021;224:1109-1114.
    >> Share

  520. DO LAH, Tsedenbal N, von Mollendorf C, Mungun T, et al
    Exploring the Possible Cause of the Dramatic Increase in Measles Mortality During the 2015-2016 Mongolian Outbreak.
    J Infect Dis. 2021;224:1266-1268.
    >> Share

  521. LEMARIE B, Boussaid G, Gault E, Prigent H, et al
    Predictors of hospitalization and superinfection in viral respiratory tract infections between influenza and paramyxoviruses: the SUPERFLUOUS study.
    J Infect Dis. 2021 Oct 12. pii: 6390777. doi: 10.1093.
    >> Share

  522. PETERSON JT, Zareba AM, Fitz-Patrick D, Essink BJ, et al
    Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F Vaccine When Co-Administered With a Tetanus, Diphtheria, and Acellular Pertussis Vaccine.
    J Infect Dis. 2021 Oct 12. pii: 6391485. doi: 10.1093.
    >> Share

  523. DODD RY, Notari EP, Brodsky JP, Foster GA, et al
    Patterns of antibody response to SARS-CoV-2 among 1.6 million blood donors: Impact of vaccination, United States December 2020 - June 2021.
    J Infect Dis. 2021 Oct 9. pii: 6385747. doi: 10.1093.
    >> Share

  524. LU Y, Jiao Y, Graham DJ, Wu Y, et al
    Risk factors for COVID-19 deaths among elderly nursing home Medicare beneficiaries in the pre-vaccine period.
    J Infect Dis. 2021 Oct 7. pii: 6383455. doi: 10.1093.
    >> Share

    September 2021
  525. BECKER T, Elbahesh H, Reperant LA, Rimmelzwaan GF, et al
    Influenza Vaccines: Successes and Continuing Challenges.
    J Infect Dis. 2021;224.
    >> Share

  526. PELUSO MJ, Lu S, Tang AF, Durstenfeld MS, et al
    Markers of Immune Activation and Inflammation in Individuals With Postacute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
    J Infect Dis. 2021 Sep 27. pii: 6376537. doi: 10.1093.
    >> Share

  527. QI Y, Shaman J, Pei S
    Quantifying the impact of COVID-19 non-pharmaceutical interventions on influenza transmission in the United States.
    J Infect Dis. 2021 Sep 22. pii: 6374002. doi: 10.1093.
    >> Share

  528. KARBIENER M, Farcet MR, Schwaiger J, Powers N, et al
    Plasma from post-COVID-19 and COVID-19-Vaccinated Donors Results in Highly Potent SARS-CoV-2 Neutralization by Intravenous Immunoglobulins.
    J Infect Dis. 2021 Sep 20. pii: 6372887. doi: 10.1093.
    >> Share

  529. XIAO J, de Mesquita JB, Leung NHL, Adenaiye O, et al
    Viral RNA and infectious influenza virus on mobile phones of influenza patients in Hong Kong and the United States.
    J Infect Dis. 2021 Sep 17. pii: 6371826. doi: 10.1093.
    >> Share

  530. GORSE GJ, Rattigan SM, Kirpich A, Simberkoff MS, et al
    Influence of Pre-Season Antibodies against Influenza Virus on Risk of Influenza Infection among Health Care Personnel.
    J Infect Dis. 2021 Sep 17. pii: 6371937. doi: 10.1093.
    >> Share

  531. BEVERLAND A, Keogan M, Connell J, De Gascun C, et al
    Longitudinal Serological Analysis Following a National Seroprevalence Study to Investigate COVID-19 Infection in People Living in Ireland.
    J Infect Dis. 2021;224:1100-1101.
    >> Share

  532. TONG M, Zheng Q, Chen F, Zhu Y, et al
    Comment on: Cell Adhesion Molecules and Vascular Endothelial Growth Factor at the Systemic and Alveolar Level in Coronavirus Disease 2019 Acute Respiratory Distress Syndrome.
    J Infect Dis. 2021;224:1103-1104.
    >> Share

  533. KRISTENSEN MK, Plovsing RR, Berg RMG, Krogh-Madsen R, et al
    Cell Adhesion Molecules and Vascular Endothelial Growth Factor at the Systemic and Alveolar Level in Coronavirus Disease 2019 Acute Respiratory Distress Syndrome.
    J Infect Dis. 2021;224:1101-1103.
    >> Share

  534. CHOE PG, Kang CK, Kim KH, Yi J, et al
    Persistence of Neutralizing Antibody Response up to 1 Year After Asymptomatic or Symptomatic SARS-CoV-2 Infection.
    J Infect Dis. 2021;224:1097-1099.
    >> Share

  535. ERREN TC, Lewis P, Morfeld P
    Factoring in Coronavirus Disease 2019 Seasonality: Experiences From Germany.
    J Infect Dis. 2021;224:1096.
    >> Share

  536. HEATON PM
    Herd Immunity: The Journey Is as Important as the Destination.
    J Infect Dis. 2021;224:931-933.
    >> Share

  537. FERREIRA IATM, Kemp SA, Datir R, Saito A, et al
    SARS-CoV-2 B.1.617 Mutations L452R and E484Q Are Not Synergistic for Antibody Evasion.
    J Infect Dis. 2021;224:989-994.
    >> Share

  538. SMITH RL, Gibson LL, Martinez PP, Ke R, et al
    Longitudinal Assessment of Diagnostic Test Performance Over the Course of Acute SARS-CoV-2 Infection.
    J Infect Dis. 2021;224:976-982.
    >> Share

  539. KOECKERLING D, Barker J
    Accelerating the Evolution of Severe Acute Respiratory Syndrome Coronavirus 2: A Risk of Combining Dexamethasone and Tocilizumab for Severe Coronavirus Disease 2019.
    J Infect Dis. 2021;224:934-937.
    >> Share

  540. CHO K, Keithly SC, Kurgansky KE, Madenci AL, et al
    Early Convalescent Plasma Therapy and Mortality Among US Veterans Hospitalized With Nonsevere COVID-19: An Observational Analysis Emulating a Target Trial.
    J Infect Dis. 2021;224:967-975.
    >> Share

  541. RYU S, Hwang Y, Ali ST, Kim DS, et al
    Decreased Use of Broad-Spectrum Antibiotics During the Coronavirus Disease 2019 Epidemic in South Korea.
    J Infect Dis. 2021;224:949-955.
    >> Share

  542. GRZELAK L, Velay A, Madec Y, Gallais F, et al
    Sex Differences in the Evolution of Neutralizing Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2.
    J Infect Dis. 2021;224:983-988.
    >> Share

  543. VAN PRAET JT, Vandecasteele S, De Roo A, Vynck M, et al
    Dynamics of the cellular and humoral immune response after BNT162b2 mRNA Covid-19 vaccination in Covid-19 naive nursing home residents.
    J Infect Dis. 2021 Sep 13. pii: 6369254. doi: 10.1093.
    >> Share

  544. KIM SS, Chung JR, Belongia EA, McLean HQ, et al
    mRNA Vaccine Effectiveness against COVID-19 among Symptomatic Outpatients Aged >/=16 Years in the United States, February - May 2021.
    J Infect Dis. 2021 Sep 8. pii: 6366365. doi: 10.1093.
    >> Share

  545. RICHMOND PC, Hatchuel L, Pacciarini F, Hu B, et al
    Persistence of the immune responses and cross-neutralizing activity with Variants of Concern following two doses of adjuvanted SCB-2019 COVID-19 vaccine.
    J Infect Dis. 2021 Sep 4. pii: 6364149. doi: 10.1093.
    >> Share

  546. SUNTARATTIWONG P, Mott JA, Mohanty S, Sinthuwattanawibool C, et al
    Feasibility and Performance of Self-Collected Nasal Swabs for Detection of Influenza Virus, Respiratory Syncytial Virus, and Human Metapneumovirus.
    J Infect Dis. 2021;224:831-838.
    >> Share

  547. HILL KJ, Dewar R, Templeton K
    A Multiregional Evaluation of Cycle Threshold Values in Severe Acute Respiratory Syndrome Coronavirus 2 VOC-20DEC-01 Variant.
    J Infect Dis. 2021;224:927-928.
    >> Share

  548. RAN S, Su K, Zhang S, Liu B, et al
    The Association Between Coronavirus Disease 2019 Infection and Blood Constituents: A Mendelian Randomization Analysis.
    J Infect Dis. 2021;224:922-924.
    >> Share

  549. KIM MH, Salloum S, Wang JY, Wong LP, et al
    Type I, II, and III Interferon Signatures Correspond to Coronavirus Disease 2019 Severity.
    J Infect Dis. 2021;224:777-782.
    >> Share

  550. NOH JY, Kwak JE, Yang JS, Hwang SY, et al
    Longitudinal Assessment of Antisevere Acute Respiratory Syndrome Coronavirus 2 Immune Responses for Six Months Based on the Clinical Severity of Coronavirus Disease 2019.
    J Infect Dis. 2021;224:754-763.
    >> Share

  551. PATI A, Padhi S, Panda D, Suvankar S, et al
    A CD14 Polymorphism (C-159T rs2569190) Is Associated With SARS-CoV-2 Infection and Mortality in the European Population.
    J Infect Dis. 2021;224:921-922.
    >> Share

  552. ABDELNABI R, Foo CS, De Jonghe S, Maes P, et al
    Molnupiravir Inhibits Replication of the Emerging SARS-CoV-2 Variants of Concern in a Hamster Infection Model.
    J Infect Dis. 2021;224:749-753.
    >> Share

  553. PEREZ-LAGO L, Martinez-Lozano H, Pajares Diaz JA, Diaz Gomez A, et al
    Proper Assignation of Reactivation in a COVID-19 Recurrence Initially Interpreted as a Reinfection.
    J Infect Dis. 2021;224:788-792.
    >> Share

  554. PICHLER D, Baumgartner M, Kimpel J, Rossler A, et al
    Marked Increase in Avidity of SARS-CoV-2 Antibodies 7-8 Months After Infection Is Not Diminished in Old Age.
    J Infect Dis. 2021;224:764-770.
    >> Share

  555. TSANG TK, Wu P, Lau EHY, Cowling BJ, et al
    Accounting for Imported Cases in Estimating the Time-Varying Reproductive Number of Coronavirus Disease 2019 in Hong Kong.
    J Infect Dis. 2021;224:783-787.
    >> Share

  556. RAZANI N, Malekinejad M, Rutherford GW
    Clarification Regarding "Outdoor Transmission of SARS-CoV-2 and Other Respiratory Viruses: A Systematic Review".
    J Infect Dis. 2021;224:925-926.
    >> Share

  557. KILLERBY ME, Ata Ur Rasheed M, Tamin A, Harcourt JL, et al
    Shedding of Culturable Virus, Seroconversion, and 6-Month Follow-up Antibody Responses in the First 14 Confirmed Cases of Coronavirus Disease 2019 in the United States.
    J Infect Dis. 2021;224:771-776.
    >> Share

  558. LANE STARR NM, Evans MD, Lee KE, Gern JE, et al
    Ensemble Analysis Identifies Nasal 15-Keto-PGE2 as a Predictor of Recovery in Experimental Rhinovirus Colds.
    J Infect Dis. 2021;224:839-849.
    >> Share

    August 2021
  559. GIURGEA LT, Cervantes-Medina A, Walters KA, Scherler K, et al
    Sex Differences in Influenza: The Challenge Study Experience.
    J Infect Dis. 2021 Aug 23. pii: 6356350. doi: 10.1093.
    >> Share

  560. LINNIK J, Syedbasha M, Kaltenbach HM, Vogt D, et al
    Association of host factors with antibody response to seasonal influenza vaccination in allogeneic hematopoietic stem cell transplant (HSCT) patients.
    J Infect Dis. 2021 Aug 20. pii: 6355382. doi: 10.1093.
    >> Share

  561. DE MIGUEL BUCKLEY R, Diaz-Menendez M, Garcia-Rodriguez J, Arribas JR, et al
    Seasonal coronavirus pneumonia after SARS-Cov-2 infection and vaccine: new frenemies?
    J Infect Dis. 2021 Aug 20. pii: 6355378. doi: 10.1093.
    >> Share

  562. NATHAN N, Prevost B, Lambert S, Schnuriger A, et al
    SARS-CoV-2 variant Delta infects all 6 siblings but spares Comirnaty (BNT162b2, BioNTech/Pfizer)-vaccinated parents.
    J Infect Dis. 2021 Aug 19. pii: 6354728. doi: 10.1093.
    >> Share

  563. YANG CY, Lee YY, Wei JC
    Interpreting prevention of COVID-19 and vaccines.
    J Infect Dis. 2021 Aug 18. pii: 6354219. doi: 10.1093.
    >> Share

  564. PEART AKINDELE N, Kouo T, Karaba AH, Gordon O, et al
    Distinct Cytokine and Chemokine Dysregulation in Hospitalized Children With Acute Coronavirus Disease 2019 and Multisystem Inflammatory Syndrome With Similar Levels of Nasopharyngeal Severe Acute Respiratory Syndrome Coronavirus 2 Shedding.
    J Infect Dis. 2021;224:606-615.
    >> Share

  565. BARLEV-GROSS M, Weiss S, Paran N, Yahalom-Ronen Y, et al
    Sensitive Immunodetection of Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern 501Y.V2 and 501Y.V1.
    J Infect Dis. 2021;224:616-619.
    >> Share

  566. MAZZITELLI I, Bleichmar L, Luduena MG, Pisarevsky A, et al
    Immunoglobulin G Immune Complexes May Contribute to Neutrophil Activation in the Course of Severe Coronavirus Disease 2019.
    J Infect Dis. 2021;224:575-585.
    >> Share

  567. BANDOPADHYAY P, D'Rozario R, Lahiri A, Sarif J, et al
    Nature and Dimensions of Systemic Hyperinflammation and its Attenuation by Convalescent Plasma in Severe COVID-19.
    J Infect Dis. 2021;224:565-574.
    >> Share

  568. PADHI S, Sahu S, Pati A, Mohanty AK, et al
    Minor Allele of Intercellular Adhesion Molecule-1 Polymorphism (rs5498 1462A>G) Is Associated With SARS-CoV-2 Infection and Related Mortality.
    J Infect Dis. 2021;224:734-735.
    >> Share

  569. RATCLIFF J, Nguyen D, Fish M, Rynne J, et al
    Virological Characterization of Critically Ill Patients With COVID-19 in the United Kingdom: Interactions of Viral Load, Antibody Status, and B.1.1.7 Infection.
    J Infect Dis. 2021;224:595-605.
    >> Share

  570. YAO L, Wang GL, Shen Y, Wang ZY, et al
    Persistence of Antibody and Cellular Immune Responses in Coronavirus Disease 2019 Patients Over Nine Months After Infection.
    J Infect Dis. 2021;224:586-594.
    >> Share

  571. SOUTHWICK FS
    Improving the Definition of Coronavirus Disease 2019-Related Deaths.
    J Infect Dis. 2021;224:375-376.
    >> Share

  572. AVIV R, Weber A, Anzum T, Federbush M, et al
    Prolonged Coronavirus Disease 2019 in a Patient With Rheumatoid Arthritis on Rituximab Therapy.
    J Infect Dis. 2021;224:557-559.
    >> Share

  573. ALLAN-BLITZ LT, Klausner JD
    Reply: Seroprevalence of SARS-CoV-2 After the Largest Initial Epidemic Wave in the United States: Findings from New York City, May 13-July 21, 2020.
    J Infect Dis. 2021;224:556-557.
    >> Share

  574. HALL JA, Harris RJ, Emmett HE, Lowe B, et al
    On the Sensitivity and Specificity of Postmortem Upper Respiratory Tract Testing for SARS-CoV-2.
    J Infect Dis. 2021;224:389-394.
    >> Share

  575. MEISTER TL, Fortmann J, Todt D, Heinen N, et al
    Comparable Environmental Stability and Disinfection Profiles of the Currently Circulating SARS-CoV-2 Variants of Concern B.1.1.7 and B.1.351.
    J Infect Dis. 2021;224:420-424.
    >> Share

  576. ALKHARAAN H, Bayati S, Hellstrom C, Aleman S, et al
    Persisting Salivary IgG Against SARS-CoV-2 at 9 Months After Mild COVID-19: A Complementary Approach to Population Surveys.
    J Infect Dis. 2021;224:407-414.
    >> Share

  577. BOUMAZA A, Gay L, Mezouar S, Bestion E, et al
    Monocytes and Macrophages, Targets of Severe Acute Respiratory Syndrome Coronavirus 2: The Clue for Coronavirus Disease 2019 Immunoparalysis.
    J Infect Dis. 2021;224:395-406.
    >> Share

    July 2021
  578. EIDEN J, Volckaert B, Rudenko O, Aitchison R, et al
    Single Replication M2SR Influenza Vaccine Induced Immune Responses Associated with Protection Against Human Challenge with Highly Drifted H3N2 Influenza Strain.
    J Infect Dis. 2021 Jul 29. pii: 6330582. doi: 10.1093.
    >> Share

  579. GIL RM, Freeman T, Mathew T, Kullar R, et al
    The LGBTQ+ communities and the COVID-19 pandemic: a call to break the cycle of structural barriers.
    J Infect Dis. 2021 Jul 29. pii: 6330600. doi: 10.1093.
    >> Share

  580. PARROTT JC, Maleki AN, Vassor VE, Osahan S, et al
    Prevalence of SARS-CoV-2 Antibodies in New York City Adults, June-October 2020: A Population-Based Survey.
    J Infect Dis. 2021;224:188-195.
    >> Share

  581. CASADO JL, Vizcarra P, Velasco H, Hammerle J, et al
    Progressive and Parallel Decline of Humoral and T-Cell Immunity in Convalescent Healthcare Workers with Asymptomatic or Mild-to-Moderate Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
    J Infect Dis. 2021;224:241-245.
    >> Share

  582. PANDA AK, Pati A, Padhi S, Sahoo AK, et al
    Association of Granulin rs5848 (C>T) Polymorphism With Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Mortality Rate.
    J Infect Dis. 2021;224:366-367.
    >> Share

  583. BERNAL E, Gimeno L, Alcaraz MJ, Quadeer AA, et al
    Activating Killer-Cell Immunoglobulin-Like Receptors Are Associated With the Severity of Coronavirus Disease 2019.
    J Infect Dis. 2021;224:229-240.
    >> Share

  584. JALKANEN P, Pasternack A, Maljanen S, Melen K, et al
    A Combination of N and S Antigens With IgA and IgG Measurement Strengthens the Accuracy of SARS-CoV-2 Serodiagnostics.
    J Infect Dis. 2021;224:218-228.
    >> Share

  585. VILLARINO E, Deng X, Kemper CA, Jorden MA, et al
    Introduction, Transmission Dynamics, and Fate of Early Severe Acute Respiratory Syndrome Coronavirus 2 Lineages in Santa Clara County, California.
    J Infect Dis. 2021;224:207-217.
    >> Share

  586. PATHELA P, Crawley A, Weiss D, Maldin B, et al
    Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Following the Largest Initial Epidemic Wave in the United States: Findings From New York City, 13 May to 21 July 2020.
    J Infect Dis. 2021;224:196-206.
    >> Share

  587. HALL MD, Anderson JM, Anderson A, Baker D, et al
    Report of the National Institutes of Health SARS-CoV-2 Antiviral Therapeutics Summit.
    J Infect Dis. 2021;224.
    >> Share

  588. YEO KT, Yung CF, Khoo PC, Saffari SE, et al
    Effectiveness of Palivizumab Against Respiratory Syncytial Virus Hospitalization Among Preterm Infants in a Setting With Year-Round Circulation.
    J Infect Dis. 2021;224:279-287.
    >> Share

  589. BERBERS G, Mollema L, van der Klis F, den Hartog G, et al
    Antibody Responses to Respiratory Syncytial Virus: A Cross-Sectional Serosurveillance Study in the Dutch Population Focusing on Infants Younger Than 2 Years.
    J Infect Dis. 2021;224:269-278.
    >> Share

  590. SYED F, Li W, Relich RF, Russell PM, et al
    Excessive Matrix Metalloproteinase-1 and Hyperactivation of Endothelial Cells Occurred in COVID-19 Patients and Were Associated With the Severity of COVID-19.
    J Infect Dis. 2021;224:60-69.
    >> Share

  591. DA SILVA ANTUNES R, Pallikkuth S, Williams E, Dawen Yu E, et al
    Differential T-Cell Reactivity to Endemic Coronaviruses and SARS-CoV-2 in Community and Health Care Workers.
    J Infect Dis. 2021;224:70-80.
    >> Share

  592. PETRIE JG, Bazzi LA, McDermott AB, Follmann D, et al
    Coronavirus Occurrence in the Household Influenza Vaccine Evaluation (HIVE) Cohort of Michigan Households: Reinfection Frequency and Serologic Responses to Seasonal and Severe Acute Respiratory Syndrome Coronaviruses.
    J Infect Dis. 2021;224:49-59.
    >> Share

  593. KANG CK, Kim M, Lee S, Kim G, et al
    Longitudinal Analysis of Human Memory T-Cell Response According to the Severity of Illness up to 8 Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
    J Infect Dis. 2021;224:39-48.
    >> Share

  594. DEE K, Goldfarb DM, Haney J, Amat JAR, et al
    Human Rhinovirus Infection Blocks Severe Acute Respiratory Syndrome Coronavirus 2 Replication Within the Respiratory Epithelium: Implications for COVID-19 Epidemiology.
    J Infect Dis. 2021;224:31-38.
    >> Share

  595. KRAAY ANM, Han P, Kambhampati AK, Wikswo ME, et al
    Impact of Nonpharmaceutical Interventions for Severe Acute Respiratory Syndrome Coronavirus 2 on Norovirus Outbreaks: An Analysis of Outbreaks Reported By 9 US States.
    J Infect Dis. 2021;224:9-13.
    >> Share

  596. DILLNER J, Elfstrom KM, Blomqvist J, Engstrand L, et al
    High Amounts of SARS-CoV-2 Precede Sickness Among Asymptomatic Health Care Workers.
    J Infect Dis. 2021;224:14-20.
    >> Share

  597. GIACOMELLI CAO R, Christian L, Xu Z, Jaramillo L, et al
    Early changes in interferon gene expression and antibody responses following influenza vaccination in pregnant women.
    J Infect Dis. 2021 Jul 1. pii: 6312681. doi: 10.1093.
    >> Share

    June 2021
  598. SCHWARZ TF, Johnson C, Grigat C, Apter D, et al
    Three dose levels of a maternal respiratory syncytial virus vaccine candidate are well tolerated and immunogenic in a randomized trial in non-pregnant women.
    J Infect Dis. 2021 Jun 19. pii: 6306104. doi: 10.1093.
    >> Share

  599. MA Y, Liu F, Lin T, Chen L, et al
    Large-scale identification of T cell epitopes derived from SARS-CoV-2 for the development of peptide vaccines against COVID-19.
    J Infect Dis. 2021 Jun 18. pii: 6305142. doi: 10.1093.
    >> Share

  600. BRAUNSTEIN SL, Slutsker JS, Lazar R, Shah D, et al
    Epidemiology of reported HIV and other sexually transmitted infections during the COVID-19 pandemic, New York City.
    J Infect Dis. 2021 Jun 16. pii: 6301136. doi: 10.1093.
    >> Share

  601. HAAGMANS BL, Noack D, Okba NMA, Li W, et al
    SARS-CoV-2 Neutralizing Human Antibodies Protect Against Lower Respiratory Tract Disease in a Hamster Model.
    J Infect Dis. 2021;223:2020-2028.
    >> Share

  602. HAWLEY HB, Chang JC
    Complement-Induced Endotheliopathy-Associated Vascular Microthrombosis in Coronavirus Disease 2019.
    J Infect Dis. 2021;223:2198-2199.
    >> Share

  603. DEMONBREUN AR, Sancilio A, Velez ME, Ryan DT, et al
    COVID-19 mRNA vaccination generates greater IgG levels in women compared to men.
    J Infect Dis. 2021 Jun 12. pii: 6297423. doi: 10.1093.
    >> Share

  604. RAMOS DA SILVA S, Ju E, Meng W, Paniz Mondolfi AE, et al
    Broad Severe Acute Respiratory Syndrome Coronavirus 2 Cell Tropism and Immunopathology in Lung Tissues From Fatal Coronavirus Disease 2019.
    J Infect Dis. 2021;223:1842-1854.
    >> Share

  605. ROSENBERG ES, Tesoriero JM
    A Tale of Many New York Cities.
    J Infect Dis. 2021 Jun 4. pii: 6291934. doi: 10.1093.
    >> Share

  606. RINGLANDER J, Nilsson S, Westin J, Lindh M, et al
    Low Incidence of Reinfection With Endemic Coronaviruses Diagnosed by Real-Time PCR.
    J Infect Dis. 2021;223:2013-2014.
    >> Share

    May 2021
  607. SCHNIERLE BS
    Reply to Ringlander et al.
    J Infect Dis. 2021;223:1833.
    >> Share

  608. RINGLANDER J, Martner A, Nilsson S, Westin J, et al
    Incidence and Severity of Covid-19 in Patients with and without Previously Verified Infections with Common Cold Coronaviruses.
    J Infect Dis. 2021;223:1831-1832.
    >> Share

  609. LU L, Koh CT, Lim YH, Sng A, et al
    Role of Asymptomatic Children in Community Severe Acute Respiratory Syndrome Coronavirus 2 Transmission.
    J Infect Dis. 2021;223:1834-1836.
    >> Share

  610. HAYMOND A, Damluji AA, Narayanan A, Mueller C, et al
    Durability of Viral Neutralization in Asymptomatic Coronavirus Disease 2019 for at Least 60 Days.
    J Infect Dis. 2021;223:1677-1680.
    >> Share

  611. ACOSTA-AMPUDIA Y, Rojas M, Monsalve DM, Rodriguez Y, et al
    Comment on: Nature and Dimensions of the Systemic Hyper-inflammation and Its Attenuation by Convalescent Plasma in Severe COVID-19.
    J Infect Dis. 2021;223:1833-1834.
    >> Share

  612. PEREIRA C, Harris BHL, Di Giovannantonio M, Rosadas C, et al
    The Association Between Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Post-COVID-19 Syndrome in Healthcare Workers.
    J Infect Dis. 2021;223:1671-1676.
    >> Share

  613. LEMIEUX JE, Li JZ
    Uncovering Ways That Emerging Severe Acute Respiratory Syndrome Coronavirus 2 Lineages May Increase Transmissibility.
    J Infect Dis. 2021;223:1663-1665.
    >> Share

  614. KIDD M, Richter A, Best A, Cumley N, et al
    S-Variant SARS-CoV-2 Lineage B1.1.7 Is Associated With Significantly Higher Viral Load in Samples Tested by TaqPath Polymerase Chain Reaction.
    J Infect Dis. 2021;223:1666-1670.
    >> Share

  615. DAWOOD FS, Varner M, Munoz F, Stockwell MS, et al
    Respiratory Viral Infections and Infection Prevention Practices among Women with Acute Respiratory Illness during Delivery Hospitalizations during the 2019-2020 Influenza Season.
    J Infect Dis. 2021 May 25. pii: 6284115. doi: 10.1093.
    >> Share

  616. XIE C, Su W, Sia SF, Choy KT, et al
    A(H1N1)pdm09 influenza viruses replicating in ferret upper or lower respiratory tract differed in onward transmission potential by air.
    J Infect Dis. 2021 May 24. pii: 6283765. doi: 10.1093.
    >> Share

  617. FELDSTEIN LR, Ferdinands JM, Self WH, Randolph AG, et al
    Modeling the impacts of clinical influenza testing on influenza vaccine effectiveness estimates.
    J Infect Dis. 2021 May 20. pii: 6278475. doi: 10.1093.
    >> Share

  618. SYNOLAKI E, Papadopoulos V, Divolis G, Tsahouridou O, et al
    The Activin/Follistatin Axis Is Severely Deregulated in COVID-19 and Independently Associated With In-Hospital Mortality.
    J Infect Dis. 2021;223:1544-1554.
    >> Share

  619. AVADHANULA V, Nicholson EG, Ferlic-Stark L, Piedra FA, et al
    Viral Load of Severe Acute Respiratory Syndrome Coronavirus 2 in Adults During the First and Second Wave of Coronavirus Disease 2019 Pandemic in Houston, Texas: The Potential of the Superspreader.
    J Infect Dis. 2021;223:1528-1537.
    >> Share

  620. RAMAN RS, Bhagwan Barge V, Anil Kumar D, Dandu H, et al
    A Phase II Safety and Efficacy Study on Prognosis of Moderate Pneumonia in Coronavirus Disease 2019 Patients With Regular Intravenous Immunoglobulin Therapy.
    J Infect Dis. 2021;223:1538-1543.
    >> Share

  621. TARHINI H, Recoing A, Bridier-Nahmias A, Rahi M, et al
    Long-Term Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infectiousness Among Three Immunocompromised Patients: From Prolonged Viral Shedding to SARS-CoV-2 Superinfection.
    J Infect Dis. 2021;223:1522-1527.
    >> Share

  622. RICHARDS KA, Glover M, Crawford JC, Thomas PG, et al
    Circulating CD4 T Cells Elicited by Endemic Coronaviruses Display Vast Disparities in Abundance and Functional Potential Linked to Antigen Specificity and Age.
    J Infect Dis. 2021;223:1555-1563.
    >> Share

  623. CHEN J, Vitetta L
    Increased PD-L1 Expression May Be Associated With the Cytokine Storm and CD8+ T-Cell Exhaustion in Severe COVID-19.
    J Infect Dis. 2021;223:1659-1660.
    >> Share

  624. OUWENDIJK WJD, Raadsen MP, van Kampen JJA, Verdijk RM, et al
    High Levels of Neutrophil Extracellular Traps Persist in the Lower Respiratory Tract of Critically Ill Patients With Coronavirus Disease 2019.
    J Infect Dis. 2021;223:1512-1521.
    >> Share

  625. TELUGUAKULA N
    Neutrophils Set Extracellular Traps to Injure Lungs in Coronavirus Disease 2019.
    J Infect Dis. 2021;223:1503-1505.
    >> Share

  626. CHU CY, Qiu X, McCall MN, Wang L, et al
    Airway Gene Expression Correlates of Respiratory Syncytial Virus Disease Severity and Microbiome Composition in Infants.
    J Infect Dis. 2021;223:1639-1649.
    >> Share

  627. GRIER A, Gill AL, Kessler HA, Corbett A, et al
    Temporal Dysbiosis of Infant Nasal Microbiota Relative to Respiratory Syncytial Virus Infection.
    J Infect Dis. 2021;223:1650-1658.
    >> Share

  628. BIANCHI FP, Germinario CA, Migliore G, Vimercati L, et al
    BNT162b2 mRNA Covid-19 vaccine effectiveness in the prevention of SARS-CoV-2 infection: a preliminary report.
    J Infect Dis. 2021 May 19. pii: 6278131. doi: 10.1093.
    >> Share

  629. JOFFE S, Babiker A, Ellenberg SS, Fix A, et al
    Data and Safety Monitoring of COVID-19 Vaccine Clinical Trials.
    J Infect Dis. 2021 May 19. pii: 6278127. doi: 10.1093.
    >> Share

  630. COREY L
    Behind the Scenes Heroes: the COVID-19 Vaccine Data and Safety Monitoring Board.
    J Infect Dis. 2021 May 19. pii: 6278073. doi: 10.1093.
    >> Share

  631. CHA S, Henry A, Montgomery MP, Laws RL, et al
    Morbidity and Mortality among Adults Experiencing Homelessness Hospitalized with COVID-19.
    J Infect Dis. 2021 May 16. pii: 6276529. doi: 10.1093.
    >> Share

  632. BARTSCH SM, Wedlock PT, O'Shea KJ, Cox SN, et al
    Lives and Costs Saved by Expanding and Expediting COVID-19 Vaccination.
    J Infect Dis. 2021 May 6. pii: 6267841. doi: 10.1093.
    >> Share

    April 2021
  633. BAO L, Song Z, Xue J, Gao H, et al
    Susceptibility and Attenuated Transmissibility of SARS-CoV-2 in Domestic Cats.
    J Infect Dis. 2021;223:1313-1321.
    >> Share

  634. DAVIS MF, Innes GK
    The Cat's in the Bag: Despite Limited Cat-to-Cat Severe Acute Respiratory Syndrome Coronavirus 2 Transmission, One Health Surveillance Efforts Are Needed.
    J Infect Dis. 2021;223:1309-1312.
    >> Share

  635. LUZZATTO-FEGIZ P, Temprano-Coleto F, Peaudecerf FJ, Landel JR, et al
    UVB Radiation Alone May Not Explain Sunlight Inactivation of SARS-CoV-2.
    J Infect Dis. 2021;223:1500-1502.
    >> Share

  636. JANSSEN NAF, Grondman I, de Nooijer AH, Boahen CK, et al
    Dysregulated Innate and Adaptive Immune Responses Discriminate Disease Severity in COVID-19.
    J Infect Dis. 2021;223:1322-1333.
    >> Share

  637. BAUER W, Ulke J, Galtung N, Strasser-Marsik LC, et al
    Role of Cell Adhesion Molecules for Prognosis of Disease Development of Patients With and Without COVID-19 in the Emergency Department.
    J Infect Dis. 2021;223:1497-1499.
    >> Share

  638. THIEDE JM, Gress AR, Libby SD, Ronayne CE, et al
    Immune Profiling to Determine Early Disease Trajectories Associated With Coronavirus Disease 2019 Mortality Rate: A Substudy from the ACTT-1 Trial.
    J Infect Dis. 2021;223:1339-1344.
    >> Share

  639. BOLOTIN S, Tran V, Osman S, Brown KA, et al
    SARS-CoV-2 Seroprevalence Survey Estimates Are Affected by Anti-Nucleocapsid Antibody Decline.
    J Infect Dis. 2021;223:1334-1338.
    >> Share

  640. KALKOWSKA DA, Pallansch MA, Cochi SL, Thompson KM, et al
    Updated characterization of poliovirus transmission in Pakistan and Afghanistan and the impacts of different outbreak response vaccine options.
    J Infect Dis. 2021 Apr 22. pii: 6246102. doi: 10.1093.
    >> Share

  641. KALA S, Meteleva K, Serghides L
    ACE2, TMPRSS2 and L-SIGN expression in placentae from HIV-positive pregnancies exposed to antiretroviral therapy-implications for SARS-CoV-2 placental infection.
    J Infect Dis. 2021 Apr 21. pii: 6242371. doi: 10.1093.
    >> Share

  642. MCCARTNEY MM, Linderholm AL, Yamaguchi MS, Falcon AK, et al
    Predicting influenza and rhinovirus infections in airway cells utilizing volatile emissions.
    J Infect Dis. 2021 Apr 15. pii: 6226913. doi: 10.1093.
    >> Share

  643. EL SAHLY HM, Atmar RL, Sendra E, Wegel A, et al
    Topical Imiquimod Does not Provide an Adjuvant Effect when Administered with Inactivated Influenza A/H5N1 Vaccine in Healthy Young Adults.
    J Infect Dis. 2021 Apr 14. pii: 6225864. doi: 10.1093.
    >> Share

  644. SATO M, Takashita E, Katayose M, Nemoto K, et al
    Detection of variants with reduced baloxavir marboxil and oseltamivir susceptibility in children with influenza A during the 2019-2020 influenza season.
    J Infect Dis. 2021 Apr 10. pii: 6219607. doi: 10.1093.
    >> Share

  645. ABBOUD H
    Encephalitis in the Setting of COVID-19 Infection.
    J Infect Dis. 2021;223:1303.
    >> Share

  646. TJAN LH, Furukawa K, Nagano T, Kiriu T, et al
    Early Differences in Cytokine Production by Severity of Coronavirus Disease 2019.
    J Infect Dis. 2021;223:1145-1149.
    >> Share

  647. RATHE JA, Hemann EA, Eggenberger J, Li Z, et al
    SARS-CoV-2 Serologic Assays in Control and Unknown Populations Demonstrate the Necessity of Virus Neutralization Testing.
    J Infect Dis. 2021;223:1120-1131.
    >> Share

  648. EISINGER RW, Lerner AM, Fauci AS
    HIV/AIDS in the Era of COVID-19: A Juxtaposition of Two Pandemics.
    J Infect Dis. 2021 Apr 7. pii: 6167835. doi: 10.1093.
    >> Share

    March 2021
  649. LAMARCA JH, de Carvalho FG, Machado FC, Lacerda-Santos R, et al
    Severe Acute Respiratory Syndrome Coronavirus 2: A Protocol for Disinfection of Toothbrushes.
    J Infect Dis. 2021;223:1113-1114.
    >> Share

  650. KLINGLER J, Weiss S, Itri V, Liu X, et al
    Role of Immunoglobulin M and A Antibodies in the Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2.
    J Infect Dis. 2021;223:957-970.
    >> Share

  651. HUGHES EC, Amat JAR, Haney J, Parr YA, et al
    Severe Acute Respiratory Syndrome Coronavirus 2 Serosurveillance in a Patient Population Reveals Differences in Virus Exposure and Antibody-Mediated Immunity According to Host Demography and Healthcare Setting.
    J Infect Dis. 2021;223:971-980.
    >> Share

  652. STRICH JR, Ramos-Benitez MJ, Randazzo D, Stein SR, et al
    Fostamatinib Inhibits Neutrophils Extracellular Traps Induced by COVID-19 Patient Plasma: A Potential Therapeutic.
    J Infect Dis. 2021;223:981-984.
    >> Share

  653. IZURIETA HS, Graham DJ, Jiao Y, Hu M, et al
    Natural History of Coronavirus Disease 2019: Risk Factors for Hospitalizations and Deaths Among >26 Million US Medicare Beneficiaries.
    J Infect Dis. 2021;223:945-956.
    >> Share

  654. PETITO E, Falcinelli E, Paliani U, Cesari E, et al
    Association of Neutrophil Activation, More Than Platelet Activation, With Thrombotic Complications in Coronavirus Disease 2019.
    J Infect Dis. 2021;223:933-944.
    >> Share

  655. NICOLAS DE LAMBALLERIE C, Pizzorno A, Dubois J, Padey B, et al
    Human Respiratory Syncytial Virus-Induced Immune Signature of Infection Revealed by Transcriptome Analysis of Clinical Pediatric Nasopharyngeal Swab Samples.
    J Infect Dis. 2021;223:1052-1061.
    >> Share

  656. JORDAN E, Lawrence SJ, Meyer TPH, Schmidt D, et al
    Broad Antibody and Cellular Immune Response From a Phase 2 Clinical Trial With a Novel Multivalent Poxvirus-Based Respiratory Syncytial Virus Vaccine.
    J Infect Dis. 2021;223:1062-1072.
    >> Share

  657. LAMOTH F, Lewis RE, Walsh TJ, Kontoyiannis DP, et al
    Navigating the uncertainties of COVID-19 associated aspergillosis (CAPA): A comparison with influenza associated aspergillosis (IAPA).
    J Infect Dis. 2021 Mar 26. pii: 6189669. doi: 10.1093.
    >> Share

  658. LEWNARD JA, Bruxvoort KJ, Fischer H, Hong VX, et al
    Prevention of COVID-19 among older adults receiving pneumococcal conjugate vaccine suggests interactions between Streptococcus pneumoniae and SARS-CoV-2 in the respiratory tract.
    J Infect Dis. 2021 Mar 9. pii: 6164926. doi: 10.1093.
    >> Share

  659. MCBRIDE DS, Perofsky AC, Nolting JM, Nelson MI, et al
    Tracing the source of influenza A virus zoonoses in interconnected circuits of swine exhibitions.
    J Infect Dis. 2021 Mar 4. pii: 6158869. doi: 10.1093.
    >> Share

  660. BHATNAGAR J, Gary J, Reagan-Steiner S, Estetter LB, et al
    Evidence of Severe Acute Respiratory Syndrome Coronavirus 2 Replication and Tropism in the Lungs, Airways, and Vascular Endothelium of Patients With Fatal Coronavirus Disease 2019: An Autopsy Case Series.
    J Infect Dis. 2021;223:752-764.
    >> Share

  661. GIRARDIN RC, Dupuis AP, Payne AF, Sullivan TJ, et al
    Temporal Analysis of Serial Donations Reveals Decrease in Neutralizing Capacity and Justifies Revised Qualifying Criteria for Coronavirus Disease 2019 Convalescent Plasma.
    J Infect Dis. 2021;223:743-751.
    >> Share

  662. BLOCH EM, Crowe EP, Tobian AAR
    Coronavirus Disease 2019 Convalescent Plasma and the Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Titer.
    J Infect Dis. 2021;223:740-742.
    >> Share

  663. ZHENG J, Wang Y, Li K, Meyerholz DK, et al
    Severe Acute Respiratory Syndrome Coronavirus 2-Induced Immune Activation and Death of Monocyte-Derived Human Macrophages and Dendritic Cells.
    J Infect Dis. 2021;223:785-795.
    >> Share

  664. KLUMPP-THOMAS C, Kalish H, Hicks J, Mehalko J, et al
    Effect of D614G Spike Variant on Immunoglobulin G, M, or A Spike Seroassay Performance.
    J Infect Dis. 2021;223:802-804.
    >> Share

  665. BOWMAN ER, Cameron CMA, Avery A, Gabriel J, et al
    Levels of Soluble CD14 and Tumor Necrosis Factor Receptors 1 and 2 May Be Predictive of Death in Severe Coronavirus Disease 2019.
    J Infect Dis. 2021;223:805-810.
    >> Share

  666. RIEDER M, Wirth L, Pollmeier L, Jeserich M, et al
    Serum Protein Profiling Reveals a Specific Upregulation of the Immunomodulatory Protein Progranulin in Coronavirus Disease 2019.
    J Infect Dis. 2021;223:775-784.
    >> Share

  667. JAHRSDORFER B, Kroschel J, Ludwig C, Corman VM, et al
    Independent Side-by-Side Validation and Comparison of 4 Serological Platforms for SARS-CoV-2 Antibody Testing.
    J Infect Dis. 2021;223:796-801.
    >> Share

  668. CHATZIDIMITRIOU M, Chatzopoulou F, Gavriilaki E, Chatzivasileiou P, et al
    Repeated Negative Serological Testing in Otherwise Healthy Patients With Coronavirus Disease 2019.
    J Infect Dis. 2021;223:924-926.
    >> Share

  669. CODY MEISSNER H
    Approaching the End of the Era of Uncontrolled Respiratory Syncytial Virus Disease.
    J Infect Dis. 2021;223:737-739.
    >> Share

  670. THOMAS E, Mattila JM, Lehtinen P, Vuorinen T, et al
    Burden of Respiratory Syncytial Virus Infection During the First Year of Life.
    J Infect Dis. 2021;223:811-817.
    >> Share

  671. CHORENO-PARRA JA, Jimenez-Alvarez LA, Ramirez-Martinez G, Cruz-Lagunas A, et al
    Expression of Surfactant protein D (SP-D) distinguishes severe pandemic influenza A(H1N1) from COVID-19.
    J Infect Dis. 2021 Mar 1. pii: 6154795. doi: 10.1093.
    >> Share

    February 2021
  672. BULFONE TC, Malekinejad M, Rutherford GW, Razani N, et al
    Outdoor Transmission of SARS-CoV-2 and Other Respiratory Viruses: A Systematic Review.
    J Infect Dis. 2021;223:550-561.
    >> Share

  673. LERSY F, Benotmane I, Helms J, Collange O, et al
    Cerebrospinal Fluid Features in Patients With Coronavirus Disease 2019 and Neurological Manifestations: Correlation with Brain Magnetic Resonance Imaging Findings in 58 Patients.
    J Infect Dis. 2021;223:600-609.
    >> Share

  674. TRIEU MC, Bansal A, Madsen A, Zhou F, et al
    SARS-CoV-2-Specific Neutralizing Antibody Responses in Norwegian Health Care Workers After the First Wave of COVID-19 Pandemic: A Prospective Cohort Study.
    J Infect Dis. 2021;223:589-599.
    >> Share

  675. SINHA P, Jafarzadeh SR, Assoumou SA, Bielick CG, et al
    The Effect of IL-6 Inhibitors on Mortality Among Hospitalized COVID-19 Patients: A Multicenter Study.
    J Infect Dis. 2021;223:581-588.
    >> Share

  676. BEDIN AS, Makinson A, Picot MC, Mennechet F, et al
    Monocyte CD169 Expression as a Biomarker in the Early Diagnosis of Coronavirus Disease 2019.
    J Infect Dis. 2021;223:562-567.
    >> Share

  677. LI A, Ling Y, Song Z, Cheng X, et al
    Correlation Between Early Plasma Interleukin 37 Responses With Low Inflammatory Cytokine Levels and Benign Clinical Outcomes in Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
    J Infect Dis. 2021;223:568-580.
    >> Share

  678. DAI M, Li H, Yan N, Huang J, et al
    Long-term Survival of SARS-CoV-2 on Salmon as a Source for International Transmission.
    J Infect Dis. 2021;223:537-539.
    >> Share

  679. MOHKHEDKAR M, Venigalla SSK, Janakiraman V
    Autoantigens That May Explain Postinfection Autoimmune Manifestations in Patients With Coronavirus Disease 2019 Displaying Neurological Conditions.
    J Infect Dis. 2021;223:536-537.
    >> Share

  680. MUECKSCH F, Wise H, Batchelor B, Squires M, et al
    Longitudinal Serological Analysis and Neutralizing Antibody Levels in Coronavirus Disease 2019 Convalescent Patients.
    J Infect Dis. 2021;223:389-398.
    >> Share

  681. GOLDSTEIN E, Lipsitch M, Cevik M
    On the Effect of Age on the Transmission of SARS-CoV-2 in Households, Schools, and the Community.
    J Infect Dis. 2021;223:362-369.
    >> Share

  682. LIM JT, Chew LZX, Choo ELW, Dickens BSL, et al
    Increased Dengue Transmissions in Singapore Attributable to SARS-CoV-2 Social Distancing Measures.
    J Infect Dis. 2021;223:399-402.
    >> Share

  683. MAROSSY A, Rakowicz S, Bhan A, Noon S, et al
    A Study of Universal Severe Acute Respiratory Syndrome Coronavirus 2 RNA Testing Among Residents and Staff in a Large Group of Care Homes in South London.
    J Infect Dis. 2021;223:381-388.
    >> Share

  684. GALANTI M, Shaman J
    Direct Observation of Repeated Infections With Endemic Coronaviruses.
    J Infect Dis. 2021;223:409-415.
    >> Share

  685. BEHR MA, Divangahi M, Schurr E
    Lessons From Bacille Calmette-Guerin for SARS-CoV-2 Vaccine Candidates.
    J Infect Dis. 2021;223:189-191.
    >> Share

  686. HARRIS BHL, Zuhair M, Di Giovannantonio M, Rosadas C, et al
    Asymptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in a Rehabilitation Facility: Evolution of the Presence of Nasopharyngeal SARS-CoV-2 and Serological Antibody Responses.
    J Infect Dis. 2021;223:192-196.
    >> Share

  687. BRANDSMA E, Verhagen HJMP, van de Laar TJW, Claas ECJ, et al
    Rapid, Sensitive, and Specific Severe Acute Respiratory Syndrome Coronavirus 2 Detection: A Multicenter Comparison Between Standard Quantitative Reverse-Transcriptase Polymerase Chain Reaction and CRISPR-Based DETECTR.
    J Infect Dis. 2021;223:206-213.
    >> Share

  688. CRAWFORD KHD, Dingens AS, Eguia R, Wolf CR, et al
    Dynamics of Neutralizing Antibody Titers in the Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
    J Infect Dis. 2021;223:197-205.
    >> Share

  689. DE NOOIJER AH, Grondman I, Janssen NAF, Netea MG, et al
    Complement Activation in the Disease Course of Coronavirus Disease 2019 and Its Effects on Clinical Outcomes.
    J Infect Dis. 2021;223:214-224.
    >> Share

  690. MANSBACH JM, Geller RJ, Hasegawa K, Piedra PA, et al
    Detection of Respiratory Syncytial Virus or Rhinovirus Weeks After Hospitalization for Bronchiolitis and the Risk of Recurrent Wheezing.
    J Infect Dis. 2021;223:268-277.
    >> Share

    January 2021
  691. JENNESS SM, Le Guillou A, Chandra C, Mann LM, et al
    Projected HIV and Bacterial STI Incidence Following COVID-Related Sexual Distancing and Clinical Service Interruption.
    J Infect Dis. 2021 Jan 28. pii: 6122459. doi: 10.1093.
    >> Share

  692. EATON EF, Clement ME
    Wave the Yellow Flag: Why we should prioritize routine HIV and STI care now.
    J Infect Dis. 2021 Jan 27. pii: 6121541. doi: 10.1093.
    >> Share

  693. SUNTARATTIWONG P, Mott JA, Mohanty S, Sinthuwattanawibool C, et al
    The feasibility and performance of participant-collected mid-turbinate nasal swabs for detection of influenza virus, respiratory syncytial virus, and human metapneumovirus infections among pregnant women.
    J Infect Dis. 2021 Jan 18. pii: 6103926. doi: 10.1093.
    >> Share

  694. BUI CHT, Yeung HW, Ho JCW, Leung CYH, et al
    Tropism of SARS-CoV-2, SARS-CoV and influenza virus in canine tissue explants.
    J Infect Dis. 2021 Jan 4. pii: 6062634. doi: 10.1093.
    >> Share

  695. LI L, Huang M, Shen J, Wang Y, et al
    Serum Levels of Soluble Platelet Endothelial Cell Adhesion Molecule 1 in COVID-19 Patients Are Associated With Disease Severity.
    J Infect Dis. 2021;223:178-179.
    >> Share

  696. MONCUNILL G, Mayor A, Santano R, Jimenez A, et al
    SARS-CoV-2 Seroprevalence and Antibody Kinetics Among Health Care Workers in a Spanish Hospital After 3 Months of Follow-up.
    J Infect Dis. 2021;223:62-71.
    >> Share

  697. HENSS L, Scholz T, von Rhein C, Wieters I, et al
    Analysis of Humoral Immune Responses in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
    J Infect Dis. 2021;223:56-61.
    >> Share

  698. LEE WT, Girardin RC, Dupuis AP, Kulas KE, et al
    Neutralizing Antibody Responses in COVID-19 Convalescent Sera.
    J Infect Dis. 2021;223:47-55.
    >> Share

  699. SUN H, Jain A, Leone MJ, Alabsi HS, et al
    CoVA: An Acuity Score for Outpatient Screening that Predicts Coronavirus Disease 2019 Prognosis.
    J Infect Dis. 2021;223:38-46.
    >> Share

  700. BAANG JH, Smith C, Mirabelli C, Valesano AL, et al
    Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 Replication in an Immunocompromised Patient.
    J Infect Dis. 2021;223:23-27.
    >> Share

  701. ZHU J, Wu C, Wu L
    Associations Between Genetically Predicted Protein Levels and COVID-19 Severity.
    J Infect Dis. 2021;223:19-22.
    >> Share

  702. YILMAZ A, Marklund E, Andersson M, Nilsson S, et al
    Upper Respiratory Tract Levels of Severe Acute Respiratory Syndrome Coronavirus 2 RNA and Duration of Viral RNA Shedding Do Not Differ Between Patients With Mild and Severe/Critical Coronavirus Disease 2019.
    J Infect Dis. 2021;223:15-18.
    >> Share

  703. PATI A, Padhi S, Suvankar S, Panda AK, et al
    Minor Allele of Interferon-Induced Transmembrane Protein 3 Polymorphism (rs12252) Is Covered Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Mortality: A Worldwide Epidemiological Investigation.
    J Infect Dis. 2021;223:175-178.
    >> Share

  704. KIDDE J, Sahebkar A
    From Foe to Friend in COVID-19: Renin-Angiotensin System Inhibitors.
    J Infect Dis. 2021;223:174-175.
    >> Share

  705. HICKS SM, Pohl K, Neeman T, McNamara HA, et al
    A Dual-Antigen Enzyme-Linked Immunosorbent Assay Allows the Assessment of Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Seroprevalence in a Low-Transmission Setting.
    J Infect Dis. 2021;223:10-14.
    >> Share

  706. PILOTTO A, Masciocchi S, Volonghi I, Crabbio M, et al
    Clinical Presentation and Outcomes of Severe Acute Respiratory Syndrome Coronavirus 2-Related Encephalitis: The ENCOVID Multicenter Study.
    J Infect Dis. 2021;223:28-37.
    >> Share

  707. PILAROWSKI G, Lebel P, Sunshine S, Liu J, et al
    Performance characteristics of a rapid SARS-CoV-2 antigen detection assay at a public plaza testing site in San Francisco.
    J Infect Dis. 2021 Jan 4. pii: 6061974. doi: 10.1093.
    >> Share

  708. TONG M, Zheng Q, Zhu Y
    Reply to Li et al.
    J Infect Dis. 2021;223:179-180.
    >> Share

  709. LEMPAINEN J, Korhonen LS, Kantojarvi K, Heinonen S, et al
    Associations Between IFI44L Gene Variants and Rates of Respiratory Tract Infections During Early Childhood.
    J Infect Dis. 2021;223:157-165.
    >> Share

  710. MALTEZOU HC, Raftopoulos V, Vorou R, Papadima K, et al
    Association between upper respiratory tract viral load, comorbidities, disease severity and outcome of patients with SARS-CoV-2 infection.
    J Infect Dis. 2021 Jan 3. pii: 6060070. doi: 10.1093.
    >> Share

    December 2020
  711. TENFORDE MW, Talbot HK, Trabue CH, Gaglani M, et al
    Influenza vaccine effectiveness against hospitalization in the United States, 2019-2020.
    J Infect Dis. 2020 Dec 30. pii: 6055595. doi: 10.1093.
    >> Share

  712. KUBALE J, Balmaseda A, Sanchez N, Lopez R, et al
    Pneumonia following symptomatic influenza infection among Nicaraguan children before and after introduction of the pneumococcal conjugate vaccine.
    J Infect Dis. 2020 Dec 22. pii: 6044070. doi: 10.1093.
    >> Share

  713. KIMBALL J, Zhu Y, Wyatt D, Trabue CH, et al
    Influenza Vaccine Failure Associated with Age and Immunosuppression.
    J Infect Dis. 2020 Dec 19. pii: 6041867. doi: 10.1093.
    >> Share

  714. FERDINANDS JM, Gaglani M, Ghamande S, Martin ET, et al
    Vaccine effectiveness against influenza-associated hospitalizations among adults, 2018-2019, US Hospitalized Adult Influenza Vaccine Effectiveness Network.
    J Infect Dis. 2020 Dec 18. pii: 6041424. doi: 10.1093.
    >> Share

    November 2020
  715. CLEMENS EA, Holbrook BC, Kanekiyo M, Yewdell JW, et al
    An R848 conjugated influenza virus vaccine elicits robust IgG to hemagglutinin stem in a newborn nonhuman primate model.
    J Infect Dis. 2020 Nov 27. pii: 6007684. doi: 10.1093.
    >> Share

  716. TAN TQ, Kullar R, Swartz TH, Mathew TA, et al
    Location Matters: Geographic Disparities and Impact of Coronavirus Disease 2019.
    J Infect Dis. 2020;222:1951-1954.
    >> Share

  717. SCHWAIGER J, Karbiener M, Aberham C, Farcet MR, et al
    No SARS-CoV-2 Neutralization by Intravenous Immunoglobulins Produced From Plasma Collected Before the 2020 Pandemic.
    J Infect Dis. 2020;222:1960-1964.
    >> Share

  718. VITTE J, Diallo AB, Boumaza A, Lopez A, et al
    A Granulocytic Signature Identifies COVID-19 and Its Severity.
    J Infect Dis. 2020;222:1985-1996.
    >> Share

  719. BENNER SE, Patel EU, Laeyendecker O, Pekosz A, et al
    SARS-CoV-2 Antibody Avidity Responses in COVID-19 Patients and Convalescent Plasma Donors.
    J Infect Dis. 2020;222:1974-1984.
    >> Share

  720. NARANBHAI V, Chang CC, Beltran WFG, Miller TE, et al
    High Seroprevalence of Anti-SARS-CoV-2 Antibodies in Chelsea, Massachusetts.
    J Infect Dis. 2020;222:1955-1959.
    >> Share

  721. GNIFFKE EP, Harrington WE, Dambrauskas N, Jiang Y, et al
    Plasma From Recovered COVID-19 Patients Inhibits Spike Protein Binding to ACE2 in a Microsphere-Based Inhibition Assay.
    J Infect Dis. 2020;222:1965-1973.
    >> Share

  722. SCHIEFFELIN JS
    Infectious Disease Outbreaks: The Need For an All-in Approach.
    J Infect Dis. 2020;222:1941-1942.
    >> Share

  723. FALASCA L, Nardacci R, Colombo D, Lalle E, et al
    Postmortem Findings in Italian Patients With COVID-19: A Descriptive Full Autopsy Study of Cases With and Without Comorbidities.
    J Infect Dis. 2020;222:1807-1815.
    >> Share

  724. BINDER RA, Alarja NA, Robie ER, Kochek KE, et al
    Environmental and Aerosolized Severe Acute Respiratory Syndrome Coronavirus 2 Among Hospitalized Coronavirus Disease 2019 Patients.
    J Infect Dis. 2020;222:1798-1806.
    >> Share

  725. STERLING RK, Oakes T, Gal TS, Stevens MP, et al
    The Fibrosis-4 Index Is Associated With Need for Mechanical Ventilation and 30-Day Mortality in Patients Admitted With Coronavirus Disease 2019.
    J Infect Dis. 2020;222:1794-1797.
    >> Share

  726. GUERVILLY C, Burtey S, Sabatier F, Cauchois R, et al
    Circulating Endothelial Cells as a Marker of Endothelial Injury in Severe COVID -19.
    J Infect Dis. 2020;222:1789-1793.
    >> Share

  727. ZOU Y, Wang BR, Sun L, Xu S, et al
    The Issue of Recurrently Positive Patients Who Recovered From COVID-19 According to the Current Discharge Criteria: Investigation of Patients from Multiple Medical Institutions in Wuhan, China.
    J Infect Dis. 2020;222:1784-1788.
    >> Share

  728. FJELLTVEIT EB, Cox RJ, Ostensjo J, Blomberg B, et al
    Point-of-care influenza testing impacts clinical decision, patient flow and length of stay in hospitalized adults.
    J Infect Dis. 2020 Nov 5. pii: 5957176. doi: 10.1093.
    >> Share

  729. MARTIN ET, Cheng C, Petrie JG, Alyanak E, et al
    Low influenza vaccine effectiveness against A(H3N2) associated hospitalizations in the 2016-2017 and 2017-2018 seasons of the Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN).
    J Infect Dis. 2020 Nov 3. pii: 5952469. doi: 10.1093.
    >> Share

  730. SALMON DA, Dudley MZ, Carleton BC
    Guillain-Barre Syndrome Following Influenza Vaccines Affords Opportunity to Improve Vaccine Confidence.
    J Infect Dis. 2020 Nov 2. pii: 5952166. doi: 10.1093.
    >> Share

  731. PEREZ-VILAR S, Hu M, Weintraub E, Arya D, et al
    Guillain-Barre Syndrome After High-Dose Influenza Vaccine Administration in the United States, 2018-2019 Season.
    J Infect Dis. 2020 Nov 2. pii: 5952165. doi: 10.1093.
    >> Share

    October 2020
  732. WANG W, Chen X, Wang Y, Lai S, et al
    Serological evidence of human infection with avian influenza A(H7N9) virus: a systematic review and meta-analysis.
    J Infect Dis. 2020 Oct 29. pii: 5943032. doi: 10.1093.
    >> Share

  733. HINOJOSA M, Shepard SS, Chung JR, King JP, et al
    Impact of Immune Priming, Vaccination and Infection on Influenza A(H3N2) Antibody Landscapes in Children.
    J Infect Dis. 2020 Oct 22. pii: 5934948. doi: 10.1093.
    >> Share

  734. MANCINI F, Barbanti F, Scaturro M, Fontana S, et al
    Multiplex rt-Real Time PCR assays for diagnostic testing of SARS-CoV-2 and seasonal influenza viruses. A challenge of the phase 3 pandemic setting.
    J Infect Dis. 2020 Oct 20. pii: 5932324. doi: 10.1093.
    >> Share

  735. SHANNON I, White CL, Yang H, Nayak JL, et al
    Differences in influenza-specific CD4 T cell mediated immunity following acute infection versus inactivated vaccination in children.
    J Infect Dis. 2020 Oct 19. pii: 5930368. doi: 10.1093.
    >> Share

  736. WEISS S, Klingler J, Hioe C, Amanat F, et al
    A High-Throughput Assay for Circulating Antibodies Directed Against the S Protein of Severe Acute Respiratory Syndrome Coronavirus 2.
    J Infect Dis. 2020;222:1629-1634.
    >> Share

  737. SAUCEDA JA, Neilands TB, Lightfoot M, Saberi P, et al
    Findings From a Probability-Based Survey of United States Households About Prevention Measures Based on Race, Ethnicity, and Age in Response to Severe Acute Respiratory Syndrome Coronavirus 2.
    J Infect Dis. 2020;222:1607-1611.
    >> Share

  738. SUGANO N, Ando W, Fukushima W
    Cluster of Severe Acute Respiratory Syndrome Coronavirus 2 Infections Linked to Music Clubs in Osaka, Japan.
    J Infect Dis. 2020;222:1635-1640.
    >> Share

  739. BRADFUTE SB, Hurwitz I, Yingling AV, Ye C, et al
    Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Antibody Titers in Convalescent Plasma and Recipients in New Mexico: An Open Treatment Study in Patients With Coronavirus Disease 2019.
    J Infect Dis. 2020;222:1620-1628.
    >> Share

  740. KOO BS, Oh H, Kim G, Hwang EH, et al
    Transient Lymphopenia and Interstitial Pneumonia With Endotheliitis in SARS-CoV-2-Infected Macaques.
    J Infect Dis. 2020;222:1596-1600.
    >> Share

  741. LURIE MN, Silva J, Yorlets RR, Tao J, et al
    Coronavirus Disease 2019 Epidemic Doubling Time in the United States Before and During Stay-at-Home Restrictions.
    J Infect Dis. 2020;222:1601-1606.
    >> Share

  742. LAI CKC, Chen Z, Lui G, Ling L, et al
    Prospective Study Comparing Deep Throat Saliva With Other Respiratory Tract Specimens in the Diagnosis of Novel Coronavirus Disease 2019.
    J Infect Dis. 2020;222:1612-1619.
    >> Share

  743. SHI T, Arnott A, Semogas I, Falsey AR, et al
    The Etiological Role of Common Respiratory Viruses in Acute Respiratory Infections in Older Adults: A Systematic Review and Meta-analysis.
    J Infect Dis. 2020;222.
    >> Share

  744. MILLER M
    Establishing the Value and Strategies for Respiratory Syncytial Virus (RSV) Control: The European RSV Consortium (RESCEU).
    J Infect Dis. 2020;222.
    >> Share

  745. REEVES RM, van Wijhe M, Tong S, Lehtonen T, et al
    Respiratory Syncytial Virus-Associated Hospital Admissions in Children Younger Than 5 Years in 7 European Countries Using Routinely Collected Datasets.
    J Infect Dis. 2020;222.
    >> Share

  746. LI Y, Campbell H, Nair H
    Unveiling the Risk Period for Death After Respiratory Syncytial Virus Illness in Young Children Using a Self-Controlled Case Series Design.
    J Infect Dis. 2020;222.
    >> Share

  747. WILDENBEEST JG, Zuurbier RP, Korsten K, van Houten MA, et al
    Respiratory Syncytial Virus Consortium in Europe (RESCEU) Birth Cohort Study: Defining the Burden of Infant Respiratory Syncytial Virus Disease in Europe.
    J Infect Dis. 2020;222.
    >> Share

  748. JEFFERIES K, Drysdale SB, Robinson H, Clutterbuck EA, et al
    Presumed Risk Factors and Biomarkers for Severe Respiratory Syncytial Virus Disease and Related Sequelae: Protocol for an Observational Multicenter, Case-Control Study From the Respiratory Syncytial Virus Consortium in Europe (RESCEU).
    J Infect Dis. 2020;222.
    >> Share

  749. CHUNG A, Reeves RM, Nair H, Campbell H, et al
    Hospital Admission Trends for Bronchiolitis in Scotland, 2001-2016: A National Retrospective Observational Study.
    J Infect Dis. 2020;222.
    >> Share

  750. ONER D, Drysdale SB, McPherson C, Lin GL, et al
    Biomarkers for Disease Severity in Children Infected With Respiratory Syncytial Virus: A Systematic Literature Review.
    J Infect Dis. 2020;222.
    >> Share

  751. LIN GL, Golubchik T, Drysdale S, O'Connor D, et al
    Simultaneous Viral Whole-Genome Sequencing and Differential Expression Profiling in Respiratory Syncytial Virus Infection of Infants.
    J Infect Dis. 2020;222.
    >> Share

  752. ZUURBIER RP, Bont LJ, Langedijk AC, Hamer M, et al
    Low Sensitivity of BinaxNOW RSV in Infants.
    J Infect Dis. 2020;222.
    >> Share

  753. WISEMAN DJ, Thwaites RS, Drysdale SB, Janet S, et al
    Immunological and Inflammatory Biomarkers of Susceptibility and Severity in Adult Respiratory Syncytial Virus Infections.
    J Infect Dis. 2020;222.
    >> Share

  754. ZHANG S, Akmar LZ, Bailey F, Rath BA, et al
    Cost of Respiratory Syncytial Virus-Associated Acute Lower Respiratory Infection Management in Young Children at the Regional and Global Level: A Systematic Review and Meta-Analysis.
    J Infect Dis. 2020;222.
    >> Share

  755. CHAW PS, Hua L, Cunningham S, Campbell H, et al
    Respiratory Syncytial Virus-Associated Acute Lower Respiratory Infections in Children With Bronchopulmonary Dysplasia: Systematic Review and Meta-Analysis.
    J Infect Dis. 2020;222.
    >> Share

  756. CHAW PS, Wong SWL, Cunningham S, Campbell H, et al
    Acute Lower Respiratory Infections Associated With Respiratory Syncytial Virus in Children With Underlying Congenital Heart Disease: Systematic Review and Meta-analysis.
    J Infect Dis. 2020;222.
    >> Share

  757. SHI T, Ooi Y, Zaw EM, Utjesanovic N, et al
    Association Between Respiratory Syncytial Virus-Associated Acute Lower Respiratory Infection in Early Life and Recurrent Wheeze and Asthma in Later Childhood.
    J Infect Dis. 2020;222.
    >> Share

  758. SHI T, Denouel A, Tietjen AK, Campbell I, et al
    Global Disease Burden Estimates of Respiratory Syncytial Virus-Associated Acute Respiratory Infection in Older Adults in 2015: A Systematic Review and Meta-Analysis.
    J Infect Dis. 2020;222.
    >> Share

  759. LI D, Wolk DM, Cantor MN
    Comparing Clinical Characteristics of Influenza and Common Coronavirus Infections using Electronic Health Records.
    J Infect Dis. 2020 Oct 3. pii: 5917765. doi: 10.1093.
    >> Share

  760. RABELO-DA-PONTE FD, Silvello D, Scherer JN, Ayala AR, et al
    Convalescent Plasma Therapy in Patients With Severe or Life-Threatening COVID-19: A Metadata Analysis.
    J Infect Dis. 2020;222:1575-1578.
    >> Share

  761. DEN HARTOG G, Schepp RM, Kuijer M, GeurtsvanKessel C, et al
    SARS-CoV-2-Specific Antibody Detection for Seroepidemiology: A Multiplex Analysis Approach Accounting for Accurate Seroprevalence.
    J Infect Dis. 2020;222:1452-1461.
    >> Share

  762. SCHIAFFINO MT, Di Natale M, Garcia-Martinez E, Navarro J, et al
    Immunoserologic Detection and Diagnostic Relevance of Cross-Reactive Autoantibodies in Coronavirus Disease 2019 Patients.
    J Infect Dis. 2020;222:1439-1443.
    >> Share

  763. WANG W, Liu X, Wu S, Chen S, et al
    Definition and Risks of Cytokine Release Syndrome in 11 Critically Ill COVID-19 Patients With Pneumonia: Analysis of Disease Characteristics.
    J Infect Dis. 2020;222:1444-1451.
    >> Share

  764. ZENG QL, Yu ZJ, Ji F
    Reply to Rabelo-da-Ponte et al.
    J Infect Dis. 2020;222:1578.
    >> Share

  765. HAYDEN FG, Whitley RJ
    Respiratory Syncytial Virus Antivirals: Problems and Progress.
    J Infect Dis. 2020;222:1417-1421.
    >> Share

  766. STRAY K, Perron M, Porter DP, Anderson F, et al
    Drug Resistance Assessment Following Administration of Respiratory Syncytial Virus (RSV) Fusion Inhibitor Presatovir to Participants Experimentally Infected With RSV.
    J Infect Dis. 2020;222:1468-1477.
    >> Share

    September 2020
  767. LI JZ, Yu XG
    Overcoming Challenges in Coronavirus Disease 19 Translational Research.
    J Infect Dis. 2020;222:1254-1255.
    >> Share

  768. LIU X, Tang J, Xie R, Li W, et al
    Clinical and Epidemiological Features of 46 Children <1 Year Old With Coronavirus Disease 2019 in Wuhan, China: A Descriptive Study.
    J Infect Dis. 2020;222:1293-1297.
    >> Share

  769. BOND K, Nicholson S, Lim SM, Karapanagiotidis T, et al
    Evaluation of Serological Tests for SARS-CoV-2: Implications for Serology Testing in a Low-Prevalence Setting.
    J Infect Dis. 2020;222:1280-1288.
    >> Share

  770. LEUZINGER K, Roloff T, Gosert R, Sogaard K, et al
    Epidemiology of Severe Acute Respiratory Syndrome Coronavirus 2 Emergence Amidst Community-Acquired Respiratory Viruses.
    J Infect Dis. 2020;222:1270-1279.
    >> Share

  771. MEISTER TL, Bruggemann Y, Todt D, Conzelmann C, et al
    Virucidal Efficacy of Different Oral Rinses Against Severe Acute Respiratory Syndrome Coronavirus 2.
    J Infect Dis. 2020;222:1289-1292.
    >> Share

  772. RIJKERS G, Murk JL, Wintermans B, van Looy B, et al
    Differences in Antibody Kinetics and Functionality Between Severe and Mild Severe Acute Respiratory Syndrome Coronavirus 2 Infections.
    J Infect Dis. 2020;222:1265-1269.
    >> Share

  773. LAM KW, Chow KW, Vo J, Hou W, et al
    Continued In-Hospital Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use in Hypertensive COVID-19 Patients Is Associated With Positive Clinical Outcome.
    J Infect Dis. 2020;222:1256-1264.
    >> Share

  774. FALSEY AR, Walsh EE
    Respiratory Syncytial Virus: An Old Foe in a New Era.
    J Infect Dis. 2020;222:1245-1246.
    >> Share

  775. TSENG HF, Sy LS, Ackerson B, Solano Z, et al
    Severe Morbidity and Short- and Mid- to Long-term Mortality in Older Adults Hospitalized with Respiratory Syncytial Virus Infection.
    J Infect Dis. 2020;222:1298-1310.
    >> Share

  776. FILL MA
    Multistate Outbreak of Seoul Virus: Implications for the One Health Movement and Pandemic Preparedness.
    J Infect Dis. 2020;222:1247-1249.
    >> Share

  777. ZIMMERMAN RK, South-Paul JE, Poland GA
    Rationing of civilian COVID-19 vaccines while supplies are limited.
    J Infect Dis. 2020 Sep 7. pii: 5902567. doi: 10.1093.
    >> Share

  778. NALIN D
    Immunosenescence and SARS-CoV-2 Vaccine Development.
    J Infect Dis. 2020 Sep 5. pii: 5901694. doi: 10.1093.
    >> Share

  779. SIEDNER MJ, Gandhi RT, Kim AY
    Desperate Times Call for Temperate Measures: Practicing Infectious Diseases During a Novel Pandemic.
    J Infect Dis. 2020;222:1084-1085.
    >> Share

  780. OFMAN G, Pradarelli B, Caballero MT, Bianchi A, et al
    Respiratory Failure and Death in Vulnerable Premature Children With Lower Respiratory Tract Illness.
    J Infect Dis. 2020;222:1129-1137.
    >> Share

    August 2020
  781. TAKAHASHI S, Greenhouse B, Rodriguez-Barraquer I
    Are SARS-CoV-2 seroprevalence estimates biased?
    J Infect Dis. 2020 Aug 28. pii: 5898481. doi: 10.1093.
    >> Share

  782. HASFORD J
    Large Simple Double-Blind Randomized Trials for the Rapid Assessment of the Effectiveness of COVID-19 Vaccines.
    J Infect Dis. 2020 Aug 26. pii: 5897422. doi: 10.1093.
    >> Share

  783. VAN BOVEN M, Teirlinck AC, Meijer A, Hooiveld M, et al
    Estimating Transmission Parameters for Respiratory Syncytial Virus and Predicting the Impact of Maternal and Pediatric Vaccination.
    J Infect Dis. 2020 Aug 21. pii: 5895295. doi: 10.1093.
    >> Share

  784. HALSTEAD SB, Katzelnick L
    COVID 19 Vaccines: Should we fear ADE?
    J Infect Dis. 2020 Aug 12. pii: 5891764. doi: 10.1093.
    >> Share

    July 2020
  785. MACIAS GIL R, Marcelin JR, Zuniga-Blanco B, Marquez C, et al
    COVID-19 Pandemic: Disparate Health Impact on the Hispanic/Latinx Population in the United States.
    J Infect Dis. 2020 Jul 30. pii: 5878913. doi: 10.1093.
    >> Share

  786. PANDA AK, Tripathy R, Das BK
    Plasmodium falciparum infection may protect a population from SARS-CoV-2 infection.
    J Infect Dis. 2020 Jul 29. pii: 5878042. doi: 10.1093.
    >> Share

  787. NICKBAKHSH S, Ho A, Marques DFP, McMenamin J, et al
    Reply to Li et al.
    J Infect Dis. 2020;222:696-698.
    >> Share

  788. SCHLOM J, Donahue RN
    Do Not Minimize the Impact of Cellular Immunity in the Development of Vaccines and Therapeutics for COVID-19.
    J Infect Dis. 2020 Jul 11. pii: 5870046. doi: 10.1093.
    >> Share

    June 2020
  789. HO HE, Peluso MJ, Margus C, Matias Lopes JP, et al
    Clinical outcomes and immunologic characteristics of Covid-19 in people with HIV.
    J Infect Dis. 2020 Jun 30. pii: 5864898. doi: 10.1093.
    >> Share

  790. SEPPALA EM, Oikarinen S, Lehtonen JP, Neupane S, et al
    Association of Picornavirus Infections With Acute Otitis Media in a Prospective Birth Cohort Study.
    J Infect Dis. 2020;222:324-332.
    >> Share

  791. THIELEN BK, Bye E, Wang X, Maroushek S, et al
    Summer Outbreak of Severe RSV-B Disease, Minnesota, 2017 Associated with Emergence of a Genetically Distinct Viral Lineage.
    J Infect Dis. 2020;222:288-297.
    >> Share

  792. UUSITUPA E, Waris M, Heikkinen T
    Association of Viral Load With Disease Severity in Outpatient Children With Respiratory Syncytial Virus Infection.
    J Infect Dis. 2020;222:298-304.
    >> Share

  793. MOORE HC, Lim FJ, Fathima P, Barnes R, et al
    Assessing the Burden of Laboratory-Confirmed Respiratory Syncytial Virus Infection in a Population Cohort of Australian Children Through Record Linkage.
    J Infect Dis. 2020;222:92-101.
    >> Share

  794. MIDULLA F, Di Mattia G, Nenna R, Scagnolari C, et al
    Novel Variants of Respiratory Syncytial Virus A ON1 Associated With Increased Clinical Severity of Bronchiolitis.
    J Infect Dis. 2020;222:102-110.
    >> Share

    April 2020
  795. WILLIAMS K, Bastian AR, Feldman RA, Omoruyi E, et al
    Phase 1 Safety and Immunogenicity Study of a Respiratory Syncytial Virus Vaccine with an Adenovirus 26 Vector Encoding Pre-Fusion F (Ad26.RSV.preF) in adults 60 years and older.
    J Infect Dis. 2020 Apr 22. pii: 5823828. doi: 10.1093.
    >> Share

    March 2020
  796. SIMOES EAF, Chirikov V, Botteman M, Kwon Y, et al
    Long-term Assessment of Healthcare Utilization 5 Years After Respiratory Syncytial Virus Infection in US Infants.
    J Infect Dis. 2020;221:1256-1270.
    >> Share

  797. PIEDRA PA
    Long-Term Healthcare Costs Associated With Respiratory Syncytial Virus Infection in Children: The Domino Effect.
    J Infect Dis. 2020;221:1205-1207.
    >> Share

  798. CHIRIKOV VV, Simoes EAF, Kuznik A, Kwon Y, et al
    Economic-Burden Trajectories in Commercially Insured US Infants With Respiratory Syncytial Virus Infection.
    J Infect Dis. 2020;221:1244-1255.
    >> Share

    February 2020
  799. MCFARLAND EJ, Karron RA, Muresan P, Cunningham CK, et al
    Live-attenuated respiratory syncytial virus vaccine with M2-2 deletion and with SH non-coding region is highly immunogenic in children.
    J Infect Dis. 2020 Feb 1. pii: 5719572. doi: 10.1093.
    >> Share

    October 2019
  800. KARRON RA, Luongo C, Mateo JS, Wanionek K, et al
    Safety and Immunogenicity of the Respiratory Syncytial Virus Vaccine RSV/DeltaNS2/Delta1313/I1314L in RSV-Seronegative Children.
    J Infect Dis. 2019 Oct 12. pii: 5586371. doi: 10.1093.
    >> Share

    September 2019
  801. RAMILO O, Rodriguez-Fernandez R, Peeples ME, Mejias A, et al
    Advanced Live Attenuated Vaccines for the Prevention of Respiratory Syncytial Virus Infections in Young Children.
    J Infect Dis. 2019 Sep 24. pii: 5573046. doi: 10.1093.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016